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Abstract
As an obligate intracellular parasite, human adenovirus (HAdV) must utilize host factors
for survival and replication. Early during infection, its multifunctional E1A protein
interacts with an impressive range of cellular target proteins to exert control over the
cellular environment. Through these virus-host interactions, E1A massively reprograms
both viral and cellular transcription to activate the other HAdV genes, downregulate the
host’s immune response, and induce the cell cycle. Consequently, E1A converts the
infected cell into a compliant state more amenable for HAdV replication, resulting from
its numerous protein-protein interactions. I sought to examine E1A’s interaction with
cellular protein kinase A (PKA), a well-studied component of host cAMP signaling that
plays a critical role in cellular transcription.

While characterizing the molecular

determinants of the E1A-PKA interaction, I showed that E1A uses mimicry of cellular Akinase anchoring proteins (AKAPs) to usurp PKA for the benefit of HAdV.

This

mechanism allowed E1A to outcompete endogenous AKAPs and induce an E1Amediated relocalization of PKA into the nucleus of infected cells. Here, PKA was
recruited to viral gene promoters. This ultimately resulted in increased viral transcription
from these loci as well as enhanced protein synthesis and higher levels of viral
replication. This mechanism of mimicry was conserved in E1A proteins across various,
distinct species of HAdV, indicating its evolutionary importance. Interestingly, different
E1A proteins displayed a preference for manipulating one type of PKA isoform over
another. Despite mechanistic differences, all species of HAdV that commandeered PKA
via their E1A proteins required this action for wild-type levels of both viral genome
replication and infectious progeny production. Additionally, these E1A proteins could
induce transcription from a cAMP- and PKA-regulated reporter gene suggesting that this
interaction may modulate host genes in a manner similar to viral ones. Together, these
studies show that manipulation of PKA by E1A is a conserved feature of diverse HAdVs.
This allows these viruses to subvert cellular cAMP signaling and use a host factor to
enhance multiple aspects of their replication cycles. Furthermore, this mechanistically
demonstrates HAdV E1A as the first known viral AKAP – a unique form of viral
mimicry.
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Chapter 1

1

Introduction

“Not explaining science seems to me perverse. When you're in love, you want to tell the
world.”
– Carl Sagan

1.1 General Introduction
As obligate intracellular parasites, all viruses are critically dependent on their infected
hosts for survival. Due to physical constraints and limited coding capacity, no known
viruses are capable of independently producing either their own protein or metabolic
energy. As a result of coevolution with their hosts, viruses have instead adapted to take
advantage of machinery and factors from within the cell by engaging in a wide array of
virus-host interactions (Rozenblatt-Rosen et al., 2012). Infected cells will typically be
drastically altered into environments more favourable for viral progeny production. By
teasing out the virus-host interactions that drive these changes, we gain greater
understanding of not only viral pathogenesis, but also basic cellular functions such as
gene expression, cell division, or immunological responses (Ferrari et al., 2014, 2008;
Fonseca et al., 2012; Miyake-Stoner and O’Shea, 2014; Shah and O’Shea, 2015; Soria et
al., 2010).
Human adenovirus (HAdV) has served as a prime example of the utility for using viruses
to study the molecular biology of eukaryotic cells (Berk, 2005; Cohen et al., 2013; Pelka
et al., 2008). Scientific breakthroughs related to cell cycle control, DNA replication,
mRNA splicing, gene expression, interferon (IFN) signaling, and cancer can all be
attributed to studies involving HAdV (Bayley and Mymryk, 1994; Berget et al., 1977;
Chow et al., 1977; Flint and Shenk, 1997; Gallimore and Turnell, 2001). The virus was
originally discovered and characterized in 1953 as a causative agent for respiratory
infections (Hillerman and Werner, 1954; Rowe et al., 1953). HAdVs are non-enveloped
viruses containing a linear double-stranded DNA (dsDNA) genome of approximately 36
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Figure 1.1. Schematic representation of the HAdV-5 double-stranded DNA genome.
The HAdV-5 genome is approximately 36kbp in length and composed of both early (E)
and late (L) transcription units. Arrows depict the directionality of individual transcripts
with their protein products labelled accordingly. Early genes are depicted in green while
late genes are displayed in red. VA RNA is shown in yellow. Adapted from NCBI
sequence NC_001405.1.
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kilobase pairs (kbp) (Davison et al., 2003) (Figure 1.1). There are at least 57 distinct
HAdV types which are divided across 7 unique species (A-G) based on various biological
properties (Aoki et al., 2011; Jones et al., 2007; Walsh et al., 2011) (Figure 1.2). While
broadly similar, these species have evolved molecular differences that confer specific
tissue and organ tropisms including the respiratory tract, gastrointestinal tract, ocular
tissue, and blood (Ghebremedhin, 2014). Clinically, most HAdV infections result in mild
symptoms that resolve without treatment; however, disease can occasionally progress
beyond a subclinical presentation, especially in immunocompromised hosts (Lion, 2014).
HAdVs are considered part of the genetically-distinct but functionally-similar family of
DNA tumour viruses, which include other well-studied pathogens such as human
papillomavirus (HPV) and polyomavirus (HPyV) (Howley and Livingston, 2009; Yaniv,
2009). All of these viruses can cause cancer in either animal or human systems (DiMaio
and Fan, 2013). Indeed, in 1962 HAdV type 12 was the first human virus ever shown to
be tumourigenic, albeit in a rodent model (Trentin et al., 1962). Research interest in the
DNA tumour viruses exploded after this seminal discovery, with particular focus on the
activities of the viral oncoproteins produced by these pathogens. Although not all species
of HAdV can cause tumours in rodents, all viruses tested can transform cells in tissue
culture (Berk, 2013; Freeman et al., 1967; Gallimore, 1972; McBride and Wiener, 1964)
(Figure 1.2). Differences in pathogenicity and tumourigenicity between various HAdV
types can largely be attributed to the radical changes to the cellular environment
conferred by virus-host interactions. For HAdV, its early region 1A (E1A) protein is
largely responsible for these pathophysiological changes and is the primary focus of this
thesis.

1.2 Adenovirus
1.2.1 Physical properties of adenoviruses
Adenoviruses are composed of a non-enveloped, icosahedral protein capsid that houses a
linear, dsDNA genome (Ginsberg et al., 1966; Russell, 2009). The capsid shell ranges in
size between 60-90 nm in diameter, depending on the species.

It consists of 252

capsomeres, 240 of which are hexons while 12 are pentons. Pentons form the base for a
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protruding fiber protein and together these capsid components mediate attachment and
entry of HAdV particles into targeted cells (Norrby, 1966; Norrby and Skaaret, 1967; San
Martín, 2012). For some HAdV species, the fiber interacts with the coxsakievirus and
adenovirus receptor (CAR) which is commonly found on the surface of epithelial cells
(Bergelson et al., 1997; Devaux et al., 1987; Roelvink et al., 1998; Tomko et al., 1997).
This is followed by an interaction of the arginine-glycine-aspartic acid (RGD) motif in
the penton base with cell surface integrins (αvβ3 and αvβ5 for HAdV-5), resulting in
endocytic uptake of the viral particle (Meier and Greber, 2003; Wickham et al., 1993).
Notably, not all HAdV bind CAR (species B and D HAdVs can bind cellular CD46
instead) or contain an RGD motif, contributing to altered specificity for cellular receptors
(Albinsson and Kidd, 1999; Gaggar et al., 2003; Lenman et al., 2015; Segerman et al.,
2003; Sirena et al., 2004; Wickham et al., 1995; Wu et al., 2004).
The genomes of HAdVs are linear, dsDNA ranging in size between 30-36 kbp (Davison
et al., 2003; Roberts et al., 1984) (Figure 1.1). Genomic organization is highly conserved
and contains inverted terminal repeats (ITRs) at each end, as well as a covalentlyattached 55 kilo Dalton (kDa) terminal protein (TP) which functions as a primer for viral
genome replication (Challberg et al., 1980; Rekosh et al., 1977; Steenbergh et al., 1977).
TP may also shield viral genomes from being recognized as free, damaged DNA by the
host’s DNA damage response machinery (Karen et al., 2009; Stracker et al., 2002;
Weitzman and Ornelles, 2005).

HAdV genomes have been assigned arbitrary

directionality, the ‘left’ end of which contains repeats of cis-acting packaging sequences
that direct proper packaging of viral DNA into infectious progeny virions (Gräble and
Hearing, 1992; Hearing et al., 1987; Ostapchuk and Hearing, 2003). Viral genes are
encoded on both strands of the genome and are broadly separated into two classes, early
or late (Berk, 2013; Fessler and Young, 1998; Tollefson et al., 2007). Early genes are
transcribed before the onset of viral genome replication and serve to reorganize the cell
into a suitable environment for virus replication and suppress host immune responses.
Late genes are expressed after viral genome replication and encode the structural proteins
that make up the HAdV capsid. Depending on the species, HAdVs also encode one or
two virus-associated RNAs (VA RNA) (Reich et al., 1966; Weinmann et al., 1974).
These do not encode for viral proteins but instead act to antagonize the host’s IFN-
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Figure 1.2. Classification and properties of HAdV species.
Human adenoviruses are separated into 7 distinct species comprising over 50 unique
types based on sequence similarity of their variable hexon epitopes.

Various

characteristics are shown here, including hemagglutination group, tumourigenicity,
transformation in tissue culture, percent of G-C in genome, and tissue tropisms. Figure
adapted from Field’s Virology, 7th edition with additional information from
(Ghebremedhin, 2014).
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induced activation of protein kinase R (PKR) (Andersson et al., 2005; Reichel et al.,
1985.; Schneider et al., 1984). Both early and late HAdV transcripts are produced by the
host RNA polymerase II (RNAPII) with the exception of VA RNA (transcribed by
RNAPIII) (Mathews and Shenk, 1991; Weinmann et al., 1974).

1.2.2 HAdV life cycle
Internalization of HAdV occurs after viral attachment to a host cell receptor via the knob
of the fiber protein (Devaux et al., 1987). Following binding of the RGD sequence
within the penton base to αvβ3 and αvβ5 integrins, receptor-mediated endocytosis ensues
(Meier and Greber, 2003; Wickham et al., 1993). Acidification of the endosome causes
partial disassembly of the viral capsid and release of the core viral particle into the
cytosol through an undefined mechanism (Greber et al., 1993; Mellman, 1992; Svensson,
1985; Varga et al., 1991). Partially-uncoated virions are subsequently trafficked to the
nucleus via an interaction between hexon and the host microtubule network (Dales and
Chardonnet, 1973; Leopold et al., 2000; Mabit et al., 2002). At nuclear pore complexes
(NPC), final uncoating occurs, allowing viral DNA bound by HAdV protein VII to be
actively transported into the nucleus (Greber et al., 1997, 1996; Karen and Hearing, 2011;
Spector et al., 2003). The attachment, entry, and subcellular trafficking phase of HAdV
infection is rapid, taking place in under two hours (Martin-Fernandez et al., 2004;
Trotman et al., 2001). In the nucleus, the viral genome becomes decorated by cellular
histones and the transcription of early genes begins (Chen et al., 2007; Komatsu et al.,
2011; Trotman et al., 2001). It is this early transcriptional phase of the viral life cycle
that is a molecular focus of the thesis and will be discussed in more detail in subsequent
sections.
As HAdV gene products encoding viral genome replication machinery accumulate, the
infection enters its late phase (Berk, 2013; Nevins et al., 1979). This can begin as soon as
six hours post-infection, depending on the type of infected cells and multiplicity of
infection (MOI). The ITRs of the HAdV genome serve as the origin of replication for the
virally-encoded DNA polymerase (Lechner and Kelly, 1977).

New genomes are

replicated via a strand-displacement mechanism not involving Okazaki fragments as
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present in cellular DNA replication intermediates.

This is concomitant with the

production of viral capsid proteins and the assembly of capsomeres in the cytoplasm
(Horwitz et al., 1969; Velicer and Ginsberg, 1970). These are subsequently transported
into the nucleus where the assembly of progeny virions occurs. An association between
the HAdV late proteins and the packaging signal in newly-synthesized genomes
facilitates the assembly of infectious particles (Daniell, 1976; Hearing et al., 1987;
Ostapchuk and Hearing, 2005). Final release of potentially 10,000 – 100,000 mature
HAdV progeny occurs as the infected cell lyses (Green and Daesch, 1961; Tollefson et
al., 1996a).

1.2.3 HAdV transcripts
Once an incoming viral genome reaches the cell nucleus, the first gene transcribed is the
early region 1A gene (E1A), driven by a strong enhancer upstream of the E1A promoter
(Hearing and Shenk, 1983; Nevins et al., 1979) (Figure 1.1). E1A is the main focus of
this thesis and will be discussed later in more detail.

Briefly, E1A performs key

functions that suppress the cell’s immune response, push the infected cell into S-phase,
and drive expression of other HAdV genes (Bayley and Mymryk, 1994; Berk, 2005;
Ferrari et al., 2014, 2008; Flint and Shenk, 1997; Fonseca et al., 2012; Gallimore and
Turnell, 2001; Pelka et al., 2008; Schaack et al., 2004). Transcription of the other early
genes follows closely after E1A and includes E1B, E2, E3, and E4. The rest of the late
proteins are encoded mainly by the Major Late transcription unit (Ahi and Mittal, 2016;
Shaw and Ziff, 1980; Tollefson et al., 2007). Most HAdV transcripts undergo extensive
splicing, increasing the potential number of protein products upon translation (Berget et
al., 1977; Berk, 2013).
Along with E1A, the E1 region of HAdV-5 includes the E1B gene encoding for two
proteins named for their molecular weights: E1B-55k and E1B-19k, both of which are
anti-apoptotic (Cuconati and White, 2002; Yew and Berk, 1992). E1B-55k functions as
an E3 ubiquitin-ligase complex promoting the ubiquitination and subsequent degradation
of the p53 tumour suppressor (Blanchette et al., 2004; Harada et al., 2002; Querido et al.,
2001). E1B-19k functions as a viral mimic of cellular Bcl-2 by binding to BAK and
BAX, blocking apoptosis via the release of mitochondrial cytochrome-c (Chiou et al.,
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1994; Farrow et al., 1995; Rao et al., 1992). E1B-55k also functions as a SUMO (small
ubiquitin-like modifier) ligase to modify p53 and force its nuclear export through an
interaction with promyelocytic leukemia nuclear bodies (PML) and works in conjunction
with HAdV open reading frame (ORF) E4-ORF6 to export viral mRNA into the
cytoplasm via recruitment of the Nxf1/Tap export machinery (Gonzalez et al., 2006;
Gonzalez and Flint, 2002; Muller and Dobner, 2008; Pennella et al., 2010; Yatherajam et
al., 2011). The combination of both HAdV E1A and E1B is also capable of transforming
primary cells in culture, demonstrating E1B’s functionality as an oncoprotein (Bayley
and Mymryk, 1994; Subramanian et al., 1991; Van den Elsen et al., 1983).
The E2 region contains three genes encoding proteins required for viral genome
replication.

These include a DNA-dependent DNA polymerase (Ad Pol), terminal

protein (TP), and a single-stranded DNA binding protein (DBP) (Challberg and Kelly,
1979; Levine et al., 1976; van der Vliet and Levine, 1973). As mentioned earlier, TP
serves as a protein primer for viral genome replication (Kelly and Lechner, 1979). DNA
replication occurs in the standard 5’ to 3’ direction by Ad Pol, which contains
exonuclease activity for proofreading capability (Field et al., 1984; King et al., 1997). As
single-stranded intermediates are produced by strand displacement, they are bound by
DBP to prevent hairpin formation and/or destruction.

Newly-synthesized genomes,

whether double or single stranded, serve as templates for additional rounds of replication
(Challberg and Kelly, 1981; Kelly and Lechner, 1979; van Breukelen et al., 2003; van der
Vliet and Levine, 1973).
The E3 region encodes for one transcript that is differentially spliced to code for several
unique protein products, including receptor internalization and degradation complex αβ
(RIDαβ), gp19k, 14.7k, 12.5k, 6.7k, and adenovirus death protein (ADP) (Berk, 2013;
Lichtenstein et al., 2004). E3 proteins are all involved in modulating cell death and
immune signaling. In conjunction with other E3 proteins, RIDαβ blocks extrinsic death
signal ligands such as TNF (tumour necrosis factor), Fas ligand, and TRAIL (TNFrelated apoptosis-inducing ligand) (Benedict et al., 2001; Friedman and Horwitz, 2002;
Shisler et al., 1997; Tollefson et al., 2001). RIDαβ downregulates the proapoptotic
receptors of these ligands by promoting internalization and subsequent lysosomal
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degradation. E3-gp19k is a transmembrane glycoprotein that inhibits the cell-surface
function of major histocompatibility complex class I (MHC I) (Burgert et al., 1987;
Burgert and Kvist, 1985; Wold et al., 1985). It promotes immune evasion by binding and
retaining MHC I molecules in the endoplasmic reticulum (ER) and also blocks the
tapasin-mediated peptide loading of MHC (Bennett et al., 1999). E3-14.7k binds and
inhibits the apoptotic signaling activities of TNF, NF-κB, and Caspase 8 (Carmody et al.,
2006; Gooding et al., 1990, 1988; Kim and Foster, 2002). E3-6.7k works with RIDαβ to
downregulate TRAIL and TNF signaling via blockage of arachidonic acid release
(Benedict et al., 2001; Moise et al., 2002).

Despite its genomic locus, ADP is

predominantly produced later during infection and serves a proapoptotic role mediating
release of progeny virus via cell lysis (Tollefson et al., 1996b, 1992). Lastly, E3-12.5k
has no known function and is not required for viral replication, yet its presence is highly
conserved among various HAdV species suggesting it may play an important, yet
undiscovered, role (Hawkins and Wold, 1992).
Similar to E3, the HAdV E4 region encodes one mRNA that is differentially-spliced to
encode many protein products. These include E4ORF1, E4ORF3, E4ORF4, E4ORF6,
and E4ORF6/7 and are involved in a wide array of biological functions (Berk, 2013;
Täuber and Dobner, 2001). Sequences encoding for additional ORFs have also been
predicted but have either no known function or are undetectable during infection.
Furthermore, the deletion of these ORFs via mutagenesis does not impair HAdV
replication.

Both E4ORF1 and E4ORF4 enhance viral replication by modulating

metabolism. E4ORF1 activates the mechanistic target of rapamycin (mTOR) pathway by
activating phosphatidylinositol 3-kinase (PI3K) (Frese et al., 2003; O’Shea et al., 2005).
It also modulates glycolysis through an interaction with MYC resulting in cellular
metabolites being rerouted for nucleotide biosynthesis (Miyake-Stoner and O’Shea, 2014;
Thai et al., 2014). E4ORF4 also activates mTOR independently of E4ORF1, by binding
cellular phosphatase PP2A (O’Shea et al., 2005; Zhang et al., 2011).

Though the

mechanistic details are unclear, this function increases viral replication under nutrientlimiting conditions. E4ORF3 inhibits the cell’s DNA double-stranded break response
(DSBR) by sequestering the MRN DNA damage complex (MRE11/RAD50/NBS1)
(Araujo et al., 2005; Evans and Hearing, 2005; Sohn and Hearing, 2012; Stracker et al.,

10

2002). It also inhibits antiviral functions of PML bodies mediated through the PMLassociated protein, Daxx, and inhibits p53 (in an E1B-independent manner) by inducing
heterochromatin at p53-targeted promoters (Soria et al., 2010; Ullman and Hearing,
2008).

E4ORF6 works mainly in a complex with E1B-55k to either degrade p53

(described earlier) (Dobner et al., 1996; Harada et al., 2002; Querido et al., 2001) or
perform various other tasks to enhance viral DNA replication, nuclear export of viral
mRNA, and blocking host protein synthesis (Bridge and Ketner, 1990; Halbert et al.,
1985; Yatherajam et al., 2011). Finally, E4ORF6/7 binds cellular E2F transcription
factors (TFs) and recruits them to the HAdV E2 promoter, inducing transcription of the
aforementioned E2 genes (Hardy et al., 1989; Helin and Harlow, 1994; Huang and
Hearing, 1989).
Overall, the early gene products serve to reprogram/reorganize the cell into an optimal
environment for HAdV replication, by inducing DNA replication, and protecting progeny
from destruction by immune responses (Berk, 2013). The late products then form the
basis for assembling and egressing mature virions for infecting new hosts. Along with
the U-exon protein (UXP), the major late transcription unit codes for both the structural
and non-structural proteins required for virion assembly and packaging (Ahi and Mittal,
2016; Shaw and Ziff, 1980; Tollefson et al., 2007). These arise from differential splicing
of the major late mRNA into a plethora of products, which are further classified into 5
regions (L1-L5). Penton, hexon, and fiber (described earlier) are encoded on L2, L3, and
L5 respectively.

1.2.4 HAdV diversity and virulence
Historically, HAdV types were categorized into various serotypes by their resistance or
sensitivity to neutralization by antisera against other HAdV types (Wold and Ison, 2013).
More recently, molecular techniques utilizing amino acid or nucleotide sequence
similarities within the main neutralizing epitopes (the hexon capsid protein) have been
adopted to classify different types (Aoki et al., 2011; Jones et al., 2007; Madisch et al.,
2005).

Consequently, there are currently seven accepted HAdV species (A-G)

encompassing over 50 distinct HAdV types (Adams et al., 2017) (Figure 1.2). All
HAdVs are quite species-specific in their ability to infect and replicate within hosts, as is
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the case for non-human adenoviruses as well. Even nonhuman primates make typically
poor hosts for HAdV and these viruses are generally non-pathogenic in animals (Wold
and Ison, 2013). In cell culture models, modest replication will occur in cells from rats,
mice, dogs, pigs, and hamsters (Jogler et al., 2006; Ternovoi et al., 2005; Thomas et al.,
2006; Toth et al., 2005). However, human-derived immortalized cell lines (such as
HEK293, HeLa, and A549) are by far the best culture system for abundant production of
HAdV.
Epidemiologically, HAdVs are ubiquitous in the human population (Ghebremedhin,
2014; Lion, 2014; Wold and Ison, 2013). The lower-numbered HAdV types (such as
HAdV-5) are especially seroprevalent, particularly in children and adolescents.
Transmission occurs via the fecal-oral route or aerosols, leading to viral entry through the
mouth, nasopharynx, and ocular tissues (Couch et al., 1966; Fox et al., 1977; Russell et
al., 2006). Most HAdVs share similar cellular receptors (discussed earlier), however the
mechanisms underlying preferred organ/tissue tropisms are not well understood. HAdVs
primarily infect a wide array of tissue sites, depending on the species (Ghebremedhin,
2014; Law and Davidson, 2005; Lenman et al., 2015; Nicklin et al., 2005; Wold and Ison,
2013; Zhang and Bergelson, 2005). These include respiratory tissues (species A, B, C,
E), gastrointestinal tract (species A, B, C, D, and especially F and G), and eye (B, D, E).
As human pathogens, HAdVs are well-adapted to their hosts and typically cause
asymptomatic or mild infections (Ghebremedhin, 2014; Lion, 2014; Wold and Ison,
2013). However, these infections can also cause acute respiratory disease (ARD), most
commonly in children and military recruits.

HAdV is thought to contribute to

approximately 8% of the global viral disease burden, including 10% of all febrile
illnesses in children. More severe disease can include pharyngitis, gastroenteritis, and
conjunctivitis depending on the site of infection and HAdV species responsible (Binder et
al., 2017). In young children or immunocompromised individuals, HAdV infection can
cause pneumonia, fulminant hepatitis, or encephalitis (Krilov, 2005; Walls et al., 2003).
Occasionally, severe outbreaks have occurred, such as the emergence of fatal pneumonia
cases linked to HAdV-14 across multiple American states in 2005 (Kajon et al., 2010;
Lewis et al., 2009; Metzgar et al., 2007; Seto et al., 2009).
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Figure 1.3. Comparison of human and simian adenoviruses.
Phylogenetic analysis of HAdVs and SAdVs based on the amino acid sequence of the
viral E1A proteins. E1A sequences were imported into the PHYLIP suite of software to
calculate

phylogenetic

distance

using

the

programs

PROTDIST.EXE

and

NEIGHBOR.EXE (Dr. Joe Felsentein, University of Washington, Seattle, WA) and
visualized with TreeView (Page, 1996).

Branch lengths are proportional to genetic

distance and some regions are magnified by the indicated factor for better visualization.
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At the cellular level, HAdV infection causes characteristic cytopathic effects (CPE), such
as enlarged cell nuclei and formation of inclusion bodies, eventually leading to cell death
(Boyer et al., 1959; Kasel, 1979; Wold and Ison, 2013). Host cell synthesis of DNA,
RNA, and protein are also broadly inhibited. The viral replication cycle in primary sites
of infection is typically rapid and cytolytic; however, virus can be shed at low levels for
months after visible symptoms have passed, often from secondary tissue sites (King et al.,
2016c; Lion, 2014). HAdV can sometimes establish persistent-style infections in humans
(Abken et al., 1987; Garnett et al., 2009; Rowe et al., 1953). While some recent studies
have revealed molecular details on how HAdV can re-task the host cell’s own antiviral
response to establish persistence, these have been difficult to reproduce in cell culture and
are poorly understood (Zheng et al., 2016). Persistent infections are characterized as
long-term with occasional and low-level shedding of progeny virus that may cause little
or no harm to host tissue (Zhang et al., 2010). Persistence is an effective and common
strategy for maintaining virus production beyond the primary infection, while
simultaneously avoiding immune surveillance. This alternative lifestyle likely benefits
the virus by allowing the continuous production of new progeny at intermediate levels
over a vastly extended timeframe. It also partially explains why HAdV was originally
isolated from the secondary lymphoid tissues (adenoids and tonsils) of visibly healthy
individuals in 1953 (Rowe et al., 1953).
Despite the label of being a DNA tumour virus, HAdV does not cause cancer in humans
(Mackey et al., 1976; Mende et al., 2004). Some HAdVs are, however, tumourigenic in
rodent species and can stably transform primary rodent or human cells in culture (Berk,
2013; Freeman et al., 1967; Gallimore, 1972; McBride and Wiener, 1964).

These

oncogenic properties were initially observed in 1962 when injection of HAdV-12 into
newborn hamsters induced malignant and aggressive tumours (Trentin et al., 1962). This
was the first demonstration of a human virus causing cancer (albeit in a rodent model)
and caused a burgeoning interest in the field of adenovirology research. Transformation
by HAdV requires the activities of both its major oncoproteins, E1A and E1B, a process
driven largely by the many protein-protein interactions made by these viral antigens with
host target proteins (Graham et al., 1977; Houweling et al., 1980; Subramanian et al.,
1991; Van den Elsen et al., 1983; Whittaker et al., 1984).

Following these initial
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discoveries, researchers have used HAdV as a model for uncoupling the molecular
pathways that lead to cancer when dysregulated. The E1A protein itself has undoubtedly
had the largest impact on these findings and continues to be utilized as a molecular tool
today.
While considered rare, cross-species transmission events of HAdV have evidently
occurred between humans and nonhuman primates (Ersching et al., 2010; Hoppe et al.,
2015; Robinson et al., 2013; Roy et al., 2009; Wevers et al., 2011). Adenovirus zoonosis
(the ability to transmit from human to non-human and vice versa) has given rise to
multiple HAdV types now endemic in humans. HAdV-4 (the only member of species E)
is a recombinant virus comprised of hexon epitopes of HAdV-16 (encompassing 2.5% of
the whole genome) within the backbone of simian adenovirus-26 (SAdV) (Dehghan et
al., 2013).

The newly-classified and lone member of species G (HAdV-52) has

extremely low detection rates in humans and is most closely related to SAdV-1,
suggesting the virus has recently crossed into the human population (Jones et al., 2007;
Lenman et al., 2015). The closest HAdV relatives to HAdV-52 are those of species F
(HAdV-40 and -41) as they have the highest amino acid similarity (Figure 1.3). Species
F and G contain the only HAdV types with two distinct fiber genes, and all readily infect
the GI tract (Kidd et al., 1993).

Cross-talk between adenoviruses of humans and

nonhuman primates is still ongoing, as recently a novel titi monkey adenovirus (TMAdV)
caused a deadly pneumonia outbreak in a New World monkey colony in California (Chen
et al., 2011). Most of the monkeys died, one of the human workers became seriously ill,
and the virus was also transmitted to a family member of this worker. The fact that
TMAdV could readily transmit between both monkeys and humans demonstrates that
zoonotic adenoviruses need to be monitored as potentially deadly causes of viral disease
outbreaks.

1.3 HAdV Early Region 1A (E1A)
1.3.1 E1A gene, transcripts, and protein products
The HAdV E1A gene is found at the very left end of the viral genome, downstream of a
strong transcriptional enhancer and the left ITR (Hearing and Shenk, 1983; Nevins et al.,
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Figure 1.4. HAdV-5 E1A splice products.
(A) The E1A transcript is differentially spliced into 5 products, each named for their
sedimentation coefficients (13S, 12S, 11S, 10S, and 9S). Black bars represent coding
RNA while the lines represent excised sequence. All splicing events maintain the same
translational reading frame except for the C-terminus of the 9S mRNA (denoted by the
checkered bar). (B) Diagram of the E1A protein products resulting from differential
splicing. Conserved regions 1 – 4 are denoted as is each protein’s length in amino acid
residues. The unique sequence in the 55R product is denoted by the checkered bar.
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1979) (Figure 1.1). E1A is the first viral gene expressed upon HAdV infection and is
essential for productive viral replication unless extremely high multiplicities of infection
are used (Jones and Shenk, 1979). Broadly, E1A-encoded products function to activate
expression of the other HAdV early genes (Berk et al., 1979; Montell et al., 1984, 1982;
Winberg and Shenk, 1984) and condition the cellular environment into a compliant state
amenable to an efficient and successful HAdV infection (Bayley and Mymryk, 1994;
Berk, 2005; Flint and Shenk, 1997; Gallimore and Turnell, 2001; Pelka et al., 2008). The
E1A transcript is differentially spliced into five isoforms, denoted by their sedimentation
coefficients (13S, 12S, 11S, 10S, and 9S in HAdV-5) (Berk, 2013) (Figure 1.4A). All
splicing events preserve the reading frame except for the 9S product, which has a unique
29 amino acid stretch in its C-terminus (Virtanen and Pettersson, 1983) (Figure 1.4B).
The two largest mRNAs yield proteins of 289 and 243 amino acids respectively and are
expressed highly during the early phase of infection (Perricaudet et al., 1979). These
differ only by the absence of an internal 46 amino acid stretch in the smaller isoform.
Both localize to the nucleus and the cytoplasm and carry out the majority of E1A’s
known functions (Rowe et al., 1983; Turnell et al., 2000). The three smaller isoforms
(encoding proteins of 217, 171, and 55 amino acids) are produced at later times postinfection (Spector et al., 1978; Stephens and Harlow, 1987; Svensson et al., 1983;
Ulfendahl et al., 1987). While they can enhance the HAdV life cycle, their precise roles
are far less-characterized than their larger and more highly-expressed counterparts (Miller
et al., 2012). Sequence comparisons of the largest E1A protein across different HAdV
species revealed four regions of sequence similarity termed conserved region (CR) 1
through 4 (Avvakumov et al., 2004, 2002b; Kimelman et al., 1985; van Ormondt and
Hesper, 1983) (Figure 1.5). The highly conserved nature of these sequences suggests
they play crucial roles in the viral life cycle.

1.3.2 E1A is a viral hub protein
E1A’s crucial biological role is a direct result of its numerous protein-protein interactions
within the host cell. In contrast to other well-studied viral hub proteins, E1A has no
intrinsic DNA-binding or enzymatic activities (Avvakumov et al., 2002a; Chatterjee et
al., 1988; Zu et al., 1992); instead it acts in a modular fashion by binding to and altering
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Figure 1.5. Alignment of E1A proteins from representative members of each HAdV
species.
The amino acid sequences of the largest E1A isoforms from HAdV-3, -4, -5, -9, -12, -40,
and -52 (representing species B, E, C, D, A, F, and G respectively) are shown. Sequence
alignment was performed using CLUSTAL W (Thompson et al., 1994). Alignments were
edited manually using GeneDoc as previously described (Avvakumov et al., 2004) and
shaded to four levels of conservation using the Dayhoff PAM 250 score table. The
positions of the conserved regions are indicated as solid bars.
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the functions of over 50 distinct cellular targets (Pelka et al., 2008) (Figure 1.6). Indeed,
many of these targets are highly-connected hub proteins themselves. By embedding itself
so deeply within the cell’s protein interaction network, E1A exerts tremendous control
over both viral and host gene expression (Berk et al., 1979; Ferrari et al., 2014, 2008;
Horwitz et al., 2008). Consequently, E1A is able to modulate the production of other
HAdV gene products, as well as suppress the cell’s immune response, force the cell into
S phase, and block differentiation.
As a relatively small protein, E1A’s ability to bind promiscuously to host targets and
affect several cellular processes stems from the many features contained within its
sequence. Consistent with the constraints of viruses’ limited coding potential, E1A
serves as a prime example of efficiency; as typifies many hub proteins (both viral and
cellular) E1A is largely unstructured (with only a few globular regions) and is packed
with short linear interaction motifs (SLiMs) (Davey et al., 2011; Ferreon et al., 2009;
Pelka et al., 2008) (Figure 1.7). SLiMs allow E1A to exist in a dynamic and flexible
state, enabling it to sample various conformations to carry out its plethora of overlapping
protein-protein interactions (Dunker et al., 2005; Kim et al., 2008). While CR1 and CR2
of E1A bear some similarity to parts of human papillomavirus (HPV) E7 and
polyomavirus (HPyV) large T antigen, E1A has no known cellular ortholog (Figge et al.,
1988; Phelps et al., 1988; Vousden and Jat, 1989). Instead, its protein interaction motifs
have likely evolved independently as functional mimics of cellular counterparts,
presumably providing selective advantages for HAdV.

1.3.3 E1A can act as either an oncoprotein or tumour suppressor
Radical alterations to cellular protein interaction networks are seen not only during
infections by DNA tumour viruses, but also in many types of cancer. Given that the
functions of viral oncoproteins like E1A and the cis-acting genome variations found in
tumours often converge on the same pathways, E1A is a valuable tool for identifying host
proteins affected by the processes of transformation and tumourigenesis (RozenblattRosen et al., 2012). In fact, trans-acting viral products have been demonstrated to be
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Figure 1.6. The HAdV-5 E1A interactome.
Diagrammatic representation of the E1A protein interaction network. The network was
constructed using Gephi 0.9.1 with data from BioGRID build 3.4.144. E1A is placed in
the centre of the network with its primary interacting partners depicted as the large circles
emanating outward. Each primary interactor is supported by at least two peer-reviewed
publications and is sized proportional to the number of its own binding partners. These
secondary interactors are depicted as the smaller circles and are coloured and positioned
near the primary E1A interactor to which they bind.
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capable of successfully predicting cancer-relevant targets at rates on par with functional
genomics and large-scale cataloguing of tumour mutations.
As mentioned previously, HAdV does not cause cancer in humans as the lytic infection is
typically rapid and self-limiting and the viral genome does not normally integrate into the
host genome (Lion, 2014; Mackey et al., 1976; Mende et al., 2004). However, E1A alone
is capable of immortalizing cells in culture when introduced by stable transfection
(Graham et al., 1977; Houweling et al., 1980; Whittaker et al., 1984). In combination
with a cooperating oncogene, such as HAdV E1B or activated Ras, it can fully transform
these cells (Gallimore and Turnell, 2001; Subramanian et al., 1991; Van den Elsen et al.,
1983). For instance, these properties led to the creation of the widely-used HEK293 cell
line which stably express the E1 region of HAdV-5, inserted into chromosome 19 of a
cell derived from a primary human embryonic kidney culture (Graham et al., 1977; Louis
et al., 1997).

E1A is also required for the ability of HAdV to cause tumours in

immunocompromised rodents (Trentin et al., 1962).

Consequently, E1A can help

identify critical regulators of cell growth and gene expression that are likely relevant to
cancer.
Paradoxically, exogenous expression of E1A in previously-transformed cell lines can
suppress oncogenic phenotypes (Deng et al., 2002, 1998; Frisch and Mymryk, 2002;
Mymryk, 1996).

This ability to act as a tumour suppressor reduces metastasis,

angiogenesis, and tumourigenicity in vivo. E1A can also induce apoptosis and convert
cells from a mesenchymal-like to an epithelial-like cell type in this context. While the
complete mechanisms driving E1A’s oncogenic and tumour suppressive abilities are not
yet completely understood, E1A can be used as a tool to enhance knowledge of these
fundamental processes and shed insight on how both viruses and cancers disrupt them.

1.3.4 E1A as a tool for identifying eukaryotic regulatory proteins
The E1A protein is extremely modular and multifunctional, as each of its conserved
regions (Figure 1.5) can function differently and independently from each other (Bayley
and Mymryk, 1994). This highly modular nature has made E1A ideal for mutagenesis
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studies, as insertions, deletions, and point mutations typically only affect a subset of
functions while leaving others intact. Even small fragments of E1A protein can retain
functionality when expressed in isolation. Thus, E1A has a remarkable history for being
used to discover and study novel host regulatory proteins (Pelka et al., 2008).
Many of E1A’s binding partners are intimately linked with transcription and cell cycle
control (Granberg et al., 2005; White, 2001; Zhao et al., 2003) (Figure 1.6). Therefore,
the study of these virus-host interactions has revealed deep molecular knowledge of vital
cellular processes.

One well-known example is the interaction between E1A and

retinoblastoma protein (pRb), which was the first example of a viral oncoprotein
interacting with a tumour suppressor (Whyte et al., 1988). Here E1A used two distinct
binding interfaces to supplant the E2F family of proteins from pRb, benefitting the virus
in multiple ways (Fattaey et al., 1993). First, released E2Fs induce activation of HAdV
genes, particularly the E2 transcription unit (indeed, E2Fs derive their proper name from
this initial observation) (Reichel et al., 1987). Second, E2Fs also activate E2F-responsive
cellular genes, which control entry into S-phase of the cell cycle (Ghosh and Harter,
2003; Pagano et al., 1992). In addition, the molecular characterization of the E1A-pRb
interaction led to the identification of the LxCxE SLiM (Figure 1.7), which was also
subsequently found to be required for pRb-binding by a number of cellular proteins
(Avvakumov et al., 2004; Corbeil and Branton, 1994; Dahiya et al., 2000; Ikeda and
Nevins, 1993).
Another well-characterized transcriptional repressor, C-terminal binding protein (CtBP1
and 2), was also discovered through its interaction with HAdV E1A (Boyd et al., 1993).
As its name suggests, CtBP binds to E1A via a PxDLS SLiM in E1A’s C-terminus
(Avvakumov et al., 2004; Quinlan et al., 2006; Schaeper et al., 1995). E1A appears to
compete with endogenous proteins to bind CtBP1/2 and relieve its repression of host
genes involved in cell growth and apoptosis (Bergman and Blaydes, 2006; Chinnadurai,
2009, 2002). E1A may also use CtBP1/2 to bring itself to, and activate, promoters that
are normally repressed (effectively converting these cellular repressors into coactivators)
(Bruton et al., 2008). These interactions between E1A and various eukaryotic regulatory
proteins have been widely exploited in defining the molecular biology of the cell.
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Figure 1.7. Diagrammatic representation of E1A’s protein interaction motifs.
Experimentally-validated protein interaction motifs are displayed. These include both
SLiMs and globular domains. Generic α-helix and zinc finger structures were adapted
from the Protein Data Bank (PDB): 2GLH and 1GDC (Andreotti et al., 2006; Baumann et
al., 1993). Notable interactions with cellular proteins conferred by these motifs are also
listed.
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Therefore, by continuing to use genetic and biochemical approaches to discover novel
interacting partners of E1A we may identify yet unknown proteins important in various
cellular processes.

1.3.5 E1A modulates viral transcription
Many viruses require host enzymes to produce nucleic acid polymers in the form of either
viral genomes and/or transcripts. HAdV is no exception and requires both host RNA
polymerases and DNA-binding transcription factors in order to transcribe its own genes
(Berk, 2013). The HAdV genome has evolved to contain many cis-acting elements
capable of engaging with RNAPII and various TFs, but the coordination of these virushost interactions is multifactorial and complex (Fernandes and Rooney, 1997; Hurst and
Jones, 1987; Kovesdi et al., 1986; Parks et al., 1988; Reichel et al., 1987; SivaRaman and
Thimmappaya, 1987; Watanabe et al., 1988; Williams et al., 1990; Wu and Berk, 1988).
E1A’s ability to act as a molecular hub is crucial in this context. It can associate with
various eukaryotic transcriptional components and modify their activities to initiate viral
gene expression (Figure 1.6). As such, E1A has served as a paradigm for studying viral
transcription via the retasking of cellular TFs.
A productive HAdV infection requires E1A-mediated activation of the other viral early
genes, as they encode crucial components that perform various tasks during infection
including: inhibiting apoptosis, replicating the viral genome, suppressing the immune
response, and transporting viral mRNA (discussed in more detail above) (Berk, 2013).
Transactivation (a portmanteau of ‘transcriptional activation’) ability of E1A has been
largely mapped to its N-terminus and CR3 regions (both of these can drive reporter gene
expression when fused to a heterologous DNA-binding domain), though E1A makes
protein-protein interactions along its entire sequence that contribute to modulating
transcription, consistent with its modular nature (Bondesson et al., 1994; Lillie and
Green, 1989; Martin et al., 1990; Yousef et al., 2009).
Transactivation by E1A has been best-characterized within its CR3 region, one of the few
portions of E1A containing a structure (a zinc finger) (Culp et al., 1988; Fahnestock and
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Lewis, 1989; Jelsma et al., 1988). Via this region, E1A binds and recruits several
components of TFIID complex to nucleate formation of the RNAPII preinitiation
complex (PIC) (Geisberg et al., 1994; Webster et al., 1991; Webster and Ricciardi, 1991).
These include TATA-binding protein (TBP) and various TBP-associated factors
(Geisberg et al., 1995; Mazzarelli et al., 1995). Unsurprisingly, these interactions alone
are necessary but not sufficient for wild-type (WT)-levels of E1A transactivation. E1A
also binds MED23, a component of the multi-protein Mediator adaptor complex, and its
recruitment to promoters serves as a potent activation step (Ablack et al., 2010; Boyer et
al., 1999; Cantin et al., 2003; Stevens et al., 2002). While E1A lacks direct DNA-binding
ability itself, it does bind to several promoter-targeting transcription factors, including
members of the cAMP (cyclic adenosine monophosphate) response element/activating
transcription factor (ATF) family, activator protein-1 (AP-1), upstream stimulatory factor
(USF), and Sp1 (Liu and Green, 1994, 1990; Ström et al., 1998). Additionally, E1A CR3
binds coactivators (such as pCAF) as well as repressors of transactivation, including
GCN5 and BS69 (Ablack et al., 2012; Hateboer et al., 1995; Shuen et al., 2002).
Therefore, this portion of E1A appears to coordinate the presence of sequence-specific
transcription factors with both activating and repressive complexes, allowing for tight
control of viral transcription kinetics.
The N-terminus of E1A also can enhance transcription and it is densely-packed with
many protein-protein interaction sites (Figure 1.8). These include motifs that confer
interactions with transcription factors/cofactors like p300/CBP, myogenein, AP-2, p400,
protein kinase A (PKA), Bre1, TRRAP, thyroid hormone receptor (TR), components of
the proteasome, among others (Arany et al., 1995; Deleu et al., 2001; Eckner et al., 1994;
Fax et al., 2001; Fonseca et al., 2012; Fuchs et al., 2001; Grand et al., 1999; King et al.,
2016a; Meng et al., 2003; Somasundaram et al., 1996; Taylor et al., 1993; Turnell et al.,
2000; Wahlström et al., 1999). Many of these interactions remain quite uncharacterized.
It is clear, however, that different regions of E1A cooperate to maximize control over
specific interaction partners or establish novel connections servicing viral gene
expression. Instead of encoding its own RNA polymerase and proteins to act as DNAbinding TFs, HAdV can use a single viral hub (E1A) to coordinate a massive reshuffling
of host transcriptional machinery. Excitingly, the roles of many binding partners and
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Figure 1.8. Binding partners of the N-terminus of E1A.
Protein sequence of HAdV-5 E1A N-terminus (residues 1-82) is shown. Key features are
denoted by blue text and include the N-terminal transactivation domain (TAD), nuclear
export signal (NES), and a non-canonical nuclear localization signal (NLS). The mapped
binding sites of cellular target proteins are depicted by dashed lines. Less-characterized
interactors or those that were experimentally-demonstrated only in yeast are italicized.
Note that several interactors have multiple binding sites on full-length E1A, including
TBP, p300/CBP, and Rb and family members.
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their place within the E1A proteome still require vigorous investigation to delineate their
potential roles in transcription in both infected and uninfected conditions.
Research on E1A-mediated viral gene expression has largely focused on the initiation
step of transcription. However, transcription is a complex, multi-stage process involving
regulation of initiation as well as elongation and termination (Weake and Workman,
2010). More recent studies on E1A have revealed that it also plays a role in enhancing
the elongation step of HAdV transcripts produced by RNAPII. The potential for E1A to
enhance elongation was originally established from observations that cellular factors
recruited to promoters in an E1A-dependent manner were also found associated on
downstream areas being actively transcribed (Rasti et al., 2006). These initial findings
were expanded upon in studies examining E1A’s direct interaction with MED23.
MED23 bridged associations between E1A and multiple other components of the
Mediator complex, including MED26 and MED26-associated super elongation complex
(SEC) (Vijayalingam and Chinnadurai, 2013). These interactions all contributed to E1Amediated activation of HAdV early gene expression. However, the SEC also contains
factors known to regulate the elongation of mRNA transcripts produced by RNAPII.
Specifically, the SEC can relieve pausing of RNAPII on nascent transcripts, which serves
as a form of checkpoint control (Luo et al., 2012). While a specific role for the SEC on
elongation of HAdV transcripts wasn’t elucidated, the authors’ findings demonstrated
that E1A-mediated transactivation was likely more complex than merely triggering the
efficient formation of pre-initiation complexes. Subsequent investigation into elongation
effects conferred by E1A resulted in discovery of a bona fide mechanism driving
elongation of HAdV transcripts (Fonseca et al., 2014). E1A associated indirectly with
the human Paf1 complex, composed of several proteins that accompany RNAPII from
promoter to 3’ end of mRNA. In this capacity, Paf1 participates in multiple aspects of
transcription including recruitment of histone modifying enzymes, assembly of
elongation factors that prevent dissociation of RNAPII from template, and association
with factors required for proper termination of newly-synthesized mRNA (Fonseca et al.,
2013; Tomson and Arndt, 2013).

Loss of an E1A-Paf1 interaction during HAdV

infection did not noticeably affect the initiation of HAdV early gene expression;
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however, there was a drastic decrease in both E1A and RNAPII occupancy at the 3’ ends
of early transcription units, implying a severe defect in elongation efficiency of these
viral transcripts. This was confirmed by demonstrating a decreased frequency both of
full-length transcripts and H3K36 trimethylation (an elongation-specific chromatin mark)
in these conditions (Butler and Dent, 2012; Fonseca et al., 2014).
The aforementioned studies have established an enhanced model of E1A-mediated viral
transcription that includes both initiation- and elongation-specific functions; however, the
understanding of E1A’s effects on elongation is in its infancy. If and how E1A interacts
with components in other complexes that comprise elongation machinery remains
unknown, as does a role for E1A in modulating elongation of host transcripts. Also,
while

other

human

pathogens

such

as

influenza

A

virus

(IAV),

human

immunodefficiency virus (HIV), and herpes simplex virus (HSV) have been previously
shown to manipulate elongation in various ways, it remains to be determined whether
E1A from all HAdV species behave similarly (Fox et al., 2017; Lu et al., 2013; Pflug et
al., 2017).

1.3.6 E1A modulates cellular transcription
The dawn of next-generation sequencing (NGS) technology aided in expanding the scope
of E1A-mediated gene expression to include a global view of host cell transcription.
During HAdV-5 infection of primary cells, it was discovered that E1A associated with
the regulatory regions of more than 17,000 host genes (Ferrari et al., 2008; Horwitz et al.,
2008). It was also demonstrated that E1A could either activate or repress many of these
genes via the recruitment of cellular transcriptional machinery in a manner similar to how
it controls viral gene expression (discussed above). Despite large sets of published data,
the means by which E1A individually regulates the overwhelming number of host target
genes is still being dissected (Ferrari et al., 2014, 2009; Radko et al., 2015). E1A can
recruit transcriptional activators (such as p300/CBP) to activate transcription at
previously-repressed sites. Alternatively, it can use these same interactions to recruit
itself, along with transcriptional repressors (like pRb and family members p130 and
p107), to suppress transcription (Horwitz et al., 2008). E1A-mediated modulation of host
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transcription is therefore multifaceted, allowing a mere single viral protein to assert
diverse effects on the global kinetics of cellular gene expression.
Additionally, these large-scale studies have revealed how E1A can drastically alter the
regulation of cellular chromatin at the epigenetic level (Ferrari et al., 2012, 2008).
Histone post-translational modifications (hPTMs) offer an additional level of host genetic
regulation by loosening or restricting access of transcriptional machinery to nucleosomes
(Chi et al., 2010). Highlighting E1A’s ability to invade every aspect of an infected cell’s
protein network, E1A causes extensive reorganization of these PTMs during HAdV
infection. E1A can sterically inhibit histone-modifying enzymes or act as a bridge
between enzyme and substrate to enhance and establish novel connections. For instance,
E1A can restructure chromatin at cellular Cdc6 and cyclin A genes to stimulate entry into
S-phase (Ghosh and Harter, 2003). E1A displaces the repressive E2F4 and p130 proteins
associated with histone deacetylase (HDAC1/2) and Suv39H1 histone methylase, which
would normally induce repressive heterochromatin. This allows acetylation of H3K9 by
the E1A-bound TRRAP-PCAF-p400 acetyltransferase complex, activating transcription
from these loci (Fuchs et al., 2001; Sha et al., 2010). Similarly, E1A’s concomitant
associations with lysine acetyl transferases (KAT), p300 and CBP, and thousands of host
gene promoters results in widespread acetylation of H3K18 across the human genome
(Ferrari et al., 2008; Horwitz et al., 2008). Consequently, many cellular genes become
transcriptionally active from these sites including those involved in cell cycling and
macromolecular synthesis.

A more recent study from our lab demonstrated E1A’s

interaction with Bre1 (an E3 ubiquitin ligase involved in modifying histone H2B) could
block Bre1’s ability to monoubiqutinate H2B during HAdV infection (Fonseca et al.,
2012). This resulted in repression of type I interferon-stimulated genes (ISGs) which
normally require this hPTM for their full transcription.
The ultimate purpose for E1A’s transcriptional reprogramming of host genes is to block
innate immunity, induce cell cycle, and reverse the differentiated phenotype in quiescent
cells (Berk, 2013, 2005; Pelka et al., 2008). This provides the virus with abundant
precursor pools of dNTPs and NTPs for viral DNA and RNA synthesis, and activates
pathways required for protein synthesis. It also represses antiviral response genes that
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would otherwise inhibit the virus’ replication and spread to neighbouring cells. The sum
of these effects is the creation of a host environment that is more optimal for a productive
HAdV life cycle. Consequently, how E1A repurposes endogenous host factors to alter
these downstream pathways remains an intense area of molecular research.

1.4 Protein Kinase A (PKA)
1.4.1 Discovery and structure of PKA
Phosphorylation was first demonstrated to be a means of regulating protein activity in
1958 with the observation that an enzyme, phosphorylase kinase (PHK), was activated by
the addition of a phosphate moiety (Krebs et al., 1959; Krebs and Fischer, 1956). Over
the past sixty years, the widespread importance of phosphorylation in cell biology has
been conclusively demonstrated and extensively studied (Vlastaridis et al., 2017). Entire
protein networks in cells can be regulated by the additions or subtractions of phosphate
molecules, which can act as reversible switches for protein binding and localization, or
modulate the assembly of complex tertiary and quaternary structures (Taylor et al., 2013,
2012; Welch et al., 2010; Westheimer, 1987). Remarkably, approximately 2 percent of
the entire human genome encodes for protein kinases (Manning et al., 2002).
Protein kinase A (PKA) was the second kinase ever discovered (Walsh et al., 1968), was
the first to have its sequence analyzed (Shoji et al., 1981), and the first to have its
structure crystallized (Knighton et al., 1991). Consequently, much of what is known
about phosphorylation, intracellular signaling, and kinase structure stems from using
PKA as a model protein. PKA genes are conserved down to fungi or even single-celled
organisms such as Plasmodium falciparum and Trypanosomes (Haste et al., 2012;
Kannan et al., 2007).

PKA can therefore be considered an ancient evolutionary

mechanism contributing to the conversion of extracellular signals into biological
responses.
PKA primarily exists as an inactive, tetrameric holoenzyme (Taylor et al., 2013, 2012)
(Figure 1.9). Two catalytic subunits (C) are bound by two regulatory subunits (R) that
exist as a constitutive homodimer. In mammalian cells, there are three isoforms of the Csubunit (Cα, Cβ, and Cγ) (Skalhegg and Tasken, 2000; Søberg et al., 2013; Turnham and
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Figure 1.9. Organization and function of PKA.
(A) R-subunits contain a docking/dimerization (D/D) domain in their N-terminus and
two cyclic nucleotide binding (CNB) domains in their C-terminus. These structural
regions are separated by a flexible linker sequence containing an inhibitory site (IS) that
binds the catalytic subunit to maintain its inactive state. C-subunits are comprised of two
structural lobes that when folded, surround the active site cleft. The N-terminal lobe
binds ATP while the C-terminal lobe forms the framework for catalytic machinery and
binding of substrates. (B) Illustration of PKA R- and C-subunit interactions. Adapted
from PDB: 2QVS (Wu et al., 2007). (C) General PKA mechanism and downstream
function. R-subunit homodimers bind two C-subunits, completing an inactive tetrameric
holoenzyme. When local levels of cAMP rise, the binding of this 2nd messenger to the Rsubunit CNB domains causes conformational changes that free the C-subunits. Nearby
protein substrates with the consensus sequence: R-R-x-S/T-Φ can be phosphorylated on
Ser or Thr residues in an ATP-dependent manner. PKA functions in both the cytoplasm
and nucleus in a variety of biological pathways.
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Scott, 2016). These share about 93% amino acid identity and are functionally-similar.
However, Cγ is expressed only in the testis and Cβ is most highly expressed in neural
tissue. Cα is ubiquitously-expressed in all tissues, is a binding partner of HAdV E1A and
is therefore a focus of this thesis. Additional specificity for PKA is provided by the four
unique, non-redundant isoforms of R-subunits (RIα, RIIα, RIβ, and RIIβ) (Canaves and
Taylor, 2002; Skalhegg and Tasken, 2000). These share only 40% amino acid identity (at
most), and based on their cell type-specific expression and additional protein binding
partners, add layers of regulation to PKA catalytic activity. RIα and RIIα are both direct
binding targets of E1A and like Cα will be the main focus of this thesis.
As the earliest solved kinase structure, the study of PKA subunits provided crucial
insights into the structural nature of all eukaryotic kinases (Hanks et al., 1988; Knighton
et al., 1991; Kornev et al., 2006). The catalytic core of the Cα subunit is composed of
two ‘lobes,’ an N-terminal β-sheet and an α-helical C-terminus (a general organization
that is common across the human kinome). Highly conserved residues cluster around the
active site cleft that lies between the two lobes (Taylor et al., 2013, 2012). Binding of
adenosine triphosphate (ATP) commits Cα for catalysis, where it adds a phosphate
moiety to serine (Ser) or threonine (Thr) residues on substrates containing the minimal
consensus sequence Arg-Arg-x-Ser/Thr-Φ (Kennelly and Krebs, 1991; Masterson et al.,
2010; Shabb, 2001).
Both RIα and RIIα subunits form homodimers mediated by an N-terminal 4-helix bundle
termed a ‘docking/dimerization (D/D) domain’ (Taylor et al., 2013, 2012). The spatial
organization of the R-subunit isoforms are generally similar (Banky et al., 1998; Kim et
al., 2005; Wu et al., 2007). At the C-terminus are two cyclic nucleotide binding (CNB)
domains.

The D/D and CNB domains are separated by a flexible linker sequence

containing an inhibitory sequence (IS). The IS resembles a PKA substrate and binds to
the Cα active site cleft, keeping it inactive. The intrinsically disordered nature of the
linker dictates the disparate quaternary structures of PKA holoenzymes between the
different R-isoforms.
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PKA auto-phosphorylates itself during initial folding which is essential for full
maturation (Keshwani et al., 2012; Steichen et al., 2012). Additional phosphorylation by
either another PKA or 3-phosphoinositide-dependent protein kinase 1 (PDK1) after
leaving the ribosome is required for full functionality (Cauthron et al., 1998; Cheng et al.,
1998). However, turnover activity is not regulated by auto-phosphorylation, but rather by
cyclic adenosine monophosphate (cAMP).

Around the same time that protein

phosphorylation was being initially characterized, cAMP (produced by adenylyl cyclase)
was discovered as a 2nd messenger molecule (Northup et al., 1980; Rall and Sutherland,
1958). Binding by cAMP to each of the CNB domains on PKA R-subunits causes them
to undergo major conformational changes that release the C-subunits. Free Cα is then
able to phosphorylate its cognate substrates.

1.4.2 Cellular functions of PKA
PKA is ubiquitous in every mammalian cell and carries out functions in both the
cytoplasm and nucleus to regulate a wide array of biological events (Taylor et al., 2012).
Specificity of function is conferred not only by the numerous PKA subunit isoforms and
additional splice variants, but also cell-type specific expression and localization of related
signaling components (Skalhegg and Tasken, 2000; Taskén and Aandahl, 2004; Welch et
al., 2010; Wong and Scott, 2004). These can include dozens of different G proteincoupled receptors (GPCR), adenylyl cyclase that produces cAMP, phosphodiesterases
(PDE) that break cAMP down, phosphatases, A-kinase anchoring proteins (discussed
later), and the dedicated PKA substrates.

In this sense, cells carefully organize

machinery to create discrete foci of cAMP signaling.
The list of cellular gene products predicted or validated as phosphorylated by PKA has
long been known to number in the hundreds (Diella et al., 2004; Gao et al., 2008; Shabb,
2001). Unsurprisingly, this kinase exerts functional consequences within a plethora of
biological pathways, including memory formation, cell differentiation, proliferation,
transcription, metabolism, apoptosis, and trafficking, among others (Johnson et al., 2001;
Taylor et al., 2012).

Additionally, new substrates for PKA are continually being

described, aided by the advent of molecular tools such as catalytic inhibitors (H89 or
PKI), cAMP stimulants like forskolin (fsk), and anchoring disruptors (RIAD and
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sAKAPis) (Alasbahi and Melzig, 2012; Carlson et al., 2006; Chijiwa et al., 1990; Gold et
al., 2006).
In the broadest sense, PKA is a master regulator of intracellular molecular signaling, even
participating in feedback within its own signaling pathway. When intracellular cAMP
levels are high, PKA phosphorylates the β2-adrenergic receptor which causes the
downstream inhibitory Gi protein to inhibit adenylyl cyclase, lowering cAMP production
(Daaka et al., 1997; Hausdorff et al., 1990). Similarly, PKA also activates multiple PDEs
which hydrolyze cAMP to reduce overall levels of this 2nd messenger (Conti, 2000). In
addition to cAMP signaling, PKA cross-talks in other discrete pathways by targeting
proteins in the cGMP, calcium, Rho, mitogen-activated protein kinase (MAPK), and
protein phosphatase 1 (PP1) signaling networks (Shabb, 2001).
At a more focused level, one of PKA’s major functions involves modulating cellular
transcription.

Many PKA substrates include TFs or cofactors localized within the

nucleus that function through the cis-acting cAMP response element (CRE) commonly
found in promoters. Well-characterized TFs, whose CRE-binding ability is modulated
via phosphorylation by PKA, include CRE-binding protein (CREB), CRE modulator
(CREM), and members of the activating transcription factor (ATF) family (De Cesare
and Sassone-Corsi, 2000; Gonzalez and Montminy, 1989; Rehfuss et al., 1991). Through
CREB alone, PKA is putatively capable of affecting transcription of thousands of cellular
genes (Daniel et al., 1998; Mayr and Montminy, 2001; Zhang et al., 2005). Additional
TF targets of PKA include NF-κB and nuclear factor of activated T cells (NFAT), though
their roles in cAMP-mediated transcriptional signaling are less clear (Serfling et al.,
2000; Ye, 2000). Given the roles for both PKA and HAdV E1A in regulating gene
expression, PKA is a well-connected and attractive target for molecular reprogramming
by E1A during a HAdV infection.
Additional miscellaneous functions of PKA phosphorylation are numerous. They include
epigenetic modifications of histones - in fact, histone H1 was the first PKA substrate to
have its phosphorylation site established in vivo (DeManno et al., 1999; Langan, 1969).
PKA also signals within cascades controlling cell death, phosphorylating proapoptotic
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factors such as BAD or glycogen synthase kinase-3 (GSK-3) (Li et al., 2000; Lizcano et
al., 2000). Over a third of PKA’s known targets are involved in controlling ion channels
and water homeostasis, allowing PKA to affect molecular interactions mediating muscle
contractions and cell-to-cell signaling in cardiovascular and neuronal tissues (Dagda and
Das Banerjee, 2015; Gold et al., 2013; Shabb, 2001). Metabolic targets of PKA include
enzymes in the glycolysis and gluconeogenesis pathways, allowing PKA to integrate into
the control of blood glucose levels (Okar and Lange, 1999). Lastly, PKA has been wellstudied for its capacity to affect cytoskeletal arrangements. PKA activity regulates actin
bundling and downstream cell motility and adhesion (Chen et al., 2013; McKenzie et al.,
2011). It also participates in the dynein-mediated transport of cargo along microtubule
networks, a process actually usurped by HAdV virions during the entry phase of infection
(Bremner et al., 2009; Scherer et al., 2014; Suomalainen et al., 2001). To summarize, the
diversity of its substrates, along with its flexible recognition properties make PKA a
crucial component for molecular control of a cell.
In general, kinases are highly conserved across widely distinct phyla, underlining their
biological importance (Kannan et al., 2007). Kinase mutations are often associated with
disease, making them ideal targets for drug discovery and PKA is no exception (Taylor et
al., 2012). Given the range of functions PKA’s reach extends into, it has been studied as
a molecular component in several human disease contexts, including cataracts, diabetes,
cardiovascular disease, and multiple types of cancer (Gold et al., 2013; McKenzie et al.,
2011; Palorini et al., 2016; Pattabiraman et al., 2016). In addition, dysregulation of the
cAMP signaling pathway is exploited by a diverse range of viral pathogens such as HSV,
HIV, varicella-zoster virus (VZV), HPV, hepatitis C virus (HCV), and hepatitis B virus
(HBV) (Barnitz et al., 2010; Benetti and Roizman, 2004; Boon et al., 2015; Cartier et al.,
2003; Delury et al., 2013; Desloges et al., 2008; Giroud et al., 2013; Majeau et al., 2007;
Okabe et al., 2006). How this occurs in the context of HAdV infection via E1A is the
focus of this thesis.

1.4.3 A-kinase anchoring proteins (AKAPs)
Localization of the PKA holoenzyme is a major contributing factor for achieving its
functional specificity.

This spatiotemporal control of PKA activity is conferred by
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Figure 1.10. Organization and function of AKAPs.
(A) Structural representation of an AKAP amphipathic α-helix motif binding across the
D/D domain of PKA R-subunit homodimer. Adapted from PDB: 3IM4 (Sarma et al.,
2010). (B) The general organization of functional domains within AKAPs is depicted.
AKAPs are variably-sized, polyvalent, and differentially-localized within the cytoplasm
of cells. AKAP-PKA interactions can be RI-, RII, or dual-specific. Along with their
PKA-binding helix, AKAPs typically contain interaction motifs for other components of
cAMP signaling, such as PDEs, phosphatases, and PKA substrates. They also tend to
possess a targeting domain that directs AKAPs along with their compartmentalized
binding partners to distinct subcellular compartments.
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cellular A-kinase anchoring proteins (AKAPs), a set of polyvalent and highly dynamic
scaffold proteins (Taylor et al., 2012; Welch et al., 2010; Wong and Scott, 2004). First
discovered in the 1980s, there are now over 30 distinct AKAPs in humans, each
providing similar but distinct abilities to regulate PKA (Theurkauf and Vallee, 1982).
AKAPs all contain a hallmark PKA-binding motif comprised of an amphipathic α-helix
(Carr et al., 1991). This directly binds with high-affinity to the hydrophobic groove in
the D/D domain of PKA R-subunit dimers (Figure 1.10). AKAP-PKA interactions occur
in the cytoplasm and are usually specific for either RIα or RIIα subunits, but dualspecificity AKAPs exist as well (Carlson et al., 2006; Gold et al., 2006).
In addition to binding PKA, AKAPs can contain motifs directing their subcellular
localization to specific compartments such as the cytoskeleton, centrosome, golgi, ER,
mitochondria, or NPC (Taylor et al., 2012; Welch et al., 2010; Wong and Scott, 2004).
Here AKAPs will simultaneously tether interactions between PKA, substrates, and up- or
down-stream regulators of the cAMP pathway. By carefully controlling the proximity of
this broad-specificity kinase, AKAPs enable tight and efficient control of cAMP
signaling mediated through PKA. The interface between AKAPs and PKA therefore
offers a target for manipulation, a feature exploited by HAdV E1A.

1.5 Viral Mimicry
How individual viral proteins can radically alter the robust interaction networks found in
eukaryotes remains a fascinating topic of study. The highly organized nature of cells
requires orchestration of countless protein-protein interactions mediated via structural
domains or interaction motifs such as SLiMs (Davey et al., 2015; Dunker et al., 2005;
Kim et al., 2008). This feature is also shared by some viral proteins, whose enhanced
evolutionary flexibility allows them to quickly adapt to cellular environments, enabling
integration into and rewiring of their protein networks (Davey et al., 2011). This includes
ex nihilo evolution of SLiMs – the ability to rapidly develop a functional domain within a
previously non-functional protein sequence.

Consequently, viruses always have an

advantage in the unceasing arms race between pathogen and host. Viral hubs like HAdV
E1A can manipulate target proteins (and secondary interactors) using only small stretches
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of amino acid sequence, including motifs that mimic cellular counterparts (King et al.,
2016a; Pelka et al., 2008).

Instead of encoding entire orthologs of large cellular

components or evolving complicated globular structures, this strategy is an efficient
means of increasing the functionality of the size-constrained HAdV genome (Avgousti et
al., 2016; Chahal et al., 2012; King et al., 2016b). The success of viral mimicry is
overwhelmingly demonstrated by how often it has evolved convergently in geneticallydistinct viruses (Brito and Pinney, 2017; Chemes et al., 2015; Via et al., 2015). It is also
telling that the full complement of cellular processes have been shown as susceptible to
viral “corruption” in this manner (Davey et al., 2011). Understanding the mechanisms
driving viral hijacking of host components via mimicry will reveal new molecular aspects
of cell regulation, viral pathogenesis, and human disease.

1.6 Thesis Overview
The work within this thesis involves the biochemical and functional analysis of the
protein-protein interaction between HAdV E1A and cellular PKA. Originally identified
in 2001, the E1A-PKA association remained largely uncharacterized and its biological
importance unknown (Fax et al., 2001). Here, extensive mutagenesis was utilized to
determine the precise molecular mechanism of this virus-host interaction, ultimately
revealing a novel example of viral mimicry. Subsequent findings validated the functional
importance of this role for E1A in enhancing the HAdV replication cycle.

The

conservation of this function across the seven HAdV species was also determined,
demonstrating its evolutionary importance. Finally, a detailed model was established
explaining E1A’s ability to engage in mimicry for the purpose of rewiring cellular cAMP
signaling to benefit HAdV infection.

1.6.1 Chapter 2: Functional and structural mimicry of cellular protein
kinase A anchoring proteins by a viral oncoprotein
In this study, we performed extensive mutational analysis on both HAdV-5 E1A and
cellular PKA subunits to characterize the molecular determinants of their protein-protein
interaction. We demonstrated that the N-terminus of E1A has evolved to structurally
mimic the PKA-binding domain of cellular AKAPs. We also showed this mimicry to be
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functional, as E1A could emulate AKAP activity in vivo. E1A relocalizes PKA to the
nucleus of infected cells via an interaction with the D/D domain in PKA’s regulatory
subunits. This required an AKAP-like amphipathic α-helix motif in E1A’s N-terminus.
Importantly, we showed that during HAdV infection, E1A competes with endogenous
AKAPs for PKA binding. We also showed that incorporation of E1A’s AKAP-like motif
into a cellular AKAP mutant unable to bind PKA restored the interaction. Functionally,
E1A’s ability to act like a ‘viral AKAP’ (vAKAP) contributed to efficient viral
transcription, protein synthesis, and progeny production.

1.6.2 Chapter 3: Mimicry of cellular A kinase anchoring proteins is a
conserved and critical function of E1A across various human
adenovirus species
Following the previous chapter, we examined the ability of E1A proteins from all seven
species of HAdV to act as ‘viral AKAPs.’ We showed that E1A from representative
viruses from five of seven HAdV species make protein-protein interactions with PKA
subunits. The conserved mechanism of this binding included each of these distinct E1As
using small, AKAP-like motifs in their N-terminal regions to bind the D/D domain of
PKA R-subunits. Like with HAdV-5, this caused relocalization of PKA into the nucleus.
Interestingly, different HAdV species had a preference for one particular PKA isoform
(RIα or RIIα) over another. Notably, we showed these newly characterized vAKAPs
could integrate into cAMP signaling to activate transcription from a cAMP-responsive
promoter. Additionally, we demonstrated the vAKAP function of E1A contributes to
viral genome replication and infectious progeny production for several, unique HAdV
species. These data established that mimicry and subversion of this important cellular
regulatory pathway is a conserved feature for multiple viral pathogens and enhanced the
knowledge of how vAKAPs function.

1.6.3 Chapter 4: General Discussion
To conclude the thesis, I examine the overall significance of my work and address
lingering questions related to the projects presented. Additionally, I present potential
follow-up experiments including some preliminary analysis of genome-wide changes to
cellular transcription possibly linked to the E1A’s role as a vAKAP.
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Chapter 2

2

Functional and structural mimicry of cellular protein
kinase A anchoring proteins by a viral oncoprotein

“Research is what I'm doing when I don't know what I'm doing.”
– Wernher von Braun

2.1 Introduction
As obligate intracellular parasites, all viruses are critically dependent upon the host cell.
Intensive selective pressure, rapid replicative cycle times and severe restrictions on viral
genome size combine to drive virus evolution.

As a consequence, viral regulatory

proteins have been relentlessly forged into exquisitely sophisticated instruments that
functionally reprogram the infected cell (Rozenblatt-Rosen et al., 2012). Studies of
human adenovirus (HAdV), a small DNA tumour virus, illustrate the profound impact of
viral proteins on multiple host functions to maximize viral propagation (Ferrari et al.,
2014, 2008; Fonseca et al., 2012; Miyake-Stoner and O’Shea, 2014; Shah and O’Shea,
2015; Soria et al., 2010).
The multifunctional E1A proteins of HAdV are particularly adept at targeting key cellular
regulators. Through these interactions, E1A creates a cellular milieu more conducive for
replication by altering or inhibiting the normal function of host targets and establishing
new connections in the host protein interaction network. Indeed, E1A enhances cell
cycle entry, subverts innate immunity and intensively reprograms the cellular gene
expression program (Ferrari et al., 2014, 2008; Pelka et al., 2008). The modular E1A
proteins are dense with short linear sequence motifs that bind to and alter the activity of
dozens of critical cellular proteins (Ferrari et al., 2009; Ferreon et al., 2013). Many of the
interaction motifs in E1A are functional mimics of highly similar sequences present in
cellular regulatory proteins. Thus, viral evolution has converged to generate specific high
affinity protein interaction surfaces that perturb cell regulation by competing with
endogenous targets.
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Cellular compartmentalization of proteins is a widespread cellular mechanism that
ensures the interaction of signalling molecules with a localized subset of appropriate
effector proteins. As one well studied example, the activation of protein kinase A (PKA)
signalling by the second messenger cyclic AMP (cAMP) is precisely restricted to discrete
subcellular regions (Taylor et al., 2012). This is primarily achieved by a diverse set of
cytoplasmic scaffolds collectively known as A-kinase anchoring proteins (AKAPs).
AKAPs bind to PKA regulatory subunits via a well characterized amphipathic α-helix,
localizing them to distinct cellular loci near PKA’s substrates (Wong and Scott, 2004).
Compartmentalization of PKA allows its enzymatic activity to be directed in a spatially
defined and temporally specified manner and dysregulation of this compartmentalization
has pathophysiological consequences (Gold et al., 2013).
Although the E1A proteins from multiple HAdVs can synergize with cAMP to alter viral
and cellular gene expression (Engel et al., 1991, 1988; Hardy and Shenk, 1988; B H Lee
and Mathews, 1997; Müller et al., 1989) the exact mechanism remains unclear.
Interestingly, HAdV-12 E1A binds directly to the regulatory subunits of PKA, resulting
in the relocalization of one isoform from the cytoplasm to the nucleus (Brockmann and
Esche, 2003; Fax et al., 2001). These results suggest that E1A may function as a ‘viral
AKAP’ by redirecting the subcellular localization of PKA to alter transcription.
Here we show that HAdV E1A mimics cellular AKAPs in both structure and function.
We found that the PKA RIα and RIIα subunits are conserved targets of most HAdV E1A
species. Structural modeling and a docking analysis predict a remarkable similarity
between the binding of E1A and cellular AKAPs to PKA, which was confirmed
experimentally. In addition, we observed E1A-mediated relocalization of PKA subunits
and competition between E1A and cellular AKAPs during infection that contribute to
HAdV gene expression and overall viral replication. Together, our studies identify E1A
as the first known viral AKAP, and reveal a unique example of viral subversion of the
PKA pathway via structural mimicry.
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2.2 Materials and Methods
2.2.1 Cell lines and transfections
Human A549 (provided by Russ Wheeler, Molecular Pathology/Genetics London Health
Sciences Centre), HT1080 (purchased from the American Type Culture Collection), and
HEK293 cells (Graham et al., 1977) were grown at 37ᵒC with 5% CO2 in DMEM
(Multicell) supplemented with 10% fetal bovine serum (FBS) (Gibco). Plasmids were
transfected into A549 and HT1080 cells using XtremegeneHP (Roche) following the
manufacturer’s recommendation. After 24 hours of incubation, transfected cells were
used for downstream experiments.

2.2.2 Virus infection of cells
All viruses were derived from the HAdV-5 dl309 background and express the 289R and
243R E1A proteins (Egan et al., 1988; Jones and Shenk, 1979). A549 cells were infected
with WT (dl309) or HAdV containing the indicated E1A mutant: ΔE1A (dl312), Δ4-25
(dl1101). Cells were infected at a multiplicity of infection (MOI) of 5 pfu (plaqueforming units)/cell. Cell cultures were infected at 50% confluence and subconfluent cells
were collected at indicated time points for downstream experiments.

2.2.3 RNAi knockdown
Downregulation of PKA subunits RIα, RIIα, and Cα was performed using Silencer Select
siRNA (Thermo). The following PKA oligos were utilized: s286 (PRKAR1A), s11086
(PRKAR2A), and s11065 (PRKACA). Four hours after seeding, siRNA was delivered to
A549 cells via transfection with Silentfect (BioRad) according to the manufacturer’s
instructions. A scrambled siRNA was used as a negative control. Treated cells were
used for experiments 48 hours post-transfection. Downregulation of E1A in HEK293
cells was performed using a cocktail of E1A-specific siRNAs generated by Thermo
Fisher’s

design

platform:

(GAUUUUUCCCGAGUCUGUAtt,

CGGAGGUGUUAUUACCGAAtt, and CUGUAUGAUUUAGACGUGAtt).
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Table 2.1. List of plasmids used in this chapter
Clone

Backbone(s)

Notes

13S Ad3 E1A
13S Ad4 E1A
13S Ad5 E1A
13S Ad9 E1A
13S Ad12 E1A
13S Ad40 E1A
Ad5 E1A 1-82
Ad5 E1A 93-139
Ad5 E1A 139-204
Ad5 E1A 187-289
*Ad5 E1A Δ1-82
*Ad5 E1A Δ1-29
*Ad5 E1A Δ1-14
Ad5 E1A Δ4-25
*Ad5 E1A Δ16-28
Ad5 E1A Δ26-35
Ad5 E1A Δ30-49
Ad5 E1A Δ48-60
Ad5 E1A Δ61-69
Ad5 E1A Δ70-81
*Ad5 E1A 1-29
*Ad5 E1A 1-14
*Ad5 E1A 14-28
*Ad5 E1A 16-28
*Ad5 E1A 29-49
*Ad5 E1A D21K
*Ad5 E1A E26K
*Ad5 E1A V27K
*Ad5 E1A E26A V27A
*Ad5 E1A E25K
*PKA RIα
*PKA RIIα
*PKA Cα
*PKA RIα Q28E
*PKA RIα L31A K32A
*PKA RIα I35A V36A
*PKA RIα Δ1-63
*PKA RIIα Δ1-45
*PKA RIα 1-63
*PKA RIIα 1-45
RIAD

pEGFP-C2
pEGFP-C2
pEGFP-C2, pcDNA3
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pcDNA3
pcDNA3
pcDNA3
pcDNA3
pcDNA3
pcDNA3
pcDNA3
pcDNA3
pcDNA3
pcDNA3
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pcDNA3
pcDNA3
pcDNA3
pcDNA3
pcDNA3
pcDNA-HA, pcDNA-MYC
pcDNA-HA, pcDNA-MYC
pcDNA-HA
pcDNA-HA
pcDNA-HA
pcDNA-HA
pcDNA-MYC
pcDNA-MYC
pEGFP-N1
pEGFP-N1
pEGFP-C2

Species B
Species E
Species C
Species D
Species A
Species F
N-terminus and CR1
CR2
CR3
Exon 2 including CR4

sAKAPis

pEGFP-C2

D-AKAP1
*D-AKAP1 Δ344-357
*AKAP-E1A

pEGFP-C2
pEGFP-C2
pEGFP-C2

*Novel clone generated for this study

dl1101

From Addgene 23741
From Addgene 23789
From Addgene 23495

ΔD/D
ΔD/D
D/D only
D/D only
LEQYANQLADQIIKEAT, from
Alan Howe
QIEYLAKQIVDNAIQQAK,
from Alan Howe
From Thomas Kuntzinger
AKAP-E1A chimera
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2.2.4 Plasmids
All constructs were expressed in vectors under control of the CMV promoter. WT RIα,
RIIα, and Cα were PCR amplified (from Addgene 23741, 23789 and 23495) and cloned
into pcDNA4-HA and pCANmyc. RIα Δ1-63 and RIIα Δ1-45 were similarly derived and
expressed in pCANmyc. D/D fragments of RIα and RIIα were both expressed as EGFP
fusions from pEGFP-N1. E1A fragments were expressed as fusions to EGFP and either
described previously (1-82, 93-139, 139-204, 187-289) (Pelka et al., 2011) or derived via
PCR and cloned into pEGFP-C2 (1-29, 1-14, 14-28, 16-28, 29-49). WT HAdV-5 E1A
and its associated deletion mutants were all expressed in pcDNA3.

These constructs

were previously described (Δ4-25, Δ26-35, Δ30-49, Δ48-60, Δ61-69, Δ70-81) (Pelka et
al., 2011) or generated via PCR (Δ1-82, Δ1-14, Δ1-29, Δ16-28). Point of mutants of E1A
(D21K, E26K, V27K, E26A V27A, E25K) and RIα (Q28E, L31A K32A, I35A V36A)
were generated by PCR and expressed in pcDNA3 and pcDNA-HA respectively.

The

largest E1A isoform from six HAdV species were cloned as EGFP fusions. D-AKAP1
mutants were generated via PCR of a construct kindly provided by Thomas Kuntziger
(Oslo) and expressed in pEGFP-C2. RIAD-EGFP and sAKAPis-EGFP were provided by
Alan Howe (Vermont). A list of plasmids used in this chapter can be found in table 2.1.

2.2.5 Western blotting and co-immunoprecipitation
Cells were lysed in NP-40 lysis buffer (150mM NaCl, 50mM Tris-HCL pH 7.5, 0.1%
NP-40) with protease inhibitor cocktail. Protein concentrations were determined using
BioRad protein assay reagent using BSA as a standard. Immunoprecipitations were
carried out at 4ᵒC for 4 hours, or overnight for endogenous interactions. 2% of sample
was kept as input control. After washing with NP-40 buffer, complexes were boiled in
25 µL of LDS sample buffer for 5 minutes. Samples were separated on NuPage 4-12%
Bis-Tris gradient gels (Life Technologies) and transferred onto a PVDF membrane
(Amersham). Membranes were blocked in 5% skim milk constituted in TBS with 0.1%
Tween-20. Horseradish peroxidise-conjugated secondary antibody was detected using
Luminata Forte or Crescendo substrate (Millipore). For biochemical fractionation of
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Table 2.2. List of primary antibodies used in this chapter
Reactivity

Purpose

Description

Company

RIα
RIα
RIIα
RIIα
Cα
Cα
M73 (E1A)
M58 (E1A)
Actin
EGFP
9E10 (MYC)
3F10 (HA)
AKAP7
2A6 (E1B-55K)
B68 (DBP)
E3-19K
1807-4 (E4orf6)
Ad5 capsid
Histone H3

Western
IF, ChIP
Western
IF, ChIP
Western
IF, ChIP
Western, IP, IF
Western
Western
Western, IP
Western
Western
Western, IP
Western
Western, IF
Western
Western
Western
Western

Mouse monoclonal
Rabbit polyclonal
Mouse monoclonal
Rabbit polyclonal
Mouse monoclonal
Rabbit polyclonal
Mouse monoclonal
Mouse monoclonal
Rabbit polyclonal
Rabbit polyclonal
Mouse monoclonal
Rat monoclonal
Rabbit polyclonal
Mouse monoclonal
Mouse monoclonal
Rabbit serum
Rabbit polyclonal
Rabbit polyclonal
Rabbit polyclonal

BD
Thermo
BD
Santa Cruz
BD
Santa Cruz
In-house
In-house
Sigma
Clontech
In-house
Roche
Santa Cruz
In-house
In-house
In-house
In-house
Abcam
Abcam
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infected A549 cells, nuclear and cytoplasmic extracts were acquired using an NE-PER kit
from Thermo-Fisher. Primary antibodies used in this chapter can be found in table 2.2.

2.2.6 Immunofluorescence microscopy and image analysis
Cells were fixed in 3.7% paraformaldehyde, permeabilized on ice using 0.2% Triton X100, and blocked using 3% BSA in phosphate-buffered saline (PBS).

Samples were

incubated in the indicated primary antibody for 1 hour at room temperature or 4ᵒC
overnight and another hour at room temperature with secondary antibodies (Alexa Fluor
594 α-rabbit, Alexa Fluor 488 α-mouse) (Life Technologies). Samples were mounted
with Prolong Gold reagent containing DAPI (Life Technologies). Confocal images were
acquired using a Fluoview 1000 laser scanning confocal microscope (Olympus Corp).
Non-confocal images were acquired using an Eclipse Ti-U inverted laser microscope
(Nikon). Quantification of total cellular signal and nuclear signal was conducted using
ImageJ. Cells were normalized for both cytoplasmic and nuclear size and %nuclear
signal was determined as previously described (Magico and Bell, 2011).

2.2.7 Quantitative RT-PCR
Total RNA was prepared with Trizol extraction (Life Technologies). A total of 1 µg of
RNA was reverse transcribed into cDNA by random priming using the qScript cDNA
supermix

(Quanta

Biosciences)

following

the

manufacturer’s

instructions.

Quantification of cDNA was done using Power SYBR-Green mastermix (Applied
Biosystems) with oligonucleotide sequences that specifically recognize the indicated
target. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a control for
total cDNA along with a no-RT negative control.

Results were normalized to the

GAPDH and uninfected samples and calculated using the ΔΔCt method (Schmittgen and
Livak, 2008). A list of all primers used in this chapter can be found in tables 2.3 and 2.4.

2.2.8 Chromatin immunoprecipitation
Approximately 107 cells per sample were cross-linked in 2mM ethylene glycol
bis(succinimidyl succinate) (EGS) for 1 hour followed by 1% formaldehyde for 15
minutes at room temperature.

Reactions were quenched with 0.125M glycine and
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Table 2.3. List of qPCR primers used in this chapter

Target

Region

Location

Forward

Reverse

Size

GAPDH

Transcript

566-644

Transcript

715-834

E1B

Transcript

578-697

E2

Transcript

17-155

E3

Transcript

13-162

E4

Transcript

3-129

GAPDH

Promoter

E1B

Promoter

231 bp
upstream
of TSS
1546-1708

ATGGCATGGACTGTGGT
CATGAGTC
TTATTGCCCAGGCTCGTT
AAGC
CACTCAGGACGGTGTCT
GG
GCGGATGAGGCGGCGTA
TCGAG
GCTCTCCCTGGGCGGTA
AGCCGG
GGCTGCCGCTGTGGAAG
CGC
AGGCGGAGGACAGGATG
GC
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E1A

ACTGCTTAGCACCCCTGG
CCAA
ACACCTCCTGAGATACA
CCC
GACAATTACAGAGGATG
GGC
GGGGGTGGTTTCGCGCT
GCTCC
GAGGCAGAGCAACTGCG
CC
GCCCCCATAGGAGGTAT
AAC
TTCGCCCCAGGCTGGAT
GG

Promoter

E4

Promoter

CAGATGTAACCAAGATT
AGCCC
TCTGAAATGTCCCGTCCG
G
TGCGGTTTTCTGGGTGTT
TT

162

E3

GGTGTAAACCTGTGATT
GCG
GGCGGCTTTCGTCACAG
GG
CAGCTCAATCAGTCACA
GTGTAAAAAAGGGCC

2750127633
3558535694

120
120
138
150
127
126

132
110

78

Table 2.4. List of cloning primers used in this chapter
Clone

Forward

Reverse

Ad5 E1A
Δ1-82
Ad5 E1A
Δ1-29
Ad5 E1A
Δ1-14
Ad5 E1A
Δ16-28

ATCCGAATTCATGTTTCCGCCGGCG
CCCGG
CCACGAATTCGATAATCTTCCACCT
CCTAGC
TTCGAATTCATGGCCGCCAGTCTTT
TG
ATTACCGAAGAAATGGCTGATAAT
CTTCCACC
CGACGAATTCATGAGACATATTATC
TGC
CGACGAATTCATGAGACATATTATC
TGC
CGACGAATTCATGAGACATATTATC
TGC
GATGGAATTCGAAATGGCCGCCAG
TC
GATGGAATTCGCCGCCAGTCTTTTG

CGGCTCGAGCTCCACACACGCAA
TCACAGG
CGGCTCGAGCTCCACACACGCAA
TCACAGG
ACTGTCGACTTATGGCCTGGGAC
GTTTACAGCTC
GGTGGAAGATTATCAGCCATTTC
TTCGGTAAT
CGGCTCGAGCTCCACACACGCAA
TCACAGG
GTTGTCGACTTAAGCCAGTACCT
CTTCG
CATCCTCGAGCTATTCTTCGGTA
ATAAC
CATCCTCGAGCTACAGTACCTCT
TCGATC
CATCCTCGAGCTACAGTACCTCT
TCGATC
CATCCTCGAGCTATAAATCATAC
AGTTCG
CTTCGATCAGCTGTTTCAAAAGA
CTGGCGG
CGGCTCGAGCTCCACACACGCAA
TCACAGG
GATTATCAGCCAGTACTTTTTCG
ATCAGCTGGTC
CGGCTCGAGCTCCACACACGCAA
TCACAGG
GAAGATTATCAGCCAGTTTCTCT
TCGATCAGCTG
CGGCTCGAGCTCCACACACGCAA
TCACAGG
GATTATCAGCCAGGGCGGCTTCG
ATCAGCTGGTC
CGGCTCGAGCTCCACACACGCAA
TCACAGG
ATCAGCCAGTACCTCTTTGATCA
GCTGGTCCAA
CGGCTCGAGCTCCACACACGCAA
TCACAGG
GATGCTCGAGTCAGACAGACAGT
GACACAAAAC
TATTCTCGAGCTACTGCCCGAGG
TTGCCCAG
GCCGGTCGACCTAAAACTCAGAA
AACTCCTT
ATCTTTGAGCAGCGCTTCAATGT
TATGCTTCTG
GATGCTCGAGTCAGACAGACAGT
GACACAAAAC
GCACAATAGAATCGGCGGCCAG
CGCTTGAATGTT
GATGCTCGAGTCAGACAGACAGT
GACACAAAAC

Ad5 E1A
1-29
Ad5 E1A
1-14
Ad5 E1A
14-28
Ad5 E1A
16-28
Ad5 E1A
29-49
Ad5 E1A
D21K

Ad5 E1A
E26K

Ad5 E1A
V27K

Ad5 E1A
E26A
V27A
Ad5 E1A
E25K
PKA RIα
PKA RIIα
PKA Cα
PKA RIα
Q28E
PKA RIα
L31A
K32A

GATGGAATTCGCTGATAATCTTCCA
C
CCGCCAGTCTTTTGAAACAGCTGAT
CGAAG
CGACGAATTCATGAGACATATTATC
TGC
GACCAGCTGATCGAAAAAGTACTG
GCTGATAATC
CGACGAATTCATGAGACATATTATC
TGC
CAGCTGATCGAAGAGAAACTGGCT
GATAATCTTC
CGACGAATTCATGAGACATATTATC
TGC
GACCAGCTGATCGAAGCCGCCCTG
GCTGATAATC
CGACGAATTCATGAGACATATTATC
TGC
TTGGACCAGCTGATCAAAGAGGTA
CTGGCTGAT
CGACGAATTCATGAGACATATTATC
TGC
ATCCGGATCCATGGAGTCTGGCAGT
ACC
AGTCGGATCCATGAGCCACATCCA
GATC
ATACGGATCCATGGGCAACGCCGC
CGCC
CAGAAGCATAACATTGAAGCGCTG
CTCAAAGAT
ATCCGGATCCATGGAGTCTGGCAGT
ACC
AACATTCAAGCGCTGGCCGCCGAT
TCTATTGTGC
ATCCGGATCCATGGAGTCTGGCAGT
ACC

Notes

Internal
Flanking

Internal
Flanking
Internal
Flanking
Internal
Flanking
Internal
Flanking
Internal
Flanking

Internal
Flanking
Internal
Flanking
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PKA RIα
I35A
V36A
PKA RIα
Δ1-63
PKA RIIα
Δ1-45
PKA RIα
1-63
PKA RIIα
1-45
D-AKAP1
Δ344-357

AKAP1E1A

CTGCTCAAAGATTCTGCCGCCCAGT
TGTGCACTGC
ATCCGGATCCATGGAGTCTGGCAGT
ACC
ATCCGGATCCCAGATTCAGAATCTG
CAG
AGCCGGATCCATGCCAGCCTCAGT
CCTGCCCGC
ATCCCTCGAGATGGAGTCTGGCAGT
ACC
AGCCCTCGAGATGAGCCACATCCA
GATC
GATAGAAATGAGGAGGAAGCAACC
GAACAGG
GATGGAATTCATGGCAATCCAGTTC
CG
GAGGTACTGGAAGCAACCGAACAG
GTG

GCAGTGCACAACTGGGCGGCAG
AATCTTTGAGCAG
GATGCTCGAGTCAGACAGACAGT
GACACAAAAC
GATGCTCGAGTCAGACAGACAGT

GAAATGAGGAGGAAATGGCCGCCA
GTC

CGGTTGCTTCCAGTACCTCTTCG
ATCAG

GATGGAATTCATGGCAATCCAGTTC
CG

CATCGCGGCCGCTCAAAGGCTTG
TGTAGTAG

TATTCTCGAGCTACTGCCCGAGG
TTGCCCAG
CATCGGATCCTTTGCCTCCTCCTT
CTC
CATAGGATCCGCGCGGGCCTCGC
GCAG
CCTGTTCGGTTGCTTCCTCCTCAT
TTCTATC
CATCGCGGCCGCTCAAAGGCTTG
TGTAGTAG
CGGCCATTTCCTCCTCATTTCTAT
CCAAG

Internal
Flanking

Internal
Flanking
Internal
(AKAP
template)
Internal
(E1A
template)
Flanking
(AKAPE1A)
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washed twice with cold PBS. Cell pellets were processed in ChIP buffer 1 (10mM
HEPES [pH 6.5], 10mM EDTA, 0.5mM EGTA, 0.25% Triton X-100), ChIP buffer 2
(10mM HEPES [pH 6.5], 1mM EDTA, 0.5 mM EGTA, 200mM NaCl), and ChIP buffer
3 (50mM Tris-HCl [pH 8], 10mM EDTA, 0.5% Triton X-100, 1% SDS, and protease
inhibitors). Lysates were sonicated in an ultrasonic bioruptor bath (Diogenode) to yield
DNA fragments between 200-500 basepairs. Eighty µg of chromatin supernatant was
used for ChIP, 1% of this was kept for input controls. Samples were diluted 10-fold in
ChIP dilution buffer (50mM Tric-HCl [pH 8], 10mM EDTA, 150mM NaCl, 0.1% Triton
X-100, protease inhibitors) and precleared with 30µL of Protein G Dynabeads
(Invitrogen) for 1 hour at 4ᵒC. Immunoprecipitations were performed overnight at 4ᵒC
using 5µg of the indicated antibody. The next morning, 30µL of Dynabeads were
incubated with each sample for 2 hours. Beads were then washed with twice each with
wash buffer 1 (20mM Tris-HCl [pH 8], 2mM EDTA, 150mM NaCl, 1% Triton X-100,
0.1% SDS), wash buffer 2 (20mM Tris-HCl [pH 8], 2mM EDTA, 500mM NaCl, 1%
Triton X-100, 0.1% SDS), and wash buffer 3 (10mM Tris-HCl [pH 8], 1mM EDTA).
Immunocomplexes were extracted twice with 150µL of elution buffer (0.1M NaHCO3,
1% SDS). Twenty five µL of 2.5M NaCl was added to the 300µL pooled elutions and
incubated overnight at 65ᵒC to de-crosslink the complexes. DNA was purified using a
PCR purification kit (Thermo). qPCR using SYBR-Green was performed as described
previously using 80nM oligos and 0.5µL of ChIP DNA per 15µL reaction.

2.2.9 Statistical analysis
All experiments were carried out with three biological replicates performed in duplicate.
Graphs represent mean and standard error of the mean (S.E.M.) of all biological
replicates. For western blots a representative image was selected. Statistical significance
of numerical differences was calculated using one-way ANOVA and Holm-Sidak posthoc comparison between experimental conditions.

2.2.10 Docking methods
To model the interaction between PKA and E1A, we first performed a structural
prediction of the amino terminus of E1A by submitting the primary sequence to Phyre 2
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(Kelley et al., 2015). The predicted structure of E1A was subsequently docked onto PKA
(PDB ID: 3IM4) using the standard settings profile of ClusPro2.0 (Kozakov et al., 2013).
Residues forming an E1A-PKA binding interface within 4 Angstroms were selected for
further experimental analysis. All images were generated in the PyMOL Molecular
Graphics System, Version 1.8 Schrödinger, LLC. Additional in silico comparisons of
HAdV-5 and HAdV-4 E1A were conducted using Clustal Omega (Goujon et al., 2010)
and the UCL Department of Computer Science’s PSI-PRED protein sequence analysis
workbench (Buchan et al., 2013).

2.3 Results
2.3.1 Multiple PKA subunits are conserved targets of HAdV E1A
The E1A proteins from multiple HAdVs synergize with cAMP to alter viral and cellular
gene expression. A direct interaction between HAdV-12 E1A and the type I and type II
regulatory subunits of PKA (RIα and RIIα) was previously reported, but has not been
investigated further (Fax et al., 2001). It was also not known if this interaction was
specific to HAdV-12 E1A. To further explore the E1A-PKA interaction, A549 lung
adenocarcinoma cells were infected with wildtype (WT) HAdV-5 or a ΔE1A virus and
co-immunoprecipitations were performed (Figure 2.1A). Similarly to HAdV-12 E1A,
HAdV-5 E1A interacted with endogenous PKA regulatory subunits RIα and RIIα.
Interestingly, we also found a previously unknown interaction between HAdV-5 E1A and
the endogenous PKA catalytic subunit Cα. siRNA-mediated downregulation of specific
PKA subunits demonstrated that E1A’s association with Cα required expression of RIα
and RIIα (Figure 2.1B). This suggests that the interaction with the Cα subunit may be
indirect and that E1A binds the entire PKA holoenzyme.
To determine if the interactions between E1A and the PKA subunits are evolutionarily
conserved across the different HAdV species, HT1080 fibrosarcoma cells were
transfected with vectors expressing the PKA subunits and the largest E1A isoform from
six different HAdV species. Co-immunoprecipitation analysis revealed that RIα, RIIα,
and Cα all interacted with each of the E1A proteins tested, with the exception of HAdV-4
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Figure 2.1. Multiple subunits of PKA are conserved targets of HAdV-5 E1A during
infection.
(A, B) A549 cells were infected with either WT (dl309) or ΔE1A HAdV-5 (dl312) at an
MOI of 5 pfu/cell and cell lysates were harvested for co-immunoprecipitation. (A)
Associations between E1A and endogenous PKA subunits RIα, RIIα, and Cα are shown.
(B) Cells were treated with the indicated siRNAs (shown in the inset panel) prior to
infection. Associations between E1A and endogenous PKA subunits RIα, RIIα, and Cα
are shown. The interaction between E1A and the PKA catalytic subunit Cα required the
presence of PKA regulatory subunits, indicating an indirect association.

E1A’s

interaction with the regulatory subunits was unaffected by the Cα knockdown. (C, D)
HT1080 cells were co-transfected with PKA subunits and various E1A constructs
expressed

as

fusions

to

EGFP

and

cell

lysates

were

harvested

for

co-

immunoprecipitation. (C) Full-length E1A proteins from 6 different HAdV species all
interacted with PKA subunits RIα, RIIα, and Cα to varying degrees, with the exception of
HAdV-4. (D) Of the E1A fragments tested (shown in the inset panel) only the Nterminus was sufficient for interaction with PKA. This region of E1A has several regions
of high amino acid sequence conservation between various HAdV species (E).
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(Figure 2.1C). The conservation of the E1A-PKA interaction across most HAdV species
suggests that targeting of PKA is an important evolutionarily conserved function of E1A.
E1A is comprised of a series of protein interaction modules that often can function
independently (Pelka et al., 2008). To grossly define which portion of E1A is required
for PKA interaction, lysates from HT1080 cells expressing the PKA subunits and the
indicated large fragments of HAdV-5 E1A expressed as EGFP-fusions, were subjected to
Co-IP. The N-terminal 82 residues of HAdV-5 E1A were sufficient for association with
PKA (Figure 2.1D). Interestingly, this region of E1A has been previously shown to be
involved in alterations in cAMP signaling (Gedrich et al., 1992).

In addition, the

interaction of HAdV-12 E1A with PKA similarly mapped to residues 1-79 in a yeast
interaction assay (Fax et al., 2001). As can be seen from the amino acid sequence
alignment, there are several areas of high sequence similarity in this region in the E1A
proteins from various HAdV species (Figure 2.1E).

2.3.2 The sequence of E1A that binds PKA resembles a cellular
AKAP
To determine the minimal region of HAdV-5 E1A necessary and sufficient for PKA
interaction, we carried out a detailed mutational analysis of the N-terminus of E1A. Cells
were co-transfected with vectors expressing PKA subunits and the indicated E1A
mutants, each expressed in the context of full-length HAdV-5 E1A and containing a
small in-frame deletion in the N-terminus.

As expected, deletion of residues 1-82

abrogated interaction with PKA, confirming that the E1A N-terminus as necessary and
sufficient for binding PKA (Figure 2.2A). Several smaller, overlapping deletions also
had similar defects for PKA-binding, specifically Δ1-29, Δ4-25, Δ16-28, and Δ26-35.
However, adjacent deletion mutants Δ1-14 and Δ30-49, or more distant deletions retained
interaction. This suggests that a region spanning residues 14-29 of HAdV-5 E1A is
necessary for PKA binding.
We next co-transfected cells with PKA and small E1A fragments expressed as EGFP
fusions. Co-immunoprecipitation on lysates of these cells demonstrates that the 14-28
region of E1A was sufficient to confer an interaction with PKA (Figure 2.2B). This
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Figure 2.2. E1A contains an AKAP-like domain that is necessary and sufficient for
binding PKA.
HT1080 cells were co-transfected with PKA subunits and various E1A constructs and
cell lysates were harvested for co-immunoprecipitation. (A) Mutational analysis using
N-terminal deletion mutants of full-length E1A (shown in the inset panel) revealed that
amino acids 14-28 are necessary for binding PKA subunits. (B) The N-terminal region
of E1A, when expressed as a fragment fused to EGFP (shown in the inset panel), was
also sufficient for binding PKA subunits. This region of E1A bears amino acid similarity
to a variety of known AKAPs and is predicted to contain an amphipathic α-helix (C).
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region is similar in the E1A proteins from most HAdV species (Figure 2.1E) and also has
noticeable sequence similarity to the PKA-binding regions of a number of cellular
AKAPs (Figure 2.2C).

Interestingly, AKAPs bind PKA regulatory subunits via an

amphipathic α-helix secondary structure motif (Newlon et al., 1999; Sarma et al., 2010),
and modeling of the N-terminus of HAdV-5 E1A predicts it also forms an amphipathic αhelix (Figure 2.3). Furthermore, the E1A proteins from all HAdV species are strongly
predicted to form an α-helix in this region (Gedrich et al., 1992; Pelka et al., 2008), with
the exception of HAdV-4 E1A, which is predicted to form a lower-confidence helix
(Figure 2.4A) and does not bind PKA efficiently (Figure 2.1C). Taken together, this
suggests that E1A binds PKA by structurally mimicking the AKAPs’ amphipathic α-helix
motif.

2.3.3 E1A binds the same surface of PKA targeted by cellular AKAPs
We performed in silico molecular modeling to predict the docking of the N-terminus of
E1A with PKA. Docking simulations performed using the crystal structure of a dualspecificity cellular AKAP in complex with the RIα homodimer of PKA suggest that the
interaction of E1A with RIα is virtually equivalent to that of the cellular AKAP (Figure
2.3A-D, F). This model predicts a number of distinct interactions between E1A and RIα
(Figure 2.3E, G), which were experimentally tested (Figure 2.3H, I). E1A mutants
D21K, E26K, V27K and E26A/V27A, reduced the interaction with RIα as predicted,
whereas substitution of E25 with K, which is not predicted to alter binding, had no effect
(Figure 2.3H). Similarly, RIα mutants Q28E, L31A K32A and I35A/V36A displayed a
reduced ability to bind E1A as predicted by the model (Figure 2.3I). These results
indicate that the docking model can correctly predict key residues necessary for binding,
which further suggests that E1A structurally mimics a cellular AKAP in order to bind
PKA.
Cellular AKAPs bind to the docking/dimerization (D/D) domain located at the Nterminus of the PKA regulatory subunits RIα and RIIα (Banky et al., 1998; Newlon et al.,
1999). Given the sequence and predicted structural similarity between E1A and cellular
AKAPs, we tested if the D/D domain was necessary for the interaction with E1A.
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Figure 2.3. E1A is predicted and confirmed to dock to PKA equivalently to a
cellular AKAP.
(A,B,C) Cartoon and stick representations of the predicted E1A helix docking to Protein
Kinase A regulatory subunit R1α (dimer;red). Residues represented in sticks are within
4A of each other, suggesting potential interactions. Key predicted interactions are circled.
(D) Electrostatic surface representation of PKA R1α and alpha carbon tracing of E1A
demonstrates limited potential electrostatic interactions, and multiple hydrophobic
interactions. (E) Sequence analysis reveals the residues of PKA R1α important for
AKAP binding are similar to the residues implicated in the predicted interaction with
E1A. (F) Crystal structure of AKAP interacting with PKA regulatory subunit RIα (PDB
ID 3IM4). AKAP structure is shown in blue, Surface electrostatics of PKA are depicted,
with blue and red representing positive and negative charges respectively. (G) Sequence
of the predicted E1A helix and the residues implicated in PKA interaction according to
ClusPro2.0 docking. (H) E1A mutants D21K, E26K, V27K and E26A/V27A reduced
interaction with RIα, whereas substitution of E25 with K, which is not predicted to alter
binding, had no effect. (I) RIα mutants Q28E, L31A K32A and I35A/V36A displayed a
reduced ability to bind E1A.
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Figure 2.4. HAdV-4 E1A is not predicted to form a helix that is capable of binding
PKA in an equivalent manner as the HAdV-5 E1A AKAP-like sequence.
(A) The PSI-PRED protein sequence analysis workbench was used to predict the helical
propensity of the N-terminal regions of HAdV-5 and HAdV-4 E1A. Although both
sequences are predicted to form helices, HAdV-4 has a lower confidence in forming this
secondary structure. (B) When attempting to dock the HAdV-4 E1A sequence to RIα
using Clus-Pro, electrostatic interactions at both the amino and carboxy ends of this lower
confidence structure are absent that are predicted to contribute to the AKAP like
interaction with PKA observed with HAdV-5 E1A. As expected, in the absence of these
interactions, even in the most energy minimized states calculated for HAdV-4, HAdV-5
E1A demonstrated a more stable energy minimization. (C) Using Clustal, the sequences
of HAdV-5 and HAdV-4 E1A are compared, with the residues demonstrated as crucial
for PKA-binding (Figure 2.3) highlighted by boxes here. The corresponding residues in
HAdV-4 E1A are quite different and lack the requisite chemical properties to form bonds
with PKA. Additionally, several bulky alphatic residues present in HAdV-5 E1A, which
appear to stabilize the interaction with PKA via hydrophobic interactions, are also absent
in HAdV-4 E1A.
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Transfected HAdV-5 E1A was unable to co-immunoprecipitate RIα or RIIα lacking their
D/D domain (Δ1-63 and Δ1-45, respectively, Figures 2.5A, B). In addition, when the
D/D domains of RIα and RIIα were expressed as fusions to EGFP, they alone were
sufficient to co-immunoprecipitate E1A (Figure 2.5C). Thus, the N-terminus of E1A not
only resembles an AKAP based on sequence, but also binds to the same site on the PKA
regulatory subunits targeted by cellular AKAPs.

2.3.4 E1A functions as a viral AKAP
We next determined if the structural similarity between E1A and cellular AKAPs
extended to functional similarity.

We tested whether E1A could compete with

endogenous AKAPs for PKA-binding during infection. A549 cells were infected with
WT HAdV-5, a ΔE1A virus, or a virus expressing an E1A mutant unable to bind PKA
(Δ4-25).

Cell lysates were prepared 18 hours post-infection, subjected to

immunoprecipitation with an anti-AKAP7 antibody and any co-precipitating PKA
subunits were detected via western blot with specific antibodies for each target. AKAP7
is a dual-specificity AKAP (Gold et al., 2006), which binds both RIα and RIIα directly,
and indirectly binds Cα. Infection with HAdV-5 did not alter the expression of AKAP7
or the various PKA subunits. However, infection disrupted the endogenous interactions
between AKAP7 and PKA. Disruption of the AKAP7-PKA interaction during infection
required E1A and was dependent on the AKAP-like domain in E1A (Figure 2.6A).
These data establish that the AKAP-like region in E1A competes with endogenous
AKAPs for PKA interaction during infection. These results also suggests that E1A can
out-compete at least some cellular AKAPs for binding to PKA, which likely contributes
to previously observed perturbation of cellular cAMP signalling by HAdV infection
(Engel et al., 1991, 1988; Gedrich et al., 1992).
We next tested whether in silico-designed peptide inhibitors, which block AKAP-PKA
interactions by binding PKA regulatory subunits with sub-nanomolar affinities, could
affect E1A’s interaction with PKA. These well characterized inhibitors are short peptides
expressed as EGFP-fusions which specifically block binding to RIα (RIAD) or RIIα
(sAKAPis) (Carlson et al., 2006; Gold et al., 2006). HT1080 cells were co-transfected
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Figure 2.5.

The D/D domains of PKA regulatory subunits are necessary and

sufficient for binding E1A.
HT1080 cells were co-transfected with E1A and a variety of PKA regulatory subunit
constructs and cell lysates were harvested for co-immunoprecipitation. Deletion of the
D/D domain (shown in the inset panels) in either RIα (A) or RIIα (B) reduced the
interaction with WT E1A. (C) When expressed as EGFP fusions (shown in the inset
panel) these D/D domains were sufficient for binding E1A. Images are cropped to
exclude the IgG heavy chain signal.
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Figure 2.6. E1A can compete with and function like an AKAP.
(A) A549 cells were infected with either WT HAdV-5, ΔE1A virus, or a virus that lacks
PKA-binding

(Δ4-25[dl1101])

and

cell

lysates

were

harvested

for

co-

immunoprecipitation. Interactions between the endogenous dual-specificity AKAP7 and
PKA subunits was disrupted in the presence of WT E1A, but remained intact in presence
of an E1A mutant unable to bind PKA. (B) HT1080 cells were co-transfected with E1A,
PKA, and the indicated high affinity AKAP-PKA binding inhibitors (shown in the inset
panel). The binding inhibitors disrupted the E1A-PKA interactions in an isoform-specific
manner. (C) HT1080 cells were co-transfected with PKA and the indicated D-AKAP1
construct. An AKAP1 mutant lacking its binding for PKA was rescued by cloning in the
AKAP-like sequence of HAdV-5 E1A.
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with vectors expressing the PKA subunits, WT E1A, and each of the inhibitors. Lysates
were subjected to immunoprecipitation with an anti-E1A antibody and interacting PKA
subunits were detected by western blot. As expected based on their high affinity, both
RIAD and sAKAPis competitively reduced E1A’s interaction with PKA in a subunitspecific manner, reinforcing E1A’s role as a dual-specificity viral AKAP (Figure 2.6B).
Using an expression construct for a known cellular dual-specificity AKAP (AKAP1)
(Gold et al., 2006), we next tested E1A’s ability to rescue the PKA-binding function of
this AKAP when its PKA-binding domain was deleted.

HT1080 cells were co-

transfected with PKA subunits and EGFP-fusions of WT AKAP1, an AKAP1 mutant
lacking its PKA-binding domain (AKAP1Δ), or an AKAP1 construct with E1A residues
14-28 cloned in lieu of the deletion (AKAP1-E1A).

Lysates were subjected to

immunoprecipitation with an anti-EGFP antibody and co-precipitating PKA was detected
via western blot.

As expected, the AKAP1Δ mutant lost the ability to bind PKA.

However, incorporation of the E1A AKAP-like sequence into this mutant rescued PKAbinding to WT levels (Figure 2.6C). Together, these results strongly suggest that the
AKAP-like motif in E1A is functionally indistinguishable from that found in an authentic
cellular AKAP.

2.3.5 E1A alters PKA subcellular localization
Transfection of cells with HAdV-12 E1A induces a relocalization of the RIIα subunit of
PKA from the cytoplasm to the nucleus (Fax et al., 2001). We tested E1A’s ability to
alter PKA’s subcellular localization in vivo during a HAdV-5 infection (Figures 2.7,
2.8A). A549 cells were infected with WT virus (dl309), a ΔE1A virus (dl312), or the Δ425 E1A deletion mutant virus (dl1101) that does not bind PKA. At 18 hours postinfection, cells were subjected to immunofluorescence staining and biochemical
fractionation to determine the subcellular localization of PKA. In WT-infected cells,
endogenous RIα was rerouted from the cytoplasm into the nucleus. Additionally, in
infected cells, RIα appeared to overlap with the HAdV-5 encoded DNA-binding protein
(DBP), suggesting possible co-localization with viral replication centres during infection
(Figure 2.9). In contrast, the distribution of PKA subunits in cells infected with either the
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Figure 2.7. E1A alters PKA R1α subcellular localization during infection.
A549 cells were infected with either WT HAdV-5, ΔE1A virus or a virus mutant unable
to bind PKA (Δ4-25).

Cells were fixed, permeabilized and stained for confocal

immunofluorescence. In the presence of WT E1A, RIα exhibited a drastic shift from
exclusively cytoplasmic localization into the cell nucleus (A). This redistribution did not
occur during ΔE1A or Δ4-25 infections. RIIα and Cα were not re-localized in the same
manner as RIα (Figure 2.8A) Scale bars represent 200µm. (B) Quantification of nuclear
signal relative to total cellular signal. Statistically significant differences are denoted
(*p<0.001) n=50.

(C) Nuclear and cytoplasmic extracts from infected cells were

prepared by biochemical fractionation and the presence of E1A and PKA subunits in each
fraction were detected by western blot. The presence of nuclear RIα in WT-infected cells
confirms the results observed by immunofluorescence.
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Figure 2.8. Subcellular localization of RIIα and Cα during HAdV-5 infection and
localization of all PKA subunits in HEK293 cells.
(A) A549 cells were infected with either WT HAdV-5 (dl309), ΔE1A virus (dl312) or a
virus lacking PKA-binding (dl1101; Δ4-25). Cells were fixed, permeabilized and stained
for confocal immunofluorescence.

RIIα appears cytoplasmic in all experimental

conditions. Cα appears nuclear-cytoplasmic in all experimental conditions, although it
may be enriched for nuclear localization in the presence of WT E1A. (B) HEK293 cells
(which are stably transformed due to expression of HAdV-5 E1A and E1B) were stained
and individual PKA subunits and were demonstrated to have a similar localization
phenotypes as in HAdV-infected cells. The nuclear relocalization of RIα appears more
diffuse and less punctate in these cells, possibly due to lack of recruitment to viral
replication centres as there is no infection occurring in these virally transformed cells. In
a separate experiment, endogenous E1A was successfully knocked down to undetectable
levels via siRNA-transfection (the knockdown efficiency of various E1A-specific
siRNAs generated for this experiment is shown in the inset panel). The amount of RIα
detected in the nucleus is greatly reduced when E1A expression is knocked down. Scale
bars represent 200µm.
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Figure 2.9.

Co-staining of PKA and viral replication centres during HAdV-5

infection.
A549 cells were infected with the indicated virus (MOI 5) and were subsequently fixed,
permeabilized and stained with antibodies specific for the indicated PKA subunits or
HAdV-5 DNA-binding protein (DBP) and DAPI as indicated. Images were acquired on a
Nikon Eclipse inverted laser microscope. During WT infection, a portion of nuclear RIα
appears to co-stain with the HAdV-5 DBP, suggesting overlap with viral replication
centres. This is not observed during infection with mutant virus encoding E1A incapable
of binding PKA (dl1101). Under both conditions, RIIα appears to remain cytoplasmic,
whereas Cα maintains a diffuse nuclear/cytoplasmic localization. Scale bars represent
200µm.
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ΔE1A or Δ4-25 virus resembled uninfected cells. Thus, the relocalization of RIα is E1Adependent and requires the AKAP motif. Subcellular localization of RIIα appeared to be
unaffected by the presence of E1A and Cα retained its nuclear/cytoplasmic phenotype in
both uninfected and infected cells, thereby rendering any conclusions regarding its
relocalization difficult (Figure 2.8A).
RIα, but not RIIα, is similarly trafficked into the nucleus of HEK293 cells, which stably
express HAdV-5 E1A. Knockdown of E1A in HEK293 cells reduces the amount of RIα
in the nucleus, further suggesting that E1A is functioning as an AKAP in these cells to
redistribute PKA (Figure 2.8B). Interestingly, HAdV-5 E1A appears to primarily affect
type-I PKA, whereas the previously reported effect of HAdV-12 E1A was restricted to
type-II PKA.

2.3.6 E1A uses PKA to enhance HAdV gene expression
Previous studies indicated that E1A and cAMP synergize to activate viral gene
expression (Engel et al., 1991, 1988; Gedrich et al., 1992; Hardy and Shenk, 1988; B. H.
Lee and Mathews, 1997; Müller et al., 1989). To determine if the E1A-PKA interaction
contributes to HAdV early gene transcription, A549 cells were first treated with control
siRNA or siRNA specific for each PKA subunit and then infected with WT (dl309),
ΔE1A (dl312), or Δ4-25 (dl1101) HAdV-5.

Cells were harvested 20 hours post-

infection, cDNA was prepared and the expression of a panel of HAdV early genes known
to be activated by E1A was determined by quantitative real-time PCR. Knockdown of
RIα, RIIα, or Cα did not affect expression of the E1A (Figure 2.10A) or E1B (Figure
2.10B) transcription units for any of the tested viruses. However, mRNA levels were
significantly reduced for both the E3 (Figure 2.10D) and E4 (Figure 2.10E) transcription
units in WT virus infected cells treated with siRNA for each of the PKA subunits,
demonstrating that PKA plays a role in the regulation of these transcription units.
Importantly, cells infected with the Δ4-25 virus also showed decreased expression of E3
and E4 as compared to WT infection, and this was not further reduced by knockdown of
any PKA subunit (Figure 2.10D, 2.10E). This is fully consistent with the inability of this
mutant E1A protein to bind PKA and relocalize it to the nucleus. Mechanistically,
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Figure 2.10. The interaction between E1A and PKA subunits is required for full
expression of HAdV-5 E3 and E4 transcripts.
A549 cells were treated with control siRNA or siRNA specific for PKA subunits (shown
in the inset panel) and infected with either WT HAdV-5 or the indicated mutants. RTqPCR was performed with a panel of HAdV-5 early genes, normalized to GAPDH and
fold change to control treated cells was plotted. Results for the HAdV-5 E1A (A), E1B
(B), E2 (C), E3 (D) and E4 (E) transcription units are shown. A statistically significant
decrease from control-treated cells is indicated (*p<0.05) n=3.
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Figure 2.11. PKA is recruited to HAdV early gene promoters in an E1A-dependent
manner.
A549 cells were infected with the indicated viruses at an MOI of 5 and harvested 20
hours post-infection.

Chromatin immunoprecipitation (ChIP) was performed with

antibodies specific for the indicated proteins.

DNA was probed via qPCR for the

presence of multiple HAdV early gene promoters (E1B, E3, and E4) and a cellular
GAPDH promoter previously shown to be unaffected by E1A in similar conditions
(Fonseca et al. 2013). Data was normalized to input samples and compared to a nonspecific control antibody and ΔE1A-infected cells. A statistically significant increase
from ΔE1A-infected cells for each specific ChIP reaction is indicated (* p<0.05, n=3). In
WT-infected cells (dl309), the catalytic subunit (Cα) is specifically recruited to the
HAdV E3 and E4 promoters whose transcription was shown to be affected by the E1APKA interaction. This recruitment is E1A-dependent as neither ΔE1A HAdV (dl312) nor
virus incapable of binding PKA (dl1101; Δ4-25) could recruit Cα. In contrast, Cα is not
recruited to the GAPDH promoter and while it was present on the E1B promoter, this was
independent of E1A and does not appear to affect transcription (Figure 2.10).
Interestingly, neither regulatory subunit of PKA was directly recruited to the HAdV
genome. Instead, it appears E1A uses the interaction with the PKA regulatory subunits to
retask the catalytic component of the holoenzyme to sites of action in the nucleus.
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chromatin immunoprecipitation (ChIP) experiments showed that PKA’s catalytic subunit
(Cα) was recruited to the HAdV E3 and E4 promoter regions in an E1A-dependent
manner (Figure 2.11). In contrast, E1A did not specifically recruit Cα to the E1B or
GAPDH promoters, whose transcription was unaffected by the E1A-PKA interaction
(Figure 2.10). These results strongly support a mechanism of early gene activation that
relies on the AKAP function of E1A.
Although knockdown of PKA regulatory subunits had no statistically significant effect on
E2 transcripts, knockdown of the catalytic subunit reduced E2 expression for both WT
and Δ4-25 virus (Figure 2.10C). This suggests an independent effect for PKA on this
transcription unit that does not rely on the AKAP motif.
To extend the observations that PKA plays a role in HAdV gene expression, we further
examined PKA’s role in HAdV-5 protein production (Figure 2.12). A549 cells were
treated with control siRNA or siRNA specific for each PKA subunits and infected with
WT HAdV-5. Cell lysates were collected at 12, 24, and 36 hours post-infection. Viral
protein production was assayed by western blot using antibodies against an array of
HAdV-5 proteins representing both early and late transcription units. Compared to
control-treated cells, knockdown of PKA subunits had no effect on the production of
HAdV-5 E1A proteins. In contrast, knockdown of the individual PKA subunits caused a
notable reduction in several early proteins. These included a reduction in E3-19K at each
time point examined, a reduced level of E4orf6 expression at 24 hours post-infection and
a delay in expression of the E2-encoded DBP. E1B-55K was also reduced, most notably
in the RIα knockdown. Interestingly, many of the late proteins also exhibited lower
expressions levels in PKA-knockdown cells, including hexon, penton, protein V, and
protein VII. This confirms a role for PKA in regulating HAdV-5 gene expression.

2.3.7 E1A uses PKA to enhance viral replication
To establish the biological significance of E1A’s role as a viral AKAP, we also assessed
the effect of the E1A-PKA interaction on viral replication (Figure 2.13). A549 cells were
treated with either control siRNA or siRNA specific for each PKA subunit and infected
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Figure 2.12. PKA is required for WT levels of HAdV-5 protein production.
A549 cells were treated with control siRNA or siRNA specific for PKA subunits and
infected with WT HAdV-5 (dl309; MOI of 5). Cells were harvested at 12, 24, and 36 hr
post-infection and viral protein production was assayed by western blot using antibodies
against representative proteins from an array of HAdV-5 transcription units.
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with either WT or Δ4-25 HAdV-5. Production of infectious virus progeny was assayed at
various time points over 72 hours by plaque assay. The production of WT virus was
reduced by knockdown of each PKA subunit when compared to control-treated cells.
Although the production of the Δ4-25 virus was reduced as compared with WT infection,
it was not further reduced by knockdown of either RIα or RIIα. This again suggests that
the lack of PKA-binding by this E1A mutant is functionally equivalent to PKA
knockdown. These results indicate that HAdV replication requires PKA activity and that
E1A’s interaction with PKA’s regulatory subunits is required for WT-levels of
replication. Interestingly, we observed a reduction in progeny production for both WT
and Δ4-25 virus in cells treated with Cα-specific siRNA.

However, the observed

reduction compared to control-siRNA treated cells was more severe in the WT infection,
suggesting an additional role for PKA in HAdV-5 infection that is E1A-independent and
specific for PKA’s catalytic subunit. Altogether, these results confirm that the targeting
of PKA by the AKAP motif in E1A is a critical aspect in the HAdV-5 replicative cycle.

2.4 Discussion
Cellular AKAPs function as scaffolds that target PKA and other signaling enzymes to
specified subcellular locations. These multivalent anchoring proteins serve as important
focal points for the processing and integration of intracellular signaling (Colledge and
Scott, 1999; Taskén and Aandahl, 2004). We report here that the adenovirus E1A
oncoproteins function as the first known viral AKAPs. Intriguingly, E1A interacts with
both the RIα and RIIα subunits of PKA in a way that precisely mimics that of cellular
dual-specificity AKAPs. Specifically, we found that E1A bound to the N-terminal D/D
domain of the regulatory subunit dimer of PKA, which is the same exact domain targeted
by cellular AKAPs (Taylor et al., 2012; Wong and Scott, 2004). We identified a short
conserved sequence in HAdV-5 E1A spanning residues 14-28 that was necessary and
sufficient for interaction with either RIα or RIIα. Like the PKA interaction domains of
cellular AKAPs, this region of E1A is predicted to form an amphipathic α-helix. This
apparent structural mimicry allows E1A to bind PKA with an affinity comparable to
cellular AKAPs, such that E1A can successfully compete with endogenous cellular
AKAPs for PKA interaction during infection (Figure 2.14).
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Figure 2.13. Interactions between E1A and PKA are required for full HAdV-5
progeny production.
A549 cells were treated with control siRNA or siRNA specific for PKA subunits and
infected with either WT HAdV-5 or a virus encoding E1A unable to bind PKA (Δ4-25).
Cells were collected at various time points up to 72 hr post-infection. Production of
infectious progeny virus was quantitatively assayed by plaque formation on HEK293
cells (A). Data are shown over 36-72 hr. Growth of WT virus was decreased by
knockdown of each PKA subunit. Growth of HAdV E1A Δ4-25 was not affected by
knockdown of PKA regulatory subunits, but was affected by knockdown of PKA Cα
(though to a lesser extent than WT HAdV-5). (B) Total viral progeny production at 60
hours post-infection when virus replication appeared to peak in most conditions. All
values are represented as mean ± SEM. The statistically significant reductions in viral
titres compared to control-treated cells are denoted (*p<0.01).
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In support of our in vivo and in vitro results, molecular modeling based on a known
structure of the AKAP/PKA interaction predicts that E1A binds the exact same surface of
the PKA regulatory subunit in a fashion virtually identical to that determined for cellular
AKAPs (Figure 2.3). Substitution of specific residues predicted by this model to make
contacts reduced the interaction in vivo, supporting the validity of this structural model of
molecular mimicry.
Functionally, as observed for cellular AKAPs, E1A relocalizes PKA to target sites of
action. In the case of E1A, the interaction with PKA induces a specific relocalization to
the nucleus, which contributes to viral gene expression and efficient virus propagation
during infection. Competition by E1A with cellular AKAPs for PKA interaction may
also influence cellular gene expression, which may provide some insight into the
previous observations that E1A influences cAMP signaling (Engel et al., 1991, 1988;
Gedrich et al., 1992; B. H. Lee and Mathews, 1997; Miller et al., 1995; Müller et al.,
1989).

The E1A region mapped as necessary and sufficient for PKA-binding also

overlaps with regions previously implicated in E1A’s ability to function as a transforming
oncoprotein (Chinnadurai, 2011). Whether PKA contributes to the immortalizing activity
of E1A remains unknown, though PKA itself has been investigated in a variety of cancerrelated functions (Gold et al., 2013; Palorini et al., 2016; Pattabiraman et al., 2016)
Our results also demonstrate that PKA is a conserved target of the E1A proteins from
multiple HAdV species, suggesting that this interaction is functionally important for the
virus. The E1A proteins from all HAdV types tested bound PKA strongly, with the
exception of HAdV-4 E1A; modeling of an interaction between HAdV-4 E1A and PKA
predicts that key electrostatic and hydrophobic contacts are absent, which are necessary
for the HAdV-5 E1A PKA interaction (Figures 2.3H, 2.4). Interestingly, HAdV-4 is
unique as it is the sole member of species E HAdV and arose from an interspecies
recombination event between chimpanzee and human adenovirus (Dehghan et al., 2013).
As mentioned above, during HAdV-5 infection, E1A was able to out-compete
endogenous cellular AKAP7 for PKA interaction; however, there exist a plethora of
other, diverse AKAPs with varying affinities for PKA. For example, the in silico-
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designed ‘super AKAPs’ RIAD and sAKAPis (Carlson et al., 2006; Gold et al., 2006)
blocked the binding of E1A to the PKA RIα and RIIα subunits, respectively. Thus, the
affinity of the E1A/PKA interaction is not high enough to compete with synthetic AKAPs
with sub-nanomolar affinities for PKA. Consequently, these inhibitors are potential tools
for further study of E1A function in the context of its role as a viral AKAP.
During HAdV-5 infection, a substantial fraction of the RIα subunit was trafficked from
the cytoplasm into the nucleus in an E1A-dependent manner. We also observed signal
overlap between RIα and HAdV DBP (Figure 2.9), suggesting co-localization with viral
replication centres. Interestingly, the HAdV-5 E1A-mediated shift in RIα localization is
the opposite finding reported for E1A from HAdV-12, which relocalized RIIα only (Fax
et al., 2001). While both E1As bound to both type-I and –II PKA in Co-IP assays, our
studies suggest that in biologically-relevant conditions they each may exhibit higher
affinity or preference for one PKA flavour over another, a property shared by many
cellular AKAPs (Gold et al., 2006; Taylor et al., 2012; Wong and Scott, 2004). The
binding affinities and potential preferences of E1A proteins from the other HAdV species
during infection remains to be fully explored. It also remains to be determined if type-I
and type-II PKA are completely interchangeable, or if there are functional consequences
driving the preference of each virus for each regulatory subunit type.
Interestingly, nuclear localization of the PKA holoenzyme is considered relatively
unusual, but has been studied in detail in HEK-293 cells (Sample et al., 2012). We
confirmed nuclear localization of RIα in these cells, which constitutively express HAdV5 E1A (Graham et al., 1977). Our results suggest that nuclear localization of PKA in
HEK-293 cells is a likely consequence of the AKAP function of E1A. Furthermore, our
data suggests that the results of studies of PKA function in these cells may be confounded
by the impact of viral manipulation of this pathway.
The targeting of PKA by E1A is required for maximal expression of the HAdV-5 E3 and
E4 transcription units. It appears that E1A is using the regulatory subunits of PKA as a
bridge to bind Cα, redistributing it to associate with other E1A binding partners at
preferred sites within the nucleus, such as the HAdV early gene promoters (Figure 2.11).
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Figure 2.14. E1A functions as a viral AKAP.
During infection, the viral E1A protein interacts with the PKA holoenzyme. This occurs
via structural mimicry of the PKA interaction domain of cellular AKAPs.

As a

consequence, competition occurs between the viral AKAP and cellular AKAPs for
interaction with PKA. The interaction of E1A with PKA leads to a relocalization of a
subset of PKA to the nucleus, likely to HAdV early gene promoters within virus
replication centres. This interaction and relocalization is required for efficient viral
transcription, protein expression and progeny production.
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This could establish new localized connections with cAMP-regulated transcriptional
machinery, such as CREB or ATF, at viral or cellular loci. This may help explain the
previously-observed ability of E1A to cooperate with cAMP in transcriptional activation
(Engel et al., 1991, 1988; Müller et al., 1989).
The importance of PKA during a productive infection is further underscored by our
observation that siRNA-mediated downregulation of PKA subunits reduces progeny
production by WT HAdV-5. It is likely that the observed defect in the virus’ ability to
express numerous crucial transcripts and proteins in the absence of PKA (or the AKAP
function of E1A) contributes greatly to this. It is also possible that the E1A-PKA
interaction affects cellular tasks that influence HAdV replication, given that PKA and
cAMP have been previously shown to extensively modulate cellular transcription, protein
expression, and cell signaling (Guo et al., 2012; Sands and Palmer, 2008; Zambon et al.,
2005; Zhang et al., 2005).

As expected, growth of a virus expressing an E1A mutant

unable to bind PKA (Δ4-25) was reduced relative to WT. Importantly, knockdown of
regulatory subunits RIα and RIIα did not further reduce the overall replication of this
mutant, confirming that the lack of the E1A-PKA interaction contributes to its growth
defect. Interestingly, loss of Cα expression negatively affected overall viral replication
for both WT and Δ4-25 viruses, suggesting an E1A-independent effect of Cα on the
HAdV life cycle. This may be related to reports that PKA activity is involved in dyneinmediated transport of species C HAdV virions to the nucleus during the establishment of
infection (Scherer et al., 2014; Suomalainen et al., 2001).
Although E1A is presently unique in its ability to function as a viral AKAP, the important
role of PKA in cellular homeostasis makes it an attractive target for modulation during
infection by other viruses. For example, the Herpes simplex virus-1 US3 kinase interacts
with and activates PKA to block apoptosis (Benetti and Roizman, 2004). Varicella-zoster
virus also upregulates PKA expression and modulates phosphorylation of PKA substrates
to improve replication (Desloges et al., 2008). More typically, PKA is recruited to
phosphorylate viral proteins, altering their stability, folding or ability to interact with
other targets (Barnitz et al., 2010; Cartier et al., 2003; Majeau et al., 2007; Okabe et al.,
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2006).

As one well characterized example, the E6 oncoprotein from human

papillomavirus (HPV) is phosphorylated by PKA during infection, allowing it to interact
with numerous cellular proteins (Boon et al., 2015; Delury et al., 2013). While E1A does
not appear to be a substrate for PKA, its unique mechanism of commandeering this
enzyme via mimicry highlights the diverse ways in which viruses can repurpose the same
cellular factors. It is also interesting that rather than encoding an entire PKA ortholog or
an entire viral protein to subvert PKA function, HAdV uses a short 15 amino acid
fragment of the versatile E1A protein to retask PKA for the benefit of the virus. The fact
that the AKAP mimic motif in E1A also overlaps regions required for targeting other
cellular regulatory proteins (Fonseca et al., 2012; Meng et al., 2005; Rasti et al., 2005)
further demonstrates the incredible effect of selective pressure on maximizing the impact
of the relatively limited coding capacity of HAdV.
In summary, we conclusively identify E1A as the first known viral AKAP.

We

demonstrate that the N-terminus of E1A has evolved to mimic the appearance, structure
and function of the PKA interaction domain of cellular AKAPs. Furthermore, we have
established that the AKAP function of E1A plays a biologically significant role in
redirecting PKA to the nucleus during infection, where it is repurposed to enhance HAdV
early gene expression and viral progeny production.
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Chapter 3

3

Mimicry of cellular A-kinase anchoring proteins is a
conserved and critical function of E1A across various
human adenovirus species

“When you run the marathon, you run against the distance, not against the other runners
and not against the time.”
– Haile Gebrselassie

3.1 Introduction
The E1A oncoprotein of human adenovirus (HAdV) is the first viral protein produced
upon infection and performs numerous crucial tasks required for viral command of the
host cell (Frisch and Mymryk, 2002; Pelka et al., 2008). By binding to and modulating
the activities of important cellular regulatory proteins, E1A alters the transcriptional
landscape of infected cells to favour viral replication (Ferrari et al., 2014, 2008; Hearing
and Shenk, 1986). The targets of E1A are diverse in both form and function, highlighting
its modular and multifunctional nature. As a relatively small protein, E1A is densely
packed with protein interaction motifs ranging in size from a mere few to dozens of
amino acids (Ferreon et al., 2013; Pelka et al., 2008). Additionally, many of these motifs
are functional mimics of cellular counterparts suggesting E1A has coevolved with its host
to be an effective competitor for its targeted binding partners.
The N-terminus of HAdV-5 E1A (~aa1-40) alone is capable of interacting with roughly a
dozen cellular proteins and contains strong transcriptional activation ability (Bondesson
et al., 1994; Pelka et al., 2008; Yousef et al., 2009). Indeed, viral genes as well as
cellular genes involved in cell cycle, signalling, differentiation, and immunity are
modulated by the protein-protein interactions from this small portion of a single viral
protein. Recently, protein kinase A (PKA) was shown to be a target of HAdV-5 E1A via
viral mimicry (King et al., 2016a). PKA primarily exists as a tetrameric holoenzyme
consisting of two catalytic subunits (C) bound by a regulatory subunit (R) homodimer
(Taylor et al., 2013). Multiple isoforms of both C- and R-subunits exist, providing
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additional levels of functional specificity based on cell-type specific expression,
additional binding partners, and substrate recognition. Cα specifically was manipulated
by HAdV-5 E1A via E1A’s ability to bind both the RIα- and RIIα-type regulatory
subunits. This was mediated through the N-terminus of HAdV-5 E1A which contains a
binding motif similar to that found in PKA’s canonical cellular interacting partner(s), Akinase anchoring proteins (AKAPs). AKAPs are polyvalent and highly dynamic scaffold
proteins that provide spatiotemporal control of PKA by localizing it within the cell
(Banky et al., 1998; Gold et al., 2006; Newlon et al., 1999). Their hallmark PKA-binding
motif is an amphipathic α-helix that directly binds with high-affinity to the hydrophobic
groove in the D/D domain of PKA R-subunit dimers. Most AKAP-PKA interactions are
specific for either RIα or RIIα subunits but dual-specificity AKAPs exist as well. In
addition to binding PKA, AKAPs typically contain motifs directing their subcellular
localization to specific intracellular compartments or organelles. AKAPs enable tight and
efficient control of cAMP signaling by simultaneously tethering interactions between
PKA, substrates, and up- or down-stream regulators of the pathway. PKA serves several
signalling roles in cell biology, including transcriptional regulation, making it an
attractive target for manipulation by a viral hub like E1A (Guo et al., 2012; Sands and
Palmer, 2008; Zambon et al., 2005; Zhang et al., 2005). E1A’s own amphipathic α-helix
motif allowed it to outcompete endogenous AKAPs to bind with PKA and relocalize it to
the nucleus. The alteration of PKA compartmentalization by this ‘viral AKAP’ (vAKAP)
was biologically significant as it enhanced viral transcription, protein synthesis, and
progeny production.
The mechanism behind E1A-mediated manipulation of PKA was well-characterized in
the context of HAdV-5 infection. However, while protein-protein binding was shown to
be largely conserved between PKA and E1A proteins of different HAdV species, very
little is known regarding how E1A from other HAdVs may affect this important cellular
kinase. The N-terminal sequence of E1A, containing the PKA-binding α-helix, is not as
conserved as other portions of this protein (Avvakumov et al., 2004) and it has been
shown that altering a single or few amino acids can disrupt the interaction between E1A
and PKA (King et al., 2016a). Whether all species of HAdV utilize E1A as a vAKAP has
yet to be determined. There may also exist varying preferences for PKA subunit binding
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or relocalization, and this may confer differential effects on replication for distinct
HAdVs.
Here we analyze representative E1A proteins from seven HAdV species for their abilities
to act as vAKAPs. We found that while not all species of E1A could engage in this form
of mimicry, the mechanism described for HAdV-5 E1A is largely conserved between
several distinct HAdVs. Building upon previous observations, different E1As exhibit a
preference for one type of PKA regulatory subunit (RIα or RIIα) over the other. While
exploring this finding, we identified individual residuesin the PKA-binding motifs of
vAKAPs that when altered by site-directed mutagenesis can convert the preferred
interaction to the alternative regulatory subunit.

Additionally, we provide new

mechanistic insights into how HAdV alters cellular cAMP signalling and show viruses
capable of manipulating PKA have an enhanced ability to drive cAMP-regulated
transcription. An E1A-PKA interaction is also a conserved requirement for wild-type
(WT) levels of viral genome replication and infectious progeny production. Together,
our results characterize a shared mechanism for viral manipulation of a cellular kinase
which enhances the life cycle of numerous human adenoviruses.

3.2 Materials and Methods
3.2.1 Cell lines and transfections
Human A549 (provided by Russ Wheeler, Molecular Pathology/Genetics London Health
Sciences Centre), HEK293, HT1080, and HeLa (purchased from the American Type
Culture Collection) were grown at 37ᵒC with 5% CO2 in DMEM (Multicell)
supplemented with 10% fetal bovine serum (Gibco). Plasmids were transfected into
HT1080 and HeLa cells using XtremegeneHP (Roche) following the manufacturer’s
recommendation.

After 24 hours of incubation, transfected cells were used for

downstream experiments.

3.2.2 Viruses and infection of cells
Wild-type (WT) HAdV-5 (dl309) was previously described (Jones and Shenk, 1979) and
mutants dl312 and dl1101 are derived from the same background to express no E1A and
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E1AΔ4-25 respectively. HAdV-5 dl520 and dl1131/520 express only the “12S” product
of E1A with the latter containing an additional C-terminal deletion (219-289) (Mymryk
and Bayley, 1993). WT serotypes of HAdV-3 (strain GB Lot 11W), -4 (strain RI-67 Lot
3W), -9 (Strain Hicks Lot 1W), and -12 (Strain Huie Lot 8W) were purchased from the
ATCC via Cedarlane. A549 cells were infected at a multiplicity of infection (MOI) of 5
plaque-forming units/mL (for HAdV-5) or 25 for all other virus species to attain similar
levels of infection. Cell cultures were infected at ~50% confluence and subconfluent
cells were collected at indicated time points for downstream experiments. For plaque
assays, HEK293 cells were infected with serially-diluted samples for 1 hour at 37ᵒC
before being overlayed with DMEM containing 1% SeaPlaque Agarose (Lonza).

3.2.3 RNAi knockdown
Downregulation of PKA subunits RIα, RIIα, and Cα was performed using Silencer Select
siRNA (Thermo), specifically s286 (PRKAR1A), s11086 (PRKAR2A), and s11065
(PRKACA). Four hours after seeding, siRNA was delivered to A549 and HT1080 cells
via transfection with Silentfect (BioRad) according to the manufacturer’s instructions. A
scrambled siRNA was used as a negative control.

Treated cells were used for

experiments 48 hours post-transfection.

3.2.4 Plasmids
All constructs were expressed in vectors under control of the CMV promoter, with the
exception of the luciferase reporter which was driven by the cAMP-responsive rat
PEPCK promoter (Klemm et al., 1996). WT RIα, RIIα, and Cα along with ΔD/D mutants
were previously described (King et al., 2016a). WT full-length HAdV-52 E1A was
synthesized using IDT’s gene synthesis platform from a published genome sequence
(Jones et al., 2007). E1A fragments, truncations, and deletion mutants for all species
were expressed as fusions to EGFP and either previously described (King et al., 2016a) or
derived via PCR and cloned into pEGFP-C2. Chimeras (HAdV-4 chimera and HAdV-5
chimera) and point mutants (HAdV-5 D21E, E26T, V27L and HAdV-3 E22D, T27E,
L28V) were cloned similarly. A list of all plasmids used in this chapter can be found in
table 3.1.
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Table 3.1. List of plasmids used in this chapter
Clone

Backbone(s)

Notes

13S Ad3 E1A
13S Ad4 E1A
13S Ad5 E1A
13S Ad9 E1A
13S Ad12 E1A
13S Ad40 E1A
*13S Ad52 E1A
Ad5 E1A 1-82
*Ad3 E1A Δ1-82
Ad3 E1A 1-82
*Ad9 E1A Δ1-81
Ad9 E1A 1-81
*Ad12 E1A Δ1-79
Ad12 E1A 1-79
*Ad40 E1A Δ1-77
Ad40 E1A 1-77
*Ad52 E1A Δ1-75
*Ad52 E1A 1-75
*Ad3 E1A 1-13
*Ad3 E1A 11-28
*Ad3 E1A 28-82
*Ad3 E1A Δ11-28
*Ad9 E1A 1-14
*Ad9 E1A 12-29
*Ad9 E1A 30-81
*Ad9 E1A Δ12-29
*Ad12 E1A 1-13
*Ad12 E1A 12-27
*Ad12 E1A 28-79
*Ad12 E1A Δ12-27
*Ad12 E1A Δ37-49
*Ad12 E1A Δ12-27,37-49
*Ad40 E1A 1-12
*Ad40 E1A 12-26
*Ad40 E1A 25-77
*Ad40 E1A Δ12-26
PKA RIα
PKA RIIα
PKA Cα
PKA RIα Δ1-63
PKA RIIα Δ1-45
Ad5 E1A Δ16-28
*Ad5 chimera E1A
*Ad4 chimera E1A
*Ad5 E1A D21E E26T V27L
*Ad3 E1A E22D T27E L28V
PEPCK-luc

pEGFP-C2
pEGFP-C2
pEGFP-C2, pcDNA3
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pcDNA-HA, pcDNA-MYC
pcDNA-HA, pcDNA-MYC
pcDNA-HA
pcDNA-HA
pcDNA-HA, pcDNA-MYC
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pEGFP-C2
pGL3-Basic

Species B
Species E
Species C
Species D
Species A
Species F
Species G, Jones et al., 2007
N-terminus and CR1

*Novel clone generated for this study

N-terminus and CR1
N-terminus and CR1
N-terminus and CR1
N-terminus and CR1
N-terminus and CR1

ΔD/D
ΔD/D
Ad5 backbone with Ad4 N-terminus
Ad4 backbone with Ad5 N-terminus

From Joshua Hamilton
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Table 3.2. List of primary antibodies used in this chapter
Reactivity

Purpose

Description

Company

RIα
RIα
RIIα
RIIα
Cα
Cα
Actin
EGFP
9E10 (MYC)
3F10 (HA)
CREB1
CREB1-pSer133
M73 (E1A)
M37 (E1A)
cAMP
B68 (DBP)

Western
IF
Western
IF
Western
IF
Western
Western, IP
Western, IP
Western
Western
Western, IF
Western, IF
IF
IF
IF

Mouse monoclonal
Rabbit polyclonal
Mouse monoclonal
Rabbit polyclonal
Mouse monoclonal
Rabbit polyclonal
Rabbit polyclonal
Rabbit polyclonal
Mouse monoclonal
Rat monoclonal
Rabbit polyclonal
Rabbit polyclonal
Mouse monoclonal
Mouse monoclonal
Rabbit monoclonal
Mouse monoclonal

BD
Thermo
BD
Santa Cruz
BD
Santa Cruz
Sigma
Clontech
In-house
Roche
Santa Cruz
Santa Cruz
In-house
In-house
Abcam
In-house
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3.2.5 Western blotting and co-immunoprecipitation
Cells were lysed in NP40 lysis buffer (150mM NaCl, 50mM Tris-HCL pH 7.5, 0.1% NP40) with protease inhibitor cocktail.

Protein concentrations were determined using

BioRad protein assay reagent using BSA as a standard. Co-immunoprecipitations were
carried out at 4ᵒC for 4 hours. 2% of sample was kept as input control. After washing
with NP40 buffer, complexes were boiled in 25 µL of LDS sample buffer for 5 minutes.
Samples were separated on NuPage Bis-Tris gels (Life Technologies) and transferred
onto a PVDF membrane (Amersham). Membranes were blocked in 5% skim milk or 3%
bovine serum albumin (BSA) constituted in TBS with 0.1% Tween-20. Horseradish
peroxidise-conjugated secondary antibody was detected using Luminata Forte or
Crescendo substrate (Millipore). Primary antibodies used in this chapter can be found in
table 2.2.

3.2.6 Immunofluorescence microscopy
Cells were fixed in 3.7% paraformaldehyde, permeabilized on ice using 0.2% Triton X100, and blocked using 3% BSA in phospho-buffered saline (PBS). Samples were
incubated in the primary antibody for 1 hour at room temperature or 4ᵒC overnight and
another hour at room temperature with secondary antibody (Alexa Fluor 594 or 488 αrabbit; Life technologies). Samples were mounted with Prolong Gold reagent containing
DAPI (Life technologies). Confocal images were acquired using a Fluoview 1000 laser
scanning confocal microscope (Olympus Corp). Quantification of total cellular signal
and nuclear signal was conducted using ImageJ.

Cells were normalized for both

cytoplasmic and nuclear size and %nuclear signal was determined as previously
described (Cohen et al., 2014).

3.2.7 Virus replication assay
A549 cells were treated with siRNAs followed by HAdV infection for 1 hour at 37ᵒC at
the indicated MOI. Total cell DNA was purified at 6 and 48 hours post-infection using a
DNeasy Blood and Tissue Kit (QIAGEN). Viral DNA levels were quantified by qPCR
with Power SYBR Green (Thermo) using a forward primer that recognizes a conserved

128

Table 3.3. List of qPCR primers used in this chapter
Target

Region

Location

Sequence

Size

GAPDH-F
GAPDH-R
E1A-All-F
Ad3E1A-R
Ad4E1A-R
Ad5E1A-R
Ad9E1A-R
Ad12E1A-R

Cellular cDNA
Cellular cDNA
Promoter
Exon1
Exon1
Exon1
Exon1
Exon1

566-587
620-644
Variable
702-721
690-709
697-715
711-730
641-659

ACTGCTTAGCACCCCTGGCCAA
ATGGCATGGACTGTGGTCATGAGTC
AGAGGCCACTCTTGAGTGC
TACAGATCGTGCAGCGTAGG
AGCGAAGGTGTCTCAAATGG
CGTCACGTCTAAATCATAC
GGGCATCTACCTCCAGATCA
CGGCAGACTCCACATCAAG

79
Variable
271
206
224
226
221
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Table 3.4. List of cloning primers used in this chapter
Clone

Forward

Reverse

Notes

13S Ad52
E1A
Ad3 E1A
Δ1-82
Ad9 E1A
Δ1-81
Ad12 E1A
Δ1-79
Ad40 E1A
Δ1-77
Ad52 E1A
Δ1-75
Ad52 E1A
1-75
Ad3 E1A 113
Ad3 E1A
11-28
Ad3 E1A
28-82
Ad3 E1A
Δ11-28

ATTGGAATTCATGAGGCTGGTCC
CC
ATCCGAATTCATGAACCCTCCTCC
TGAGACA
ATCCGAATTCATGACTCCACTTCA
TACAC
ATTCGAATTCATGCCGGAGCCTC
CTGTA
ATTGGAATTCATGAGCGGTTCGG
GTGAT
ATTGGAATTCATGTCTCACAGCA
GTGA
ATTGGAATTCATGAGGCTGGTCC
CC
TACGAATTCATGAGACACCTGCG
CTTC
ATCCGAATTCATGGTTATCTCCAG
TGAGAC
ATCCGAATTCATGCTAATGGGAG
ACGAC
TTCCTGCCACAGGAGCTAATGGG
AGACGAC
TACGAATTCATGAGACACCTGCG
CTTC
CTGGAATTCATGAGACACCTGCG
CC
ATTCGAATTCATGCCCGGTGAGC
TGGCT
ATTCGAATTCATGGACGAACTGC
ATCCA
CTGCCTTCAACTGTGGACGAACT
GCATCCA
CTGGAATTCATGAGACACCTGCG
CC
CTACGAATTCATGAGAACTGAAA
TGACTCCC
ATCCGAATTCATGTATCAGGAAG
CTGAC
ATCCGAATTCATGAACGAGGTAC
CCAGT
CCCTTGGTCCTGTCGAACGAGGT
ACCCAGT
CTACGAATTCATGAGAACTGAAA
TGACTCCC
AGTGATGATGATCTTGAGTCTGC
CGGTGAA
CTACGAATTCATGAGAACTGAAA
TGACTCCC
AGTGATGATGATCTTGAGTCTGC
CGGTGAA
CTACGAATTCATGAGAACTGAAA
TGACTCCC

CATCGTCGACTTAGGTCAGCTT
A
GGATGTCGACTCATTGCCTTGG
CAGTTT
AGTGTCGACGTCTAGTTCCTGG
GGCG
CAGGTCGACTTAATTACATCTA
GGGCGTTTC
GTGGTCGACTCAGGAGCACTTG
GGGCGC
CATCGTCGACTTAGGTCAGCTT
A
CATCGTCGACCTAACCCTCCTC
AGCCG
GGATGTCGACTTAGGAGATAAC
CT
CATCGTCGACTTAGGTATTTAC
CACAAA
AGTGTCGACTTATATGTCCAAT
CCTTCATCGG
GTCGTCTCCCATTAGCTCCTGTG
GCAGGAA
GGATGTCGACTCATTGCCTTGG
CAGTTT
CATCGTCGACTTACTCACCGGG
CACAGT
CATCGTCGACTTACTCCAATAC
TGTAT
ATAGTCGACTTAAGATTCGTTG
GCTATGTCAG
TGGATGCAGTTCGTCCACAGTT
GAAGGCAG
AGTGTCGACGTCTAGTTCCTGG
GGCG
CAGCGTCGACTTACTGATACGA
CAG
CATCGTCGACCTAAAAAAAGTT
GTCCA
TGAGTCGACTAAAAACAACCCC
TCACTGGC
ACTGGGTACCTCGTTCGACAGG
ACCAAGGG
CAGGTCGACTTAATTACATCTA
GGGCGTTTC
TTCACCGGCAGACTCAAGATCA
TCATCACT
CAGGTCGACTTAATTACATCTA
GGGCGTTTC
TTCACCGGCAGACTCAAGATCA
TCATCACT
CAGGTCGACTTAATTACATCTA
GGGCGTTTC

Jones et
al., 2007

TCAGAATTCATGAGAATGCTGCC
GG

CATCGTCGACCTACCAGTTCCC
G

Ad9 E1A 114
Ad9 E1A
12-29
Ad9 E1A
30-81
Ad9 E1A
Δ12-29

Ad12 E1A
1-13
Ad12 E1A
12-27
Ad12 E1A
28-79
Ad12 E1A
Δ12-27

Ad12 E1A
Δ37-49

Ad12 E1A
Δ12-27,3749 (same as
Δ37-49 with
Δ12-27 as
template)
Ad40 E1A
1-12

Internal
Flanking

Internal
Flanking

Internal
Flanking
Internal
Flanking
Internal
Flanking
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Ad40 E1A
12-26
Ad40 E1A
25-77
Ad40 E1A
Δ12-26

Ad5
chimera
E1A
Ad4
chimera
E1A
Ad5 E1A
D21E E26T
V27L
Ad3 E1A
E22D T27E
L28V

ATTGGAATTCATGTGGGATGACA
TGT
ATTGGAATTCATGGTGTTTGATTT
C
TTTACCGGGAACGATTTCCCTGA
ACCT
TCAGAATTCATGAGAATGCTGCC
GG
CGAGGAGGCTTCATTTCCGCCGG
CGC
TCCGAATTCATGAGGCACCTAAG
AGAC
ATTGACTTACTCACTAGCCCTAGC
TCAGA
CGACGAATTCATGAGACATATTA
TCTGC
TTTGGAGCAGCTGATCGAAACCC
TACTGG
CGACGAATTCATGAGACATATTA
TCTGC
TACTGGACTTTGTGGTAAATGAG
GTAATGGGA
TACGAATTCATGAGACACCTGCG
CTTC

CATCGTCGACCTAAAACACATA
TTCA
TCAGTCGACTTACTCTGCAGCG
CTCTCAG
AGGTTCAGGGAAATCGTTCCCG
GTAAA
GTGGTCGACTCAGGAGCACTTG
GGGCGC
GCGCCGGCGGAAATGAAGCCTC
CTCG
ACTGTCGACTTATGGCCTGGGA
CGTTTACAGCTC
TCTGAGCTAGGGCTAGTGAGTA
AGTCAAT
GTGGTCGACTTAATGCCTGGGG
CGTTTCC
CCAGTAGGGTTTCGATCAGCTG
CTCCAAA
ACTGTCGACTTATGGCCTGGGA
CGTTTACAGCTC
TCCCATTACCTCATTTACCACA
AAGTCCAGTA
GGATGTCGACTCATTGCCTTGG
CAGTTT

Internal
Flanking
Internal
Flanking
Internal
Flanking
Internal
Flanking
Internal
Flanking

131

sequence in E1A in combination with a serotype-specific reverse primer. Values are
normalized to GAPDH and the fold-increase of viral copy number at 48 hours was
calculated by normalizing to ‘input’ viral DNA at 6 hours post-infection.

Viral

replication efficiency in the presence of PKA knockdowns was presented as the relative
value compared to scrambled control siRNA-treated cells, which were normalized to 1.
A list of all primers used in this chapter can be found in tables 3.3 and 3.4.

3.2.8 Luciferase reporter assay
HT1080 cells were co-transfected with a constitutive β-galactosidase reporter plasmid for
normalization, a plasmid containing the luciferase gene driven by the rat PEPCK
promoter, and the indicated EGFP-E1A fusion constructs. The reporter was validated by
6 hours of 0.5µM forskolin (fsk) treatment and siRNA-mediated knockdown of PKA
protein. 24 hours post-transfection, cells were lysed in 200 µL of the supplied lysis
buffer (Promega). For detection of luciferase production, 50 µL of lysate was mixed with
50µL of the provided Luciferase Substrate (Promega) immediately before detection of
light was measured using a Berthold Lumat LB 9507. Relative light values were set to an
empty plasmid control, were normalized to protein levels via Bradford Assay, and further
normalized via β-galactosidase activity as detected by ONPG (Ortho-Nitrophenyl-β-DGalactopyranoside).

3.2.9 PKA activity assay
PKA activity in cell lysates was measured using the Protein Kinase A Colorimetric
Activity Kit (Thermo). 1x106 A549 cells were seeded overnight then either treated with
fsk for 6 hours or infected with the indicated virus. After harvesting at the indicated
timepoints, PKA activity of the cell lysates was assayed using the protocol outlined by
the manufacturer. Activity in uninfected cells were normalized to 1 and compared to all
other conditions.

3.2.10 Statistical analysis
All experiments were carried out with three biological replicates performed in duplicate.
Graphs represent mean and standard error of the mean (S.E.M.) of all biological
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replicates.

For western blots, a representative image was selected.

Statistical

significance of numerical differences was calculated using t-tests (Figure 3.11) or oneway ANOVA and Holm-Sidak post-hoc comparisons (Figures 3.4, 3.12, 3.13) between
experimental conditions.

3.3 Results
3.3.1 Protein kinase A subunits are conserved binding targets of the
N-terminal region of E1A across numerous HAdV species
The full-length isoforms (“13S”) of E1A proteins from representative viruses of six
HAdV species (A-F) were previously tested for protein-protein interactions with PKA
subunits. E1A from HAdV-12 (species A), HAdV-3 (species B), HAdV-5 (species C),
HAdV-9 (species D), and HAdV-40 (species F) could associate with PKA via coimmunoprecipitation (Co-IP) while HAdV-4 (species E) could not (King et al., 2016a).
However, the detailed mechanisms behind these individual interactions have only been
further explored for HAdV-5 and HAdV-12 (Fax et al., 2001; King et al., 2016a).
Additionally, a seventh species of HAdV (G) has been recently classified, containing a
lone member, HAdV-52 (Jones et al., 2007). To further investigate these E1A-PKA
interactions, HT1080 fibrosarcoma cells were transfected with vectors expressing PKA
subunits along with either WT E1A from the seven HAdV species or the indicated
fragments/portions of E1A (Figure 3.1).
Co-immunoprecipitation analysis revealed that RIα, RIIα, and Cα all associated with the
majority of the E1A proteins tested. E1A from HAdV-5 was used as a positive control
while the non-binding E1A from HAdV-4 was used as a negative control. E1A from
HAdV-4 and the less-characterized HAdV-52 were the only non-binding types observed.
For the E1As which bound (HAdV-3, -5, -9, -12, -40), the N-terminal portion of these
proteins was both necessary and sufficient for conferring these interactions, though this
was notably weakest for HAdV-40 E1A. These data show for the first time where PKA
binds on each of these unique E1As, and the observations align with those previous for
both HAdV-5 and -12 (Fax et al., 2001; King et al., 2016a). Additionally, this region of
E1A has been previously shown to be associated with alterations in cAMP signalling
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Figure 3.1. Protein Kinase A subunits are conserved binding targets of HAdV
E1A’s N-terminus.
HT1080 cells were co-transfected with PKA subunits and various WT or mutant E1A
constructs from 7 HAdV types (shown in the inset panel). Whole cell lysates were
harvested for co-immunoprecipitation. WT E1A from HAdV-3, -5, -9, -12, and -40
associates with RIα, RIIα, and Cα, whereas E1A from HAdV-4 and -52 do not. Deletion
of the entire E1A N-terminus ablated the interactions, whereas the N-terminus alone was
sufficient for binding.
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(Engel et al., 1991, 1988; Hardy and Shenk, 1988; Lee and Mathews, 1997; Müller et al.,
1989) and has been characterized as being a conserved transactivation domain
(Bondesson et al., 1994; Yousef et al., 2009).

3.3.2 E1A proteins that bind PKA use an AKAP-like sequence motif
The minimal region of E1A required to bind PKA was previously delineated for HAdV-5
(King et al., 2016a). To determine the regions within E1A for the other HAdVs whose
E1As have putative viral AKAP activity, we carried out more detailed mutational
analyses for each distinct E1A (Figure 3.2A-D). Cells were co-transfected with vectors
expressing PKA subunits and either WT or the indicated portions of E1A for several
HAdV species. For HAdV-3 (Figure 3.2A), -9 (Figure 3.2B), -12 (Figure 3.2C), and -40
(Figure 3.2D), overlapping deletions or truncations within the N-terminus were tested.
HAdV-3, -9, and -40 each contained a small region that was both necessary and sufficient
for associating with PKA subunits (amino acids 11-28, 12-29, 12-26 respectively). Each
of these regions bears strong similarity to the PKA-binding motif within HAdV-5 E1A,
as well as those of cellular AKAPs (9). Also like HAdV-5 E1A and cellular AKAPs,
these motifs are predicted to contain α-helical secondary structure (Pelka et al., 2008).
HAdV-12 E1A appeared to have two regions contributing to its binding with PKA
(amino acids 12-27 and 37-49) and deletion of both was required to fully abrogate this
interaction. While unexpected, this observation does align with that of a previous report
on this E1A’s interaction with PKA (Fax et al., 2001) and may suggest additional,
unconventional means of manipulating PKA by this E1A type. Taken together, these
results demonstrate that the utilization of AKAP mimicry is a conserved function of the
E1As which bind to PKA.

3.3.3 E1A binds to PKA via the PKA docking-dimerization domain
Cellular AKAPs bind PKA via the docking-dimerization (D/D) domain of PKA
regulatory subunits (RIα and RIIα) (Banky et al., 1998; Newlon et al., 1999). Given the
predicted sequence and structural similarities between cellular AKAPs and the E1As that
bind PKA, we tested if the D/D domain was necessary for the observed E1A-PKA
interactions (Figure 3.3). Cells were co-transfected with WT E1A from seven HAdV
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Figure 3.2. E1A proteins that bind PKA use an AKAP-like sequence motif.
HT1080 cells were co-transfected with PKA subunits and E1A constructs from either
HAdV-3, -9, -12, or -40 (A-D). Mutation schemes are shown in the inset panels. Cell
lysates were harvested and co-immunoprecipitation analysis of each E1A protein
revealed that amino acids 11-28 for HAdV-3 (A), aa12-29 for HAdV-9 (B), aa12-27, 3749 for HAdV-12 (C), and aa12-26 for HAdV-40 (D) were necessary and sufficient for
binding PKA subunits.
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Figure 3.3. HAdV species whose E1A proteins bind PKA do so via PKA’s dockingdimerization domain.
HT1080 cells were co-transfected with WT E1A from 7 species of HAdV along with
either both WT PKA regulatory subunits (“R”) or both subunits lacking their D/D
domains (“ΔR”).

Whole cell lysates were harvested for co-immunoprecipitation.

Deletion of the D/D domains in either HA-tagged RIα or MYC-tagged RIIα abrogated
the interactions with E1A.
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species along with either WT PKA regulatory subunits or mutants lacking their respective
D/D domains (RIαΔ1-63 and RIIαΔ1-45). As expected, neither HAdV-4 nor -52 E1A
interacted with any PKA construct tested. E1A from HAdV-3, -5, -9, -12, and -40 coimmunoprecipitated with WT PKA regulatory subunits but failed to associate with those
lacking the D/D domains. Thus, multiple E1As not only resemble AKAPs themselves,
but also require the same site on the PKA regulatory subunits that is targeted by cellular
AKAPs and the previously characterized HAdV-5 E1A for interaction.

3.3.4 Distinct E1A proteins relocalize PKA regulatory subunits in a
type-specific manner
The subcellular redistribution of PKA subunits was previously explored with E1A from
HAdV-5 and HAdV-12. Those two proteins were found to have contrasting preferences
for the type-I and type-II regulatory subunits, respectively (Fax et al., 2001; King et al.,
2016a). Here we sought to extend our investigation into how E1A from different HAdVs
affect PKA by utilizing both infection and transfection-based approaches. HeLa cells
were transiently transfected with EGFP-tagged WT E1A proteins from all seven HAdV
species and proteins were subsequently detected via autofluorescence (EGFP) or
immunofluorescence staining (PKA) (Figure 3.4A-C). While PKA Cα appeared nuclearcytoplasmic and broadly similar in all immunofluorescence experiments (data not
shown), notable differences emerged between RIα and RIIα.

As expected, neither

HAdV-4 nor HAdV-52 E1A, which did not bind PKA, showed any ability to alter the
subcellular localization of PKA subunits RIα or RIIα (Figure 3.4A). The relocalization
phenotypes for both HAdV-5 (RIα specific) and HAdV-12 E1A (RIIα specific) were
reproduced as positive controls. This confirmed that different E1As exhibit a type
‘preference’ for functionally altering the PKA subunits they bind (Figure 3.4B, C).
Similar to HAdV-5, E1A from HAdV-9 caused the RIα subunit to be redirected from the
cytoplasm into the nucleus (Figure 3.4B). In contrast, E1A from HAdV-3 caused the
RIIα subunit to be relocalized, similarly to E1A from HAdV-12 (Figure 3.4C). HAdV-40
E1A did not appear to relocalize either PKA regulatory subunit (Figure 3.4A).

139

Figure 3.4. Distinct E1A proteins relocalize PKA regulatory subunits in a typespecific manner.
HeLa cells were transfected with EGFP-tagged WT or mutant E1A constructs from 7
species of HAdV. Cells were fixed, permeabilized, and proteins were detected via
autofluorescence (E1A) or by immunofluorescence (PKA). Scale bars represent 100µm
and the targeted PKA subunit is indicated above each group of panels. A) EGFP alone or
E1A from HAdV-4, -52, and -40 showed no relocalization of either PKA regulatory
subunit. E1A from HAdV-3 and -12 showed no relocalization of RIα, whereas HAdV-5
and -9 E1A showed no relocalization of RIIα. B) HAdV-5 and -9 E1A caused a shift of
RIα from the cytoplasm to the nucleus that was ablated when these E1A proteins had
their AKAP-like motifs deleted. Conversely, (C) HAdV-3 and -12 E1A caused a shift of
RIIα from the cytoplasm to the nucleus that was ablated when their PKA-binding regions
were removed. Quantification of nuclear signal relative to total cellular signal is also
shown next to representative images for the indicated E1A species (values are displayed
as mean ± SD *p<0.001, n=50).
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Figure 3.5. The C-terminus of E1A, which contains the nuclear localization signal,
is required for efficient retasking of PKA.
A549 cells were infected with either HAdV-5 dl520 or dl1131/520 (the E1A proteins
expressed by these viruses are shown in the adjacent panel). After 24 hours, cells were
fixed, permeabilized, and stained for confocal immunofluorescence. E1A lacking the Cterminal bipartite NLS was deficient for both its nuclear localization and
recompartmentalization of RIα. Scale bars represent 100µm.
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Figure 3.6. Localization of PKA regulatory subunits in cells infected with various
HAdV species.
A549 cells were infected with either WT HAdV-3, -4, -5 (dl309), -9, or -12 at an MOI of
5 (for HAdV-5) or 25 (for all other viruses).

After 24 hours cells were fixed,

permeabilized, and stained for confocal immunofluorescence. RIα appears to be more
nuclear in HAdV-5 or -9 infected cells compared to uninfected cells. In contrast, RIIα
appears more nuclear in HAdV-3 or -12 infected cells. Scale bars represent 100µm.
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Mutant E1As containing deletions which abrogate PKA-binding for each species were
tested side-by-side with the cognate WT E1A control (Figure 3.4A-C). As expected, the
removal of the previously-established binding motifs within each E1A protein abrogated
the protein’s ability to relocalize PKA in transfected conditions. The relocalization of
PKA regulatory subunits was therefore E1A-dependent and required the AKAP-like
motif necessary for PKA interaction, as previously demonstrated with HAdV-5 E1A.
Using HAdV-5 as a model, we also demonstrated that the nuclear localization signal
(NLS) of E1A is needed to contribute to PKA relocalization, but not CR3 (Figure 3.5).
While WT “12S” virus (dl520) relocalized RIα despite the absence of CR3, a mutant
lacking both CR3 and the C-terminal bipartite NLS (dl1131/520) was deficient for
relocalization of RIα. This suggests that binding of the regulatory subunit by E1A is not
sufficient for efficient recompartmentalization of PKA and that relocalization requires
cooperation with other functions located in the C-terminus of E1A. PKA localization
was also examined in A549 cells infected with WT strains of HAdV-3, -4, -9, and -12
(Figure 3.6). The observed staining phenotype matched that of the transfection-based
experiments, suggesting that in vitro results faithfully reflect what occurs during an in
vivo infection.
The curious observation that E1A proteins are able to associate with both RIα and RIIα in
Co-IP experiments, yet only relocalize one isoform in vivo led us to test whether
differences in binding affinity for distinct subunits contributed to this selectivity. First,
we established a Co-IP-based squelching assay where untagged HAdV-5 E1A was
titrated in as a competitor against EGFP-tagged HAdV-5 E1A (Figure 3.7A).

As

expected, higher levels of competition eventually abrogated the ability of EGFP-E1A to
Co-IP with PKA regulatory subunits. We then applied these conditions to similarly test
HAdV-5 E1A against EGFP-tagged E1A from HAdV-3, -9, -12, and -40 (Figure 3.7B).
HAdV-3 and -12 E1As were more resistant to competition from HAdV-5 E1A when
examining their associations with RIIα; conversely, their interactions with RIα were more
susceptible to depletion in this competition assay. Together these data suggest again that
HAdV-3 and -12 have relatively higher affinity for RIIα while HAdV-5 prefers RIα.
HAdV-9 E1A was susceptible to competition in a manner similar to how HAdV-5 was
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Figure 3.7. Different E1A species display an affinity preference for either RIα or
RIIα.
A) HT1080 cells were co-transfected with EGFP-tagged HAdV-5 E1A and PKA
regulatory subunits. Untagged HAdV-5 E1A was titrated in as a competitor against
EGFP-E1A for binding PKA. Whole cell lysates were harvested for Co-IP using an
antibody against EGFP. Increasing amounts of untagged E1A squelched EGFP-E1A’s
interactions with RIα and RIIα. B) Conditions optimized from (A) were used in a larger
competition panel with EGFP-tagged E1A from HAdV-3, -9, -12, and -40. HT1080 cells
were similarly co-transfected with the indicated E1A species, PKA subunits, and
increasing amounts of untagged HAdV-5 E1A.

Co-IP analysis revealed varying

resistances and susceptibilities to competition from HAdV-5 E1A for binding either RIα
or RIIα.
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Figure 3.8. Depriving HAdV-5 E1A of type-I PKA causes E1A to retask type-II
PKA instead.
A) A549 cells were treated with the indicated control or RIα-specific siRNAs and
subsequently infected with WT (dl309) HAdV-5. Only in the absence of RIα protein
does E1A relocalize some RIIα to the nucleus.

Scale bars represent 100µm.

B)

Equilibrium models of how E1A may compete against cellular AKAPs (cAKAP) and
determine which PKA isoform it relocalizes to the nucleus.
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against itself (Figure 3.7A) reinforcing the similarity between these two E1A species.
HAdV-40 E1A was the most susceptible to competition relative to other E1A proteins
indicating that its association with PKA is the weakest.
While E1As clearly have a preference to relocalize and bind one specific PKA isoform,
the ability to functionally affect the other isoform remains a possibility. Using HAdV-5
as a model, we infected A549 cells pretreated with either a scrambled control siRNA or
siRNA knocking-down RIα, HAdV-5 E1A’s preferred regulatory subunit, with WT
(dl309) virus (Figure 3.8A). In control cells, HAdV-5 E1A behaved as expected by
relocalizing RIα into the nucleus while leaving RIIα in the cytoplasm. However, when
cells were deprived of RIα protein, some RIIα was localized within the nucleus along
with E1A, a finding only observed previously for HAdV-3 and -12 E1A. This suggests
the siRNA-mediated removal of the RIα isoform of PKA shifted the binding equilibrium
of E1A with RIIα in vivo, and that the increased interaction was sufficient to allow some
of

this

isoform

to

be

relocalized

(Figure

3.8B).

While

the

observed

recompartmentalization was not quite as dramatic as with RIα, this may be due to HAdV5 E1A’s apparent lower affinity for this particular subunit.

3.3.5 E1A’s ability to act as a vAKAP is modular and malleable by
mutagenesis
To test if the ‘viral AKAP’ function of E1A was modular, we created a set of EGFPtagged constructs that combined various portions of E1A from HAdV-4 and HAdV-5 to
form chimeric proteins.

Specifically, the N-terminal domains of each protein were

swapped for the analogous region in the other. When these constructs were tested
alongside WT counterparts for binding PKA subunits via Co-IP, the chimera with the
HAdV-5 N-terminus and HAdV-4 C-terminus gained the protein-protein interactions
exhibited by WT HAdV-5 E1A, whereas the reciprocal chimera lost them (Figure 3.9A).
Subsequently, these chimeras were transfected into HeLa cells and PKA subcellular
localization was examined via immunofluorescence staining (Figure 3.9B). As with the
Co-IP assays, the HAdV-4 chimera gained the ability to relocalize the PKA RIα subunit
when its N-terminus was replaced with that from HAdV-5. In contrast, the HAdV-5
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Figure 3.9. Viral AKAP mimicry is a modular function of E1A.
A) HT1080 cells were co-transfected with PKA subunits and either WT or chimeric E1A
constructs and cell lysates were harvested for Co-IP.

The inset panel displays the

construction of the HAdV-4 and -5 E1A chimeras (arrow indicates where N-terminal
swap occurred). The HAdV-4 chimera gained the ability to bind PKA subunits whereas
this was lost for the HAdV-5 chimera. B) HeLa cells were transfected with the indicated
EGFP-tagged E1A constructs.

Cells were fixed, permeabilized, and proteins were

detected via autofluorescence (E1A) or by immunofluorescence (PKA). Cells transfected
with WT HAdV-5 or the HAdV-4 chimera exhibited a shift of RIα from the cytoplasm
into the nucleus. In contrast, WT HAdV-4 or the HAdV-5 chimera showed no noticeable
relocalization of RIα. Scale bars represent 100µm.
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Figure 3.10. Specific residues in the AKAP-like motif of E1As induce preference for
specific PKA subunits.
A)

HT1080 cells were co-transfected with PKA subunits and the indicated E1A

constructs and cell lysates were harvested for Co-IP. Both WT HAdV-3 and -5 along
with mutants (HAdV-5 D21E, E26T, V27L and HAdV-3 E22D, T27E, L28V) retain
similar levels of binding to PKA. The mutation scheme in the inset panel shows residue
positions previously-demonstrated as crucial in HAdV-5 along with the analogous
positions in HAdV-3. B) HeLa cells were transfected with the indicated EGFP-tagged
E1A constructs.

Cells were fixed, permeabilized, and proteins were detected via

autofluorescence (E1A) or by immunofluorescence (PKA). Cells transfected with WT
HAdV-3 or the HAdV-5 D21E, E26T, V27L mutant exhibited a shift of RIIα from the
cytoplasm into the nucleus. In contrast, WT HAdV-5 or the HAdV-3 E22D, T27E, L28V
mutant exhibited a relocalization of RIα. Scale bars represent 100µm.
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chimera with the HAdV-4 N-terminus behaved like the EGFP negative control and WT
HAdV-4 E1A.
To explore this concept of modularity further, we aimed to test if swapping individual
residues within the AKAP-like motif of different E1As could alter their preference for
relocalizing one type of PKA subunit over the other. By comparing the sequences of the
AKAP-like motifs between HAdV-3 and HAdV-5 E1A, triple point mutants for both
E1As were designed (HAdV-5 D21E, E26T, V27L and HAdV-3 E22D, T27E, L28V) in
an effort to exchange specificity. These relatively conservative mutations are embedded
within the predicted α-helix portions of both proteins and are at analogous positions that
were previously demonstrated to be crucial for HAdV-5 E1A binding (King et al.,
2016a).

When tested alongside WT E1A counterparts for binding via Co-IP, both

mutants retained the interaction with PKA subunits similar to that of WT E1A (Figure
3.10A). Next, the mutants were transfected into HeLa cells and examined for their ability
to relocalize individual PKA subunits (Figure 3.10B). Both triple mutants experienced a
change in preference for which PKA subunit they relocalized to the nucleus. When
mutated in this way, HAdV-5 E1A, which previously preferred RIα, now altered RIIα
distribution like WT E1A from HAdV-3 and -12. When HAdV-3 E1A, which normally
preferred RIIα, was mutated in this fashion, it relocalized RIα like WT E1A from HAdV5 or -9. Thus, it appeared that the preference of E1As for specific PKA subunits can be
altered using targeted mutagenesis of select residues.

3.3.6 Interaction with PKA is required for full E1A-mediated
transactivation of a PKA-driven promoter
It was previously shown that the interaction between E1A and PKA could serve to
enhance viral gene expression during HAdV-5 infection (King et al., 2016a).
Additionally, co-transfected HAdV-12 E1A and PKA could activate the HAdV-12 E2
promoter (Fax et al., 2001).

However, many cellular genes are also known to be

regulated by PKA via signaling through cAMP (Guo et al., 2012; Sands and Palmer,
2008; Zambon et al., 2005; Zhang et al., 2005). Also, E1A has been demonstrated to
affect cAMP-responsive cellular genes in certain contexts (Gedrich et al., 1992; Lee and
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Figure 3.11.

Interaction with PKA is required for full E1A-mediated

transactivation of a PKA-driven promoter.
HT1080 cells were transfected with a reporter consisting of the luciferase gene driven by
the rat PEPCK promoter (sequence shown in inset panel) along with various WT or
mutant E1A constructs from 7 HAdV species. A 6-hour treatment of 0.5µM forskolin
(fsk) and siRNA-mediated PKA knockdowns were performed to demonstrate this
reporter’s cAMP-responsiveness and PKA-dependent regulation. Protein levels of each
E1A construct are also shown. Luciferase activity was measured for each condition and
light units were set relative to an empty plasmid control. Each of the 7 WT E1As tested
could transactivate this reporter, with those shown to bind PKA having the strongest
effect. For the 5 species that interacted with PKA, deletion of their PKA-binding motifs
conferred a statistically-significant reduction on E1A’s ability to induce this reporter
(with the exception of HAdV-40). Values are displayed as displayed as mean ± S.E.M.
*p<0.05, n=3.
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Mathews, 1997; Miller et al., 1995). We aimed to determine if the E1A proteins from
different HAdVs could insert themselves into this signaling pathway and alter
PKA/cAMP-regulated transactivation.

HT1080 cells were co-transfected with a

luciferase reporter demonstrated to be cAMP- and PKA-regulated (driven by the rat
phosphoenolpyruvate carboxykinase [PEPCK] promoter) along with various E1A
constructs (Figure 3.11). Initial experiments confirmed that this reporter is both cAMPinducible via forskolin treatment (an adenylyl cyclase activator that increases intracellular
levels of cAMP), as well as dependent on PKA protein as shown by siRNA-mediated
knockdown. E1As shown to bind PKA were then compared to a species-specific deletion
mutant lacking the PKA binding site for their effects on PEPCK-dependent transcription.
Although all seven species of E1A were able to transactivate this reporter to levels higher
than the EGFP (vector control) alone, those previously shown to both bind and relocalize
PKA functioned as the strongest transactivators (HAdV-3, -5, -9, -12). Deletion of the
AKAP-like PKA-binding motifs in these E1As reduced their ability to drive expression
of this reporter construct several-fold. Transactivation by HAdV-40 E1A was weaker
relative to the other E1As and deletion of its putative PKA-binding region did not affect
this function. Thus, similarly to the negative result in the relocalization assays (Figure
3.4A), HAdV-40 appears to bind PKA in the Co-IP assays, but this interaction does not
appear to functionally impact PKA-dependent transcription in vivo.

3.3.7 HAdV infection stimulates the cAMP pathway
Using HAdV-5 as a model, we further investigated how HAdV infection and E1A
expression may cooperate with cellular cAMP signalling. A549 cells infected with either
WT (dl309), ΔE1A (dl312), or E1AΔ4-25 (dl1101) all showed increased levels of cellular
cAMP over uninfected cells as visualized by immunofluorescence (WT virus is shown as
representative) (Figure 3.12A).

This was accompanied by higher levels of

phosphorylated CREB1 on Ser133 (a known PKA substrate) (Figures 12B, C) and higher
levels of PKA kinase activity (Figure 12D). Each of these findings was examined at
timepoints before and after the onset of E1A protein production. Notably, levels of PKA
kinase activity and cAMP were similar across all timepoints post-infection for all viruses,
indicating that they are independent of E1A and more likely a biological response to the
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Figure 3.12. HAdV-mediated stimulation of cAMP signalling allows WT E1A to
retarget PKA activity.
A549 cells were infected with either WT (dl309), ΔE1A (dl312), or E1AΔ4-25 (dl1101)
HAdV-5 (MOI 5) and examined at the indicated timepoints post-infection using confocal
immunofluorescence (A, B), western blot (C), or kinase assay (D). A) Cellular cAMP
levels were examined before and after the onset of viral replication (as indicated by
staining for HAdV-5 ssDNA-binding protein [DBP]). Production of cAMP is noticeably
higher relative to uninfected cells both before and after E1A is expressed. Results with
WT virus are shown as representative of all infected conditions. B) Increased levels of
phosphorylated CREB1 on Ser133 are present relative to uninfected cells and are shown
for WT virus, localizing adjacent to and overlapping with virus replication centres. Scale
bars represent 100µm. C) Western blot analysis of phosphorylated CREB1 detected
increased levels in all infected conditions, which was highest in WT-infected cells after
production of E1A protein. D) Cell lysates were measured for PKA kinase activity, and
displayed similarly higher levels of activity for all infected conditions.

Values are

displayed as mean ± S.E.M. *p<0.05, n=3. E) HT1080 cells were co-transfected with
PKA regulatory and catalytic subunits along with HAdV-5 E1A. Co-IP analysis showed
that E1A does not dissociate the PKA holoenzyme. F) HT1080 cells were co-transfected
with RIα and/or RIIα in the presence or absence of the HAdV-5 E1A N-terminus and
subjected to Co-IP. No heterodimerization of PKA regulatory subunits was detectable
even with a long exposure (LE) western blot.
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infection itself. We also showed that E1A itself is not causing aberrant interactions
between PKA subunits (Figures 3.12E, F). The coexpression of E1A did not inhibit the
association between regulatory and catalytic PKA components (consistent with what we
know of where E1A and PKA interact with each other) nor did its N-terminus induce any
noticeable heterodimerization of type-I and -II regulatory subunits. The most striking
observation from these experiments was that only in WT-infected cells and after the onset
of E1A protein expression did we observe the highest levels of phosphorylated CREB1
on Ser133. Given that the cAMP and kinase activity levels are similar between cells
expressing either WT E1A or a mutant unable to bind PKA, it is likely the increased
phosphorylation of this PKA-targeted transcription factor is due to WT E1A’s vAKAP
function. In these conditions, high levels of phosphorylated CREB1 were localized
immediately adjacent to and overlapping with virus replication centres (Figure 3.12B).

3.3.8 Requirement of PKA for viral replication is conserved across
numerous HAdV species
To firmly establish the biological significance of these distinct E1As as vAKAPs, we
assessed PKA’s role in multiple steps of the viral replicative cycle. A549 cells were
treated with either control siRNA or siRNA specific for the indicated PKA subunits and
infected with WT HAdV-3, -4, -9, -12 (MOI 25) or HAdV-5 (MOI 5) (Figure 3.13A, B).
The efficiency of viral genome replication was assessed by qPCR of genomic viral DNA
at 48 hours post-infection compared to an “input” sample at 6 hours post-infection and
normalized to cellular GAPDH (Figure 3.13A). For HAdV-3, -5, -9, and -12, knockdown
of the PKA regulatory subunits resulted in an inhibition of viral DNA replication. This
was not observed for HAdV-4, whose E1A does not bind PKA. This suggests that
viruses that bind and relocalize PKA benefit from the interaction and require it for full,
WT-levels of DNA replication. Knockdown of the catalytic subunit of PKA resulted in
an inhibition for all viruses, including HAdV-4. This may be due to an additional role for
this protein in the HAdV replicative cycle that is Cα-specific and E1A-independent.
Production of infectious progeny virus was assayed at 72 hours post-infection by plaque
assay (Figure 3.13B). The production of WT progeny for each HAdV serotype tested
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Figure 3.13.

Requirement of PKA for viral replication is conserved across

numerous HAdV species.
A549 cells were treated with control siRNA or siRNA specific for PKA subunits and
infected with either HAdV-5 (MOI 5) or HAdV-3, -4, -9, or -12 (MOI 25). Values for
each virus were normalized to 1.0 in control-treated cells and displayed as mean ±
S.E.M., n = 3. A) DNA was isolated at 6 hours post-infection as a gauge of viral input
and at 48 hours post-infection to measure viral genome replication. Relative viral DNA
levels were quantified by qPCR reactions using a forward primer that recognizes a
conserved sequence in E1A in combination with a species-specific reverse primer. B)
Cells were collected at 72 hours post-infection and production of infectious progeny virus
was quantitatively assayed by plaque formation on HEK293 cells. For both genome
replication and progeny production, knockdown of PKA regulatory subunits caused
impairment for HAdV-3, -5, -9, and -12. The non-PKA binding HAdV-4 was unaffected.
Knockdown of either the catalytic subunit or all 3 PKA components together impaired all
viruses. *p<0.05, n=3.
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mirrored the observed phenotypes for genome replication. Only HAdV-4 was unaffected
by the knockdown of PKA regulatory subunits, confirming that viruses that target PKA
via E1A do so as part of an important aspect of their replicative cycles. As observed for
viral genome replication, knocking down both the regulatory and catalytic subunits in
combination did affect all HAdVs tested. This finding matches previous observations for
HAdV-5 (Scherer et al., 2014; Suomalainen et al., 2001) and again suggests the influence
of an alternative, E1A-independent role for the Cα protein in HAdV biology.

3.4 Discussion
Mimicry is an often-exploited strategy utilized by numerous protein products of HAdV to
facilitate virus-host interactions (Avgousti et al., 2016; Chahal et al., 2012; King et al.,
2016a, 2016b). HAdV E1A in particular is a remarkably well-connected viral hub
protein capable of altering the protein interaction network in an infected cell to create an
environment conducive for viral replication (Frisch and Mymryk, 2002; Pelka et al.,
2008). By embedding itself deeply within numerous signalling pathways, E1A can exert
tremendous influence upon cellular machinery in order to enhance various aspects of the
HAdV life cycle. We previously demonstrated that HAdV-5 E1A uses mimicry to act as
a viral AKAP, facilitating an interaction with PKA that increased viral transcription,
protein synthesis, and progeny production (King et al., 2016a). In the present work, we
have determined that despite some mechanistic flexibility, the manipulation of PKA via
E1A is a conserved and important function for numerous, distinct species of HAdV.
Even with having substantial differences in primary sequence, E1A proteins are often
remarkably consistent in their functional similarities (Marshall et al., 2014). Our findings
establish that 5 representative members of the 7 species of HAdV express E1A proteins
that make protein-protein interactions with PKA. This apparent conservation suggests
that the E1A-PKA interaction has played a potentially important role in the evolutionary
history of the virus. Indeed, the two HAdVs which don’t bind PKA via E1A (HAdV-4
from species E and HAdV-52 from species G), along with HAdV-40 from species F
(which bound with lower affinity relative to other species and didn’t functionally affect
PKA) are considered more closely related to simian adenoviruses than the HAdVs that
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have E1A which demonstrably function as viral AKAPs (HAdV-3, -5, -9, and -12)
(Dehghan et al., 2013; Jones et al., 2007). Along with lacking vAKAP functionality,
these non-PKA-binding E1As also have more dramatic differences in both primary
sequence and predicted secondary structure in the region responsible for the interaction
compared to the other HAdV types (Pelka et al., 2008). In particular, HAdV-52 E1A
contains a single amino acid insertion in the core of this motif, which likely distorts the
amphipathic nature of the predicted helix. Among primate species, PKA is a wellconserved kinase (Taylor et al., 2013) and it is unknown if closely-related simian
adenovirus E1A proteins are capable of interacting with simian PKA. However, we
speculate that an interaction is unlikely given the lack of the requisite predicted
amphipathic α-helical structure in the E1A N-terminus of these viruses. Therefore, the
capability of some HAdV E1As to function as vAKAPs likely arose from their extended
coevolution with human as a result of providing a selective benefit for the virus within
this particular host.
For all viruses that did bind PKA, the N-terminus of E1A alone is both necessary and
sufficient for this interaction, as previously observed within HAdV-5. These E1As also
target the D/D domains of PKA regulatory subunits as the binding interface in the same
manner as cellular AKAPs (Banky et al., 1998; Newlon et al., 1999). Furthermore, an
AKAP-like motif in the E1A N-terminus containing a putative α-helical structure is
responsible or at least contributory to this interaction. E1A proteins from HAdV-3, -5,
and -9 all contain this motif, which strongly resembles the PKA-binding region of
cellular AKAPs. This similarity indicates strong mechanistic conservation. HAdV-12
E1A also contains such a motif, but also utilizes a second, downstream region
contributing to this E1A-PKA interaction.

This finding confirms the previously

unexplored observation that HAdV-12 E1A bound PKA via two different N-terminal
regions (Fax et al., 2001). While recent studies of cellular AKAPs have revealed the
ever-increasing diversity of PKA-binding motifs (Burgers et al., 2015), this secondary
region bears no obvious similarity to the canonical α-helical domain utilized by cellular
AKAPs. It is possible that the largely unstructured nature of E1A allows for a second,
novel binding site to form in solution, which strengthens PKA-binding, a feature
observed with other targets of E1A (Ferreon et al., 2013). This finding also reveals that
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viral protein sequences outside canonical AKAP mimics may be capable of regulating
PKA in both normal and infected conditions.
During infection, multiple HAdV species induced a subset of PKA regulatory subunits to
relocalize from the cytoplasm to the nucleus. Transfection-based experiments using a
range of E1A deletion mutants for each HAdV species confirmed that this phenotype was
dependent on the PKA-binding motifs of E1A. Different E1As had differing effects on
specific PKA regulatory subunit types. While E1A from HAdV-3, -5, -9, -12, and -40
could all bind PKA in separate Co-IP experiments, HAdV-3 and -12 E1A specifically
relocalized the RIIα subunit, whereas HAdV-5 and -9 E1A preferred the RIα subunit.
HAdV-40 E1A does not display any ability to relocalize PKA, suggesting that the
interaction may not be functionally relevant in vivo. The relative differences in binding
affinities between E1A species and PKA isoforms was confirmed in competition assays,
reinforcing the idea of type-preference. These data are consistent with previous reports
on E1A-PKA interactions for HAdV-5 and -12 (Fax et al., 2001; King et al., 2016a) and a
type-preference is also a feature of many cellular AKAPs (Gold et al., 2006). This is also
the first report of both HAdV-3 and -9 E1A acting as ‘viral AKAPs’ and explores the
molecular determinants of this conserved E1A function in the greatest detail to-date.
Our established viral AKAP model suggests that E1A uses the direct interaction with
PKA regulatory subunits as a bridge to associate with the catalytic subunit, Cα (King et
al., 2016a). Cα was previously shown to be recruited to the promoters of E1A-regulated
viral genes and was capable of enhancing transcription from these sites (King et al.,
2016a). It is unclear if the preference for either RIα or RIIα confers the same, or different
benefits and this could also be context dependent based on cell or tissue-specific
expression levels. The ability to target both regulatory types may also serve as an
evolutionary redundancy ensuring the crucial interaction with PKA’s catalytic component
regardless of the availability of individual PKA subunits. To explore this, we deprived
cells of RIα protein using siRNA then infected with HAdV-5. In these conditions, where
the preferred isoform for HAdV-5 is absent, some relocalization of RIIα occurred.
Although the degree of relocalization was reduced, this may be related to HAdV-5’s
relatively lower binding affinity for RIIα. Nevertheless, this result suggests that the
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potential to bind both type-I and -II PKA to at least some extent could be advantageous to
HAdV as they may, to a degree, compensate for each other.
While the hydrophobic component of the PKA-binding amphipathic α-helix is a
necessary feature in both cellular and viral AKAPs (Gold et al., 2006; King et al., 2016a),
adjacent residues confer critical electrostatic interactions and contribute to the preference
for either RIα or RIIα (Burgers et al., 2015). We explored this feature in the context of
HAdV E1A by successfully creating mutants in HAdV-3 and -5 E1A that reversed each
protein’s preference for the different PKA regulatory subunits.

Using previously-

validated residue positions in HAdV-5 E1A that are known to affect PKA-E1A
interaction (King et al., 2016a), triple point mutants were created in both proteins that
exchanged these residues in their analogous positions. Both the novel HAdV-3 and -5
mutants retained binding to both types of PKA subunits in Co-IP experiments, but their
abilities to relocalize RIα and RIIα were reversed. This demonstrates that like cellular
AKAPs, individual amino acids in viral AKAPs specify their differential affinities for
distinct PKA subunits, enhancing our knowledge of how type-I, type-II, and dualspecificity AKAPs function.
The targeting of PKA by E1A was previously shown to drive transcription of HAdV-5
early genes via recruitment of Cα to viral promoters (King et al., 2016a). E1A has also
been shown to synergize with cAMP (Engel et al., 1991, 1988; Hardy and Shenk, 1988;
Lee and Mathews, 1997; Müller et al., 1989). Here we sought to expand upon this
mechanism by exploring E1A-PKA interactions for various HAdV species in the context
of the cAMP signaling pathway.

A luciferase reporter driven by the previously-

characterized rat PEPCK promoter (Klemm et al., 1996) was constructed and validated to
be both cAMP-inducible and PKA-dependent. E1A proteins from all 7 species of HAdV
could activate expression from this reporter, which was expected given E1A has multiple
transactivation domains and mechanisms for inducing transcription (Ablack et al., 2012;
Bondesson et al., 1994; Duyndam et al., 1996; Pelka et al., 2008; Wong and Ziff, 1994;
Yousef et al., 2009). The E1A proteins from viruses that could bind and relocalize PKA
subunits (HAdV-3, -5, -9, -12) induced this reporter to the greatest extent. Deletion of
the PKA-binding regions of these E1As severely handicapped their ability to
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transactivate this construct. Residual activation by these mutants was comparable to the
levels observed for WT E1A species unable to bind PKA. This confirms that the PKA
interaction contributes to E1A-mediated transactivation of this PKA-responsive reporter.
During HAdV-5 infection, notable alterations to the cellular cAMP signalling pathway
occurred. Indeed, increased levels of cAMP relative to uninfected cells were observed by
immunofluorescence, as were higher levels of PKA kinase activity and phosphorylation
of CREB1 on Ser133. Most of these observations were consistent across timepoints
before and after the production of E1A protein as well as between different HAdV-5
mutants (WT, ΔE1A, and a mutant incapable of binding PKA). This indicates that the
stimulation of cAMP signalling is in response to the HAdV infection and independent of
E1A. The notable exception to this trend was that in the presence of WT E1A protein, a
far higher level of phosphorylated CREB1 was observed both by western blot and
immunofluoresence – where it localized adjacent to and overlapping with virus
replication centres.

These findings are consistent with our previously-established

vAKAP model suggesting that E1A exerts its effects on the cAMP pathway not through
broad changes in 2nd messenger levels or PKA catalytic activity, but rather via the
localized retasking of PKA to sites of action. While HAdV infection may provoke cAMP
signalling, a functional vAKAP is needed to fully take advantage of these conditions.
Notably, all E1A proteins tested also bind CBP, an important co-regulator of CREB via
an overlapping region of the N-terminus and/or CR3, providing an additional connection
between E1A and cAMP regulated transcriptional control (Pelka et al., 2009; Rasti et al.,
2005; Shuen et al., 2003).
Altogether, these data suggest that E1A proteins can integrate into the cAMP signaling
pathway to drive higher levels of cAMP-modulated gene expression, presumably in a
localized fashion. This also suggests the exciting possibility that E1A may be capable of
differentially regulating the hundreds of cellular cAMP-responsive genes during
infection. This mechanism could contribute to enhancing the infectious cycle for HAdVs
that have a functional E1A-PKA interaction or contribute to the different tropisms and
disease pathogeneses of distinct HAdV species.
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The conserved importance of PKA during infection was established by examining viral
genome replication and progeny production in the context of siRNA-mediated PKA
knockdowns for multiple HAdV types.

For HAdV-4, which does not bind PKA,

knockdown of RIα and RIIα did not notably affect either viral DNA replication or
progeny virion production. For HAdV-3, -5, -9, and -12, which all have viral AKAPs,
the loss of PKA regulatory subunits as targets for E1A reduced the efficiency and
productivity of their replicative cycles. As previously established for HAdV-5, the E1APKA interaction serves to drive viral gene expression of numerous HAdV genes
including E2, E3, and E4 (King et al., 2016a). Many transcripts from these genes encode
for crucial protein products involved in viral genome replication, transcription, cell cycle
modulation, and virus-host interactions (O’Shea et al., 2005; van Breukelen et al., 2003).
Presumably, the shortfall of these critical viral products contributes to the observed
reduction in infectious progeny virus. Loss of Cα or all PKA subunits in combination
negatively affected all viruses tested, including HAdV-4, which expresses an E1A that
does not target PKA. This result suggests an additional, E1A-independent role for Cα in
HAdV infection. Cα activity was previously shown to be crucial for transport of species
C HAdV virions to the nucleus during the establishment of infection (Scherer et al., 2014;
Suomalainen et al., 2001). Our results suggest other species of HAdV may also use this
process to kick-start this early stage of their replicative cycles. The conserved targeting
of multiple different PKA subunits by various viral components at distinct stages of
infection underscores the true importance of this cellular kinase for HAdV.
E1A has been repeatedly shown to be adept at influencing various cellular scaffold and
multiprotein complexes (Boyer et al., 1999; Glenewinkel et al., 2016; King et al., 2016a).
To date, E1As from various HAdV species are currently the only well-characterized viral
AKAPs; however, given the well-connected nature of cellular scaffolds like AKAPs,
mimicry and manipulation of similar proteins is a strategy exploited by numerous viral
pathogens (Chemes et al., 2015; Via et al., 2015).

This allows viruses to control

macromolecular networks or nucleate protein-protein interactions to facilitate their own
needs (Brito and Pinney, 2017). By studying how viral regulatory proteins integrate into
cellular signalling by mimicking scaffolds, we gain comprehension of how viruses
overcome the daunting challenge of reorganizing their hosts into environments conducive

165

for replication. Examining protein-protein interactions between viral and host factors
also offers clinically-relevant insights. For instance, the manipulation of orthologous
cellular components within distinct host species (such as PKA) by viral proteins can
contribute to successful cross-species transmission events.

By understanding these

events, we learn more about disease tropism or severity. Also, studying the molecular
basis of these virus-host interactions provides opportunity to intervene for druggable
targets, such as with the E1A-CDK9 interaction for various HAdVs (Prasad et al., 2017).
In summary, we conclusively identified E1A proteins from multiple species of HAdV can
function as viral AKAPs. We also confirmed that they structurally and mechanistically
resemble each other, although some flexibility exists presumably as a result of different
evolutionary histories.

We have also advanced the understanding of the functional

mechanism of these vAKAPs by demonstrating their ability to integrate into cAMP
signaling-dependent transcriptional activation.

Furthermore, we demonstrate that

vAKAPs play an important, biologically-significant role in enhancing genome replication
and progeny production for multiple HAdV species.
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Chapter 4

4

General Discussion

“One, remember to look up at the stars and not down at your feet. Two, never give up
work. Work gives you meaning and purpose and life is empty without it. Three, if you are
lucky enough to find love, remember it is there and don't throw it away.”
– Stephen Hawking

4.1 Thesis Summary
This body of work describes my studies of the HAdV E1A proteins and the molecular
determinants of their interaction with cellular PKA.

Specifically, I describe the

mechanism by which this virus-host interaction occurs and its functional consequences
during HAdV infections. In Chapter 2 of this thesis, multiple subunits of PKA were
shown to be targeted for binding by E1A from HAdV-5 (Figure 2.1). Using this virus as
a model, I carried out extensive mutagenesis to map the interaction interfaces on both
E1A (for HAdV-5) and PKA (Figures 2.1-2.5). Using a variety of molecular reagents, I
showed that the manner by which E1A bound PKA strongly resembled that of cellular
AKAPs (Figure 2.6). I concluded that this interaction represented a novel case of viral
mimicry and that E1A is the first known vAKAP. Furthermore, I demonstrated that the
interaction was functional during HAdV-5 infections as the interaction allowed E1A to
recruit PKA into the nucleus, specifically to HAdV early gene promoters at viral
replication centres (Figures 2.7-2.9). E1A’s ability to act as a vAKAP enhanced viral
transcription, protein synthesis, and infectious progeny production for HAdV-5 (Figures
2.10-2.13). In Chapter 3, I extended these studies to encompass representative E1A
proteins from all seven species of HAdV (A-G).

The protein-protein interactions

between different types of E1A with various PKA subunits (and the mechanism by which
they occurred) were largely conserved across most species of HAdV (Figure 3.1-3.3).
Interestingly, different E1As appeared to have a preference for one isoform of PKA Rsubunit over another, leading to different relocalization phenotypes in transfected and
infected cells (Figures 3.4, 3.6-3.10). Both vAKAP mimicry and relocalization of PKA
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subunits during infection were demonstrated to be conserved requirements for full, WTlevels of viral replication for 4 distinct HAdV species (Figure 3.13B). I also increased
the mechanistic knowledge of how PKA enhances the viral life cycle by showing it
contributes both to efficient viral genome replication as well as E1A-mediated activation
of cAMP-responsive promoters (Figures 3.5, 3.11-3.13A).

Overall, my work has

uncovered and characterized a novel example of viral mimicry carried out by the E1A
proteins of multiple HAdVs that repurposes a host target to benefit viral infection.

4.2 The interaction between E1A and PKA
The protein-protein interactions between E1A and PKA were first discovered in 2001
(Fax et al., 2001). Specifically, direct interactions between HAdV-12 E1A and both RIα
and RIIα were reported, but this was only briefly explored. PKA, already a wellcharacterized kinase, was shown to have its RIIα subunit relocalized to the nucleus in
E1A-transfected cells. This was further shown to contribute to expression of a HAdV-12
E2 reporter construct. Given the ever-increasing array of genetic and molecular tools
available for HAdV-5, we sought to further explore the E1A-PKA interaction in the
context of this better-characterized HAdV.
Our interaction studies began by reproducing the previously observed HAdV-12 findings
using HAdV-5 E1A in both transfected and infected conditions. Using siRNA-mediated
gene silencing, we also showed that the interactions with PKA R-subunits conferred an
indirect association with PKA’s catalytic component, Cα.

Through extensive

mutagenesis of both E1A and PKA, the binding sites on both partners were mapped in
fine detail.

I determined that a small portion of the N-terminus of E1A was both

necessary and sufficient for binding PKA subunits, both in transient transfection assays
and HAdV-5 infections. Deletion or truncations affecting amino acids 14-28 of E1A
abrogated the interaction whereas mutations in adjacent or downstream areas had no
effect. Structural modelling strongly indicated that the amino acid sequence in this
region of E1A formed an amphipathic α-helix that resembled the analogous PKA-binding
motifs in cellular AKAPs. Additional deletion and point mutants designed to test this
hypothesis (based on known PKA/AKAP structures) confirmed our prediction of
structural mimicry to be accurate. E1A also bound to PKA’s D/D domain, the identical
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binding site of cellular AKAPs, further strengthening the narrative of viral AKAP
mimicry.
All experiments in this thesis utilized the α-isoforms of PKA subunits (RIα, RIIα, and
Cα) encoded by the human PRKAR1A, PRKAR2A, and PRKACA genes, respectively
(Canaves and Taylor, 2002; Skalhegg and Tasken, 2000; Søberg et al., 2013; Turnham
and Scott, 2016). An interaction with the β-subunit isoforms was briefly explored both
by our lab and the previous HAdV-12 group, but no interaction with either HAdV-5 or
HAdV-12 E1A species was observed (Fax et al., 2001; King et al., 2016). This does not
rule out the possibility that E1As from the other species of HAdV are able to bind and
manipulate PKAβ, but this was not examined. A γ isoform of the catalytic subunit also
exists in humans, but is only expressed in the testis (not a tissue site typically infected by
HAdVs) (Berk, 2013).

4.3 Mimicry of cellular AKAPs by E1A
Given both the sequence and putative structural similarities of E1A’s AKAP-like motif, I
hypothesized that E1A was also capable of functioning like a cellular AKAP. This was
investigated using both transfection- and infection-based experiments. Because HAdV-5
E1A can bind to both type-I and –II regulatory subunits of PKA, it is potentially a ‘dualspecificity’ AKAP (Carlson et al., 2006; Gold et al., 2006). We first examined if the
PKA-binding motif (aa14-28) in E1A could functionally complement a binding defect in
a known dual-specificity AKAP, D-AKAP1. Indeed, a deletion mutant of D-AKAP1 that
lacked its PKA-binding ability was rescued back to WT levels when aa14-28 of HAdV-5
E1A were cloned in its place. Next, high-affinity, in silico-designed peptide inhibitors of
AKAP-PKA interactions were pitted against E1A in transfected conditions to test for
their ability to similarly disrupt E1A-PKA binding. As with cellular AKAPs, RIAD and
sAKAPis specifically blocked E1A binding to RIα and RIIα respectively. Finally, in
HAdV-5-infected cells, I showed that WT E1A expression outcompeted endogenous,
dual-specificity AKAP7 for binding PKA subunits whereas a mutant virus lacking E1A’s
AKAP-like motif could not. Collectively, these experiments established new molecular
tools for probing PKA and AKAP complexes in the context of HAdV infection.
Additionally, reagents previously used exclusively to study cellular AKAPs are
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demonstrably useful for examining viral AKAPs as well. While E1A was functionally
analogous to 2 tested AKAPs (D-AKAP1 and AKAP7), there are over 30 cellular AKAPs
variably expressed in human cells (Taylor et al., 2012; Welch et al., 2010; Wong and
Scott, 2004). How E1A may or may not compete against these other endogenous PKA
scaffolds remains to be elucidated.
The mimicry of AKAPs by E1A caused a relocalization of PKA regulatory subunits from
the cytoplasm to the nucleus in both transfected and infected cells. This served to bring
PKA proteins into closer proximity with viral replication centres and caused an E1Amediated increase of the catalytic Cα subunit on the promoters of HAdV-5 early genes.
The retargeting of PKA to specific sites of action is the hallmark of AKAP functionality.
Given that not all PKA protein is trafficked into the nucleus by E1A, it remains to be seen
if E1A-PKA interactions serve functions at other cellular loci or compartments.
Furthermore, the stoichiometric nature by which E1A acts as a scaffold to concurrently
bind multiple components of the cAMP signaling pathway is unclear. E1A’s interactions
with p300/CBP have been well-studied, and it has also been shown to potentially bind
cAMP-regulated transcription factors, such as CREB and ATFs (Eckner et al., 1994; Fax
et al., 2000; Ferrari et al., 2014, 2008; Liu and Green, 1994). Including PKA, many of
these interactions take place on E1A’s N-terminus. If at least some of these interactions
occur concurrently, it’s possible that these multiple, related interactions affect regulation
of each other by either enhancing or occluding binding. However, these precise details
have yet to be determined. Novel HAdVs encoding mutant E1As that specifically lack
binding to one (or more) of these targets could shed light on which downstream functions
result from independence or cooperation of these overlapping interactions.

4.4 Viral retasking of PKA to enhance infection
The physiological consequences of E1A’s ability to usurp PKA were examined to gauge
how they might benefit HAdV infection. Overall, E1A’s role as a vAKAP was required
for multiple aspects of the HAdV life cycle including WT levels of viral transcription,
genome replication, protein synthesis, and progeny production. For HAdV-5, viral genes
that displayed recruitment of Cα to their promoters in an E1A-dependent manner
experienced enhanced transcription from these loci. This largely correlated with what
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was subsequently observed at the protein level. Ultimately, the production of both viral
genomes and infectious progeny virus were reduced in the absence of an E1A-PKA
interaction. It’s likely that the lack of expression from the HAdV-5 E2 gene (which
encodes viral genome replication machinery) contributes to this reduction in viral DNA
levels (Challberg and Kelly, 1979; Levine et al., 1976; van der Vliet and Levine, 1973).
It’s also possible PKA may have a more direct role in viral DNA synthesis at viral
replication centres as has been shown for cellular DNA replication, but this has not been
investigated (Costanzo et al., 1999). The overall lack of progeny production is likely due
to the shortfall of crucial viral proteins that are under-expressed in the absence of E1A
being able to repurpose PKA.
Various mechanistic details of PKA’s role in the HAdV life cycle remain unclear,
however both HAdV-5 and E1A’s ability to alter the catalytic activity of Cα was briefly
explored. HAdV infection was capable of globally enhancing cellular cMAP levels and
PKA kinase activity. The phosphorylation status of PKA targets (such as CREB) appears
directly affected by E1A’s interaction with PKA, suggesting that its vAKAP function
allows HAdV to take advantage of stimulation of cellular cAMP signaling post-infection.
It would be also be of interest to test if the phosphorylation status of other PKA-regulated
TFs is altered at viral promoters and if this was dependent on E1A’s role as vAKAP.
Furthermore, the phosphorylation status and downstream functional consequences for
other classes of PKA substrates has yet to be examined. It is possible the relocalization
of Cα’s kinase activity affects both nuclear and non-nuclear processes unrelated to gene
expression. Lastly, PKA may be a suitable drug target for inhibiting viral infections as
inhibition of broad-specificity kinases has been successfully utilized in the past for
ablating virulence of HAdV (Prasad et al., 2017). Given that PKA is utilized by the virus
at multiple stages of its life cycle (Bremner et al., 2009; King et al., 2016; Scherer et al.,
2014), PKA disruption (by either catalytic or anchoring inhibitors) may slow or abrogate
the infection more potently than typical single-target drugs (provided there is no general
toxicity to the infected host).
Another unanswered question pertaining to the E1A-PKA interaction is whether or not
E1A is a substrate for the kinase. Phosphorylated forms of HAdV-5 E1A and the
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targeted residues have been studied in detail. Phosphorylation is limited largely to serine
residues, particularly Ser-89, -132, -185, -188, -219, and -231 in HAdV-5 E1A (Dumont
et al., 1993; Dumont and Branton, 1992; Mal et al., 1996; Whalen et al., 1997, 1996).
E1A is considered to be modified in this fashion predominantly by cyclin-dependent
kinases (Cdk), MAPK, and casein kinase II (CKII). However, Ser-219 is a strong
substrate for the DYRK1A kinase as well, and this PTM confers a downstream
interaction with the FOXK1/2 transcription factors (Glenewinkel et al., 2016; Komorek et
al., 2010). Therefore, E1A’s phosphorylation status is important to understand, as it
affects binding to several key partners (including Rb) and has been shown to affect its
transforming ability (Dumont et al., 1993; Mal et al., 1996). Whether PKA itself can
phosphorylate Ser or Thr residues on E1A has not been tested.

However, we can

speculate that it is unlikely given that alternatively-migrating bands were consistently not
observed in protein gels from experiments where Cα was either over- or under-expressed.
Additionally, there are only two sites in HAdV-5 E1A that somewhat resemble the PKA
consensus site; one surrounding Thr-164 and the other encompassing Thr-218 (although
neither of these sequences are conserved across any other HAdV species) (Avvakumov et
al., 2004; Jones et al., 2007). Threonine is a much lower-affinity substrate than Ser for
PKA catalysis, however, and these sites also lack the adjacent hydrophobic residue
typically found in PKA substrates (Masterson et al., 2010; Shabb, 2001).

4.5 Conservation of viral AKAPs
Conservation of the E1A-PKA interaction was briefly examined in Chapter 2 but the
majority of experiments in that chapter focused only on E1A from HAdV-5. In the
follow-up study to these findings (Chapter 3), similar experimental approaches were
utilized to examine the N-terminus of E1A from all 7 HAdV species. This portion of
E1A was necessary and sufficient to bind RIα, RIIα, and Cα for 5 of 7 HAdV types
tested: HAdV-12, -3, -5, -9, and -40 (representing species A, B, C, D, and F respectively).
E1A from HAdV-4 and -52 (representing species E and G) did not associate with any
PKA subunit. The interaction between PKA and HAdV-40 E1A was also notably weaker
in CoIP assays. The overall conservation of the E1A-PKA interaction across highly
divergent HAdVs potentially indicates importance and the observed differences between
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species likely stem from the distinct evolutionary histories of each virus. Indeed, E1As
which did not bind or bound weakly (from species E, F, and G) are more closely related
to simian adenoviruses or arose as cross-species recombinants (Dehghan et al., 2013;
Jones et al., 2007). These E1A proteins from those viruses are not predicted to contain
the same level of helical structure in their N-terminus, likely explaining their lack of
interaction with PKA’s D/D domain.

Consequently, these E1As were incapable of

relocalizing PKA subunits in either transfected or infected cells. Also, viral genome
replication and progeny production for HAdV-4 was not affected by siRNA-mediated
silencing of RIα and RIIα expression. These HAdV species may not have evolved the
means or need for manipulating human PKA subunits to enhance their viral life cycles. It
is unlikely that related SAdV E1A proteins are capable of binding simian PKA proteins
given the lack of predicted structure in the E1A N-terminus of these viruses. Amino acid
sequences of PKA R-subunits are incredibly well-conserved among primates (99%
identity between humans and macaques, for example) as is the structural basis for
AKAPs binding to PKA D/D domains (Carlson et al., 2006; Gold et al., 2006; Kannan et
al., 2007; Taylor et al., 2012). It is therefore more likely that the ability for some HAdV
E1As to act as vAKAPs arose from extended coevolution with humans as a result of
providing some selective benefit for the virus within this host.
For HAdVs that did bind and relocalize PKA subunits, they required PKA for viral
genome replication and progeny production, as well as E1A-mediated transactivation of a
cAMP-responsive gene. Interestingly, a distinct preference for affecting either RIα or
RIIα was observed. Specifically, HAdV-5 and -9 relocalized RIα to the nucleus, whereas
HAdV-3 and -12 relocalized RIIα. Preference for one PKA isoform over another is a
common feature of cellular AKAPs (Welch et al., 2010; Wong and Scott, 2004), which is
evidently also the case for viral AKAPs. This preference could be altered and swapped
within different E1As using targeted mutagenesis of critical residues (predicted in silico),
suggesting the AKAP-like helix in E1A is an evolutionarily flexible motif.

The

biological significance for preferring either R1α or RIIα is unknown. It may simply be an
artefactual byproduct of divergent evolution between these viruses. Alternatively, it may
contribute to virulence in different cells or tissues where PKA subunit expression profiles
differ (Skalhegg and Tasken, 2000). Along these lines, in cells lacking RIα protein
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expression, HAdV-5 E1A was able to switch and relocalize RIIα. It may be that being
able to bind both RIα and RIIα to some degree is a redundancy that ensures the crucial
downstream association with Cα, no matter what the availability of PKA proteins is.

4.6 Usurping PKA to alter host cell transcription
Significant amounts of research on both E1A and PKA have focused on their respective
abilities to regulate cellular gene expression. I focused most of my attention towards
effects on viral transcription and the downstream consequences on HAdV replication
(Chapters 2 and 3). However, given the amount of relocalized PKA observed during
HAdV infection, it seems extremely likely that its interaction with E1A also affects host
genes in a manner similar to viral ones. There have been numerous studies which
separately surveyed the effects of either E1A or PKA on the human transcriptome,
although no published dataset yet exists that examines E1A’s effects specifically on
PKA-regulated genes (Ferrari et al., 2014, 2008; Horwitz et al., 2008; Radko et al., 2015;
Zhang et al., 2005). This is an attractive area of future study as both E1A and PKA can
potentially regulate thousands of host genes on their own and E1A has been previously
shown to synergize with cAMP signalling to affect transcription (Brockmann and Esche,
2003; Engel et al., 1991, 1988; Hardy and Shenk, 1988; Lee and Mathews, 1997; Müller
et al., 1989).
Using NGS, the Mymryk laboratory previously produced a dataset of differentiallyregulated genes in primary cells infected by a variety of HAdV-5 mutants (Appendix A).
Additionally, information from publicly available datasets was extracted and queried
across the entire human genome for cAMP response elements (CRE) in their promoters
(Zhang et al., 2005). To gain a foothold into understanding the potential impact of E1A
on PKA-regulated genes during HAdV infection, we cross-referenced these data together.
Using Python (Appendix B) a subset of genes was selected whose expression was altered
more than 2-fold up or down in cells infected with WT HAdV-5 (dl309) versus ΔE1A
HAdV-5 (dl312).

These candidate genes were then trimmed to include only those

containing a verified CRE (as a surrogate marker for possible PKA-regulation) in either
their proximal (<300bp from TSS [transcriptional start site]) or distal (>300bp from TSS)
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Figure 4.1. Host cell genes potentially regulated via E1A’s interaction with PKA.
(A) Workflow of the analyses. Raw NGS data from the Mymryk laboratory was
converted into tabular format and information on CREs in human gene promoters was
extracted from publicly available datasets (Zhang et al., 2005).

All data were

subsequently processed using the Python programming language. Host genes that were
up- or down-regulated at least 2-fold in WT-infected cells versus ΔE1A-infected cells
were selected for further analysis. These candidates were then trimmed to include only
those with verified CREs in their upstream regulatory regions.

(B)

Results of

comparison of differentially-expressed genes in WT- versus ΔE1A-infected cells and
genes with CREs in their promoters. The number of candidate genes of interest that met
all criteria in these analyses (and are therefore potentially modulated by the E1A-PKA
interaction) is highlighted in the overlapping region of the Venn diagram. (C) Lists of
significantly impacted KEGG pathways and GO terms based on candidate genes.
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promoter regions. After removing duplicated or outlier genes that had low read numbers,
we obtained a set of putative PKA-regulated host genes was obtained whose expression
may be altered by E1A (Figure 4.1).
A total of 888 candidate genes were identified, with 557 being upregulated and 331 being
downregulated. As a positive control, a previously-validated gene (proliferating cell
nuclear antigen [PCNA]) was found amongst the list of upregulated genes (Lee and
Mathews, 1997). This dataset of differentially-expressed genes was then analyzed in the
context of pathways obtained from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) (Kanehisa et al., 2002; Kanehisa and Goto, 2000) and gene ontology from the
Gene Ontology Consortium database (Ashburner et al., 2000). Both these analyses were
facilitated by the Database for Annotation, Visualization, and Integrated Discovery
(DAVID) website (Huang et al., 2009, 2008). The most significantly affected KEGG
pathways were those involved in cell cycle, viral infections, and various cancers.
Similarly, the most significantly enriched GO terms impacted cellular processes such as
transcription, DNA replication, and cell cycle control. These hits strongly align with
E1A’s known functions during HAdV infection (Bayley and Mymryk, 1994; Berk, 2005;
Pelka et al., 2008). They also suggest that an interaction with PKA may contribute to the
ability of E1A to fine-tune transcription in infected cells to establish an environment
more favourable for HAdV replication.
These analyses should not be used as license to start inefficiently testing individual genes,
but rather as a general representation of the likelihood and scale of E1A’s ability to
modulate cAMP-responsive genes.

How E1A uses PKA to modulate host cell

transcription to affect downstream processes such as cell cycle or DNA replication
remains an exciting and open area of investigation.

Using my mapping studies,

construction of HAdV mutants encoding E1A that cleanly lack binding to only PKA
would be powerful tools aiding future work of this nature. Genome-wide RNAseq
experiments on primary cells infected by such viruses would yield powerful results and
could validate which hits from these preliminary analyses are real and reproducible.
Additional ChIPseq experiments would shed light on which genes showed the presence
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of E1A, PKA, or phosphorylated targets of PKA (such as CREB) to their promoters. It’s
possible that E1A may be inducing a global deregulation of cellular cAMP signaling to
modulate hundreds of cellular genes, but this will need to be thoroughly investigated.

4.7 Contribution of E1A-PKA interaction to oncogenic
transformation
HAdV E1A (and oncoproteins from other DNA tumour viruses) have repeatedly served
as powerful tools for discovering cancer-relevant genes (Rozenblatt-Rosen et al., 2012).
E1A’s role in oncogenic transformation stems primarily from its ability to drastically
rewire host protein-protein interactions (Bayley and Mymryk, 1994; Pelka et al., 2008).
Interestingly, the same N-terminal portion of E1A protein that binds PKA is also required
for its transformation activity (Chinnadurai, 2011; Jelsma et al., 1989; Subramanian et al.,
1988; Whyte et al., 1988). This has been largely linked to E1A’s crucial interaction with
p300/CBP (Egan et al., 1988; Howe et al., 1990; Howe and Bayley, 1992; Wang et al.,
1993). However, many of the mutants used in such studies contain large deletions or
point mutations which affect multiple E1A binding partners in this promiscuous portion
of the protein (Boyd et al., 2002; Loewenstein et al., 2006; Rasti et al., 2005) (Figure
1.8).

Also, some mutants which retain binding to p300 in vivo still have reduced

transforming ability, confirming that other N-terminal binding partners are involved in
E1A-mediated transformation. Therefore, a potential role for the E1A-PKA interaction
would need to be thoroughly and cleanly investigated.
While PKA is not typically considered an oncogene or tumour suppressor, it has been
studied in the context of several cancer types or as a molecular component in cancerrelevant pathways (Gold et al., 2013; McKenzie et al., 2011; Palorini et al., 2016;
Pattabiraman et al., 2016).

One way the E1A-PKA interaction could contribute to

transformation is through effects on host gene expression (discussed above).
Alternatively, E1A-mediated relocalization of PKA to different cellular compartments
could affect phosphorylation status of targets unrelated to transcription (such as those
involved in DNA synthesis or cytoskeletal remodeling).

E1A would of course be

valuable as a tool to probe this hypothesis and enhance molecular knowledge of these
biological pathways.

Specifically using mutants lacking PKA-binding ability,
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transformation assays on either baby rat kidney or even human cells would yield clear
evidence of a role for this host factor in the transformation process (Massimi and Banks,
2005; Vijayalingam et al., 2016).

4.8 Prevalence of cellular scaffold mimics in the viral
universe
Mechanisms that regulate the spatial and temporal control of proteins involved in cellular
signaling offer an appealing target for viral manipulation. Cellular scaffold or adaptor
proteins typically bind multiple components of signaling pathways (including residuemodifying enzymes and their cognate substrates) and localize them to distinct subcellular
loci (Taylor et al., 2012; Welch et al., 2010; Wong and Scott, 2004). These highlyconnected hubs thus nucleate the formation of signalosomes that more efficiently perform
pleiotropic functions in various signal transduction pathways.

Hijacking a host’s

interaction network by altering or mimicking cellular scaffolds is widespread among
viruses, indicative of it being a broadly beneficial strategy (Davey et al., 2011).
In addition to AKAPs, many cellular scaffolds have been shown to be targeted for
manipulation or mimicry by a range of diverse viruses such as Epstein-Barr virus (EBV),
vaccinia virus (VACV), measles virus (MeV), Kaposi’s sarcoma-associated herpes virus
(KSHV), HIV, IAV, mumps virus (MuV), and even walleye dermal sarcoma virus
(WDSV). These host targets include KSR1 (kinase suppressor of ras; which assembles
components of the RAS-ERK pathway) (Lee et al., 2008), NLRPs (NACHT, LRR and
PYD domains-containing protein; helps assemble the inflammasome) (Gerlic et al., 2013;
Gregory et al., 2011; Komune et al., 2011), RACK1 (receptor of activated protein C
kinase; tethers components of protein kinase C [PKC] signaling) among numerous others
(Baumann et al., 2000; Daniels et al., 2008; Demirov et al., 2012; Gallina et al., 2001;
Kubota et al., 2002; Mondal et al., 2017). E1A itself has been shown to use the cellular
adaptor, DCAF7 (DDB1- and CUL4-associated factor 7), to gain access to DYRK1A and
HIPK2 kinases (Glenewinkel et al., 2016); E1A has also been reported to bind RACK1
itself (Sang et al., 2001). Clearly, the manipulation of host scaffold proteins is ubiquitous
among viruses and offers a large window into examining virus-host interactions at the
protein level.
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While E1A proteins from various HAdVs are described here as the first (and only) known
viral AKAPs, it would not be surprising to discover other functionally analogous viral
mimics (Brito and Pinney, 2017; Chemes et al., 2015; Via et al., 2015). Newly-refined
bioinformatics tools have recently demonstrated an increased ability to predict and
discover AKAPs and PKA-binding motifs (Carlson et al., 2006; Gold et al., 2006). One
study was able to translate these in silico predictions into the discovery of a new, bona
fide human AKAP (Burgers et al., 2015).

It would be interesting use similar

methodology to probe the proteomes of viruses to potentially uncover vAKAPs outside
the HAdV family. Additionally, my work has enhanced the knowledge of how flexible
AKAP-like motifs can be, increasing the number of undiscovered sequences potentially
capable of binding PKA.

4.9 Concluding remarks
HAdV E1A continues to prove itself as an excellent molecular tool for studying proteinprotein interactions between viruses and hosts. Investigations into these interactions has
contributed greatly to our collective understanding of numerous processes in both viral
and cellular biology. These include (but are not limited to) transcription, splicing, cell
cycle, innate immunity, nuclear import, transformation, and cancer (Berk, 2005; Cohen et
al., 2014; Fonseca et al., 2012; Pelka et al., 2008; Rozenblatt-Rosen et al., 2012). My
work described in this thesis advances this research by providing new insights into the
molecular biology of both E1A and one of its cellular binding partners, PKA.
Mechanistic studies of how this interaction occurs revealed a novel example of viral
mimicry by HAdV, and the tools generated have laid the groundwork for future studies to
search for other viral AKAPs. Furthermore, my work demonstrated previously-unknown
roles for PKA in HAdV biology, including early gene transcription, protein synthesis,
genome replication, and progeny production. This was also examined across all seven
species of HAdV, revealing new insights into the evolutionary histories of E1A proteins
from these viruses. Moving forward, my data have identified potential roles for PKA in
E1A-mediated regulation of host gene expression and cellular transformation, which
could be the subject of follow-up projects. Therefore, despite over 30 years of intense
genetic and biochemical characterization, the E1A protein of HAdV still has much more
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to provide for scientists yearning to understand the molecular biology of both viruses and
cells.
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Appendices
Appendix A: Methods for generating high-throughput RNAseq tabular dataset.
Global cellular gene expression was examined during infections with a variety of HAdV
mutants. These experiments were carried out in primary human lung fibroblasts (IMR90) at a multiplicity of infection (MOI) of 25, 48 hours post-infection. This represents a
relatively early timepoint post-infection in primary cells. Library prep from total RNA
and high-throughput sequencing was performed on the Ilumina HISeq 2500 at the UCSD
Genomics Centre. Sequences returned were aligned against the human hg19 reference
genome (genome reference consortium human build 37) using the ELAND software.
Initial data analysis, including normalization of sequencing reads and changes in gene
expression, was performed using the HOMER software suite. This pilot experiment was
performed only once using 6 unique viruses/conditions: (mock-infected IMR-90 cells,
wild-type HAdV-5, ΔE1A HAdV, and 3 additional E1A point/deletion mutants targeting
specific sites for E1A-binding partners). In total, data on 36640 unique transcripts were
returned.
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Appendix B: Python scripts used to analyze RNAseq and human promoter datasets.
"""
This script takes a tab-delimited .txt file containing the normalized RNAseq results data and extracts the data
columns of interest.
"""
import sys
input = sys.argv[1] # call script on filename of choice
handle = open(input, 'rU')
_ = handle.readline()
outfile = open('output1.csv', 'w')
# extract 3 desired data columns
for line in handle:
items = line.strip('\n').split('\t')
accession = items[0]
annotation = items[7]
annotation_edited = annotation.replace(',', '') # removes some problematic commas from within annotation field
foldchange = items[34]
outfile.write(','.join([accession, annotation_edited, foldchange]) + '\n') # data is now comma-delimited like other
files
handle.close()
"""
This script takes the output from script1.py (output1.csv) containing our 36640 transcripts of interest and excludes
all transcripts with uninteresting or negligible changes in expression
"""
handle = open('output1.csv', 'rU')
outfile = open('output2.csv', 'w')
# trim down results to genes with at least 2-fold change in expression
for line in handle:
items = line.strip('\n').split(',')
foldchange = items[2]
if foldchange.startswith('0'):
continue # ignore results that have a positive logFoldChange less than 2-fold
elif foldchange.startswith('-0'):
continue # ignore results that have a negative logFoldChange less than 2-fold
outfile.write(line)
handle.close()
"""
This script takes a .csv-formatted list (CREpredictions.csv) of computationally-predicted fucntional cAMP
response elements (CRE) on promoters of human RefSeq genes and extracts the data columns of interest.
"""
import csv # easier handling of csv files
import sys
input = sys.argv[1] # call script on filename of choice
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with open(input) as handle:
reader = csv.reader(handle)
outfile = open('output3.csv', 'w')
_ = next(reader)
for line in reader: # extract desired data columns
accession = line[2]
cre_prediction = line[5]
outfile.write(','.join([accession, cre_prediction]) + '\n')
handle.close()
"""
This script takes the output from script3.py (output3.csv) containing our 20769 gene promoters of interest and
excludes all that have no predicted CRE.
"""
import csv # easier handling of csv files
with open('output3.csv') as handle:
reader = csv.reader(handle)
outfile = open('output4.csv', 'w')
for line in reader:
accession = line[0]
cre_prediction = line[1]
if 'others' in cre_prediction: # remove all genes that don't have a predicted CRE
continue
outfile.write(','.join([accession, cre_prediction]) + '\n')
handle.close()
"""
This script takes the data columns filtered from the two starting files and combines their contents using a
dictionary.
"""
import csv # easier handling of csv files
outfile = open('output5.csv', 'w')
dictionary = {}
reader1 = csv.reader(open('output2.csv'))
for row in reader1:
key = row[0] # establish accession numbers as keys
if key in dictionary: # avoid repeating keys, just in case
continue
dictionary[key] = row[1:] # establish values as a list of other data values
reader2 = csv.reader(open('output4.csv'))
for row in reader2:
if row[0] in dictionary: # check for existing keys (accession numbers)
dictionary[row[0]].append(row[1]) # if key found, append dictionary with CRE prediction!
# write out dictionary to comma-delimited format
for key, value in dictionary.items():
data = ','.join(str(datum) for datum in value)
outfile.write(','.join([key, data]) + '\n')
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outfile.close()
"""
This script performs final edits and formatting to the output from script5.py (output5.csv).
"""
handle = open('output5.csv', 'rU')
outfile = open('rna_cre_combined_final.csv', 'w') # final output file name
for line in handle:
items = line.strip('\n').split(',')
if len(items) > 3: # get rid of entries which don't contain all 4 desired data values
outfile.write(','.join(items[0:4]) + '\n') # get rid of any remaining duplicates of CRE data column
else:
continue

handle.close()
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SCHOLARSHIPS, AWARDS, AND DISTINCTIONS
EXTERNAL AWARDS:
Ontario Graduate Scholarship (2)
Government of Ontario
$15’000 scholarship for excellence in graduate studies
Ontario Graduate Scholarship (1)
Government of Ontario
$15’000 scholarship for excellence in graduate studies
Orange Scholars Scholarship
The Homer Fund, Canada
$2’500 scholarship based on undergraduate grades and merit

May 2015

May 2014

September 2009

INTERNAL AWARDS:
R.G.E. Murray Seminar Award (4)
September 2017
Department of Microbiology and Immunology
$500 award for having the top peer-voted seminar in the department
R.G.E. Murray Seminar Award (3)
September 2016
Department of Microbiology and Immunology
$500 award for having the top peer-voted seminar in the department
Nellie Farthing Fellowship in Medical Sciences
August 2016
Schulich School of Medicine and Dentistry
$3’000 award for excellence in research
R.G.E. Murray Seminar Award (2)
September 2015
Department of Microbiology and Immunology
$500 award for having the top peer-voted seminar in the department
R.G.E. Murray Seminar Award (1)
September 2014
Department of Microbiology and Immunology
$500 award for having the top peer-voted seminar in the department
Schulich Graduate Scholarship
September 2011 – August 2016
Schulich School of Medicine and Dentistry
$7’500 per year scholarship for a high entrance average into graduate studies
Western Scholarship of Excellence
September 2007
University of Western Ontario
$2’000 scholarship for a high entrance average into undergraduate studies
PRESENTATION AWARDS:
Sernova Oral Presentation Award
Infection and Immunity Research Forum
$200 award for top oral presentation

November 2014
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TRAVEL AWARDS:
Graduate Student Travel Grant
June 2017
American Society for Virology
$500 award to present at the American Society for Virology Conference
Dr. FW Luney Graduate Travel Award
June 2016
Department of Microbiology and Immunology
$2’000 award to present at the American Society for Virology Conference
Graduate Student Travel Award
July 2013
Division of Experimental Oncology
$1’000 award to present at the DNA Tumor Virus Meeting
DISTINCTIONS:
Transferred from M.Sc. to Ph.D. program “with distinction”
For passing the candidacy exam with top marks
Designated as an undergraduate “Western Scholar”
For meeting a minimum 80% average with no mark below 70%
Dean’s Honor List
All four years of undergraduate education

March 2013
July 2011
2007-2011

CONFERENCE ORAL PRESENTATIONS
*Award-winning presentation
Functional and Structural Mimicry of Cellular Protein Kinase A Anchoring Proteins by a
Viral Oncoprotein. King CR, Cohen MJ, Mymryk JS. American Society for Virology
Meeting. University of Wisconsin-Madison, USA. June, 2017.
Human adenovirus E1A proteins utilize functional and structural mimicry to usurp
cellular protein kinase A and enhance viral infection. King CR, Cohen MJ, Mymryk JS.
International DNA Tumor Virus Meeting. ICGEB, Trieste, Italy. July, 2015.
Human adenovirus E1A proteins utilize functional and structural mimicry to usurp
cellular machinery and enhance viral infection. King CR, Cohen MJ, Mymryk JS.
American Society for Virology Meeting. London, Canada. July, 2015.
Human adenovirus E1A proteins utilize functional and structural mimicry to usurp
cellular machinery and enhance viral infection. King CR, Cohen MJ, Mymryk JS.
London Health Research Day. London, Canada. April, 2015.
*An unhealthy relationship: manipulation of cellular protein kinase A by human
adenovirus E1A. King CR, Mymryk JS. Infection and Immunity Research Forum.
University of Western Ontario, London, Canada. November, 2014.

198

The E1A oncoprotein from human adenovirus uses mimicry to usurp cellular protein
kinase A and enhance viral replication. King CR, Mymryk JS. International DNA
Tumor Virus Meeting. University of Wisconsin-Madison, USA. July, 2014.
Characterizing the role of HAdV E1A as a viral AKAP. King CR, Mymryk JS.
International DNA Tumor Virus Meeting. University of Birmingham, Birmingham,
United Kingdom. July, 2013.
INVITED PRESENTATIONS
Functional and structural mimicry of cellular protein kinase A anchoring proteins by a
viral oncoprotein. Young Cancer Researchers Showcase. London Regional Cancer
Program, London, Canada. March 21, 2017. (Talk)
Functional and structural mimicry of cellular protein kinase A anchoring proteins by a
viral oncoprotein. Canadian Society for Virology Workshop at the 2016 American
Society for Virology Meeting. Virginia Tech, Blacksburg, VA, USA. June 18, 2016.
(Poster)
Functional and structural mimicry of cellular protein kinase A anchoring proteins by a
viral oncoprotein. London Cancer Research Trainee Forum. London Regional Cancer
Program, London, Canada. November 5, 2015. (Talk)
TEACHING EXPERIENCE
Graduate Teaching Assistant
January 2015 – April 2016
Microbiology and Immunology 4200B (Molecular Virology)
Duties included designing curriculum, marking exams, and
administering weekly presentations
Graduate Teaching Assistant
September 2012 – December 2013
Microbiology and Immunology 2100A (Biology of Prokaryotes)
Duties included facilitating weekly labs, proctoring tests, and grading reports
VOLUNTEER AND APPOINTED POSITIONS
Volunteer for 34th annual meeting for American Society for Virology
June 2015
Organized and ran oral presentation workshops
Volunteer for Departmental Outreach Committee
March 2014
Department of Microbiology and Immunology
Helped recruit and inform potential new students interested in either
undergraduate or graduate studies in Microbiology and Immunology
Graduate Representative to the Canadian Society of Microbiologists
2014 – 2016
Department of Microbiology and Immunology
Conveyed information regarding the annual general meeting of the CSM,
funding opportunities, and other relevant information from the society to
departmental students and faculty
Infection and Immunity Research Forum organizing committee
2011 – 2012
Department of Microbiology and Immunology
Organized multiple annual meetings hosted by Microbiology and
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Immunology graduate students at which scientists are invited
to present their research in the scope of infection and immunity
Social Committee
2011 – 2016
Department of Microbiology and Immunology
Active member throughout my graduate studies in which organization
of departmental functions, fundraising, and social outreach were emphasized

